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Abstract
Trial-based economic evaluations are performed on individual-level data, which almost invariably
contain missing values. Missingness represents a threat for the analysis because any statistical
method makes assumptions about the unobserved values that cannot be verified from the data at
hand; when these assumptions are not realistic, they could lead to biased inferences and mislead
the cost-effectiveness assessment.
We start by investigating the current missing data handling in economic evaluations and pro-
vide recommendations about how information about missingness and related methods should be
reported in the analysis. We illustrate the pitfalls and issues that affect the methods used in rou-
tine analyses, which typically do not account for the intrinsic complexities of the data and rarely
include sensitivity analysis to the missingness assumptions. We propose to overcome these prob-
lems using a full Bayesian approach. We use two case studies to demonstrate the benefits of our
approach, which allows for a flexible specification of the model to jointly handle the complexities
of the data and the uncertainty around the missing values.
Finally, we present a longitudinal bivariate model to handle nonignorable missingness. The
model extends the standard approach by accounting for all observed data, for which a flexible
parametric model is specified. Missing data are handled through a combination of identifying
restrictions and sensitivity parameters. First, a benchmark scenario is specified and then plau-
sible nonignorable departures are assessed using alternative prior distributions on the sensitivity
parameters. The model is applied to and motivated by one of the two case studies considered.
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Research Question and Outline of
the Thesis
Individual-level data in health economic evaluations are generally characterised by some missing
outcome values. If these unobserved values are not appropriately handled, they may affect the
inferences and possibly mislead the cost-effectiveness assessment. The modelling task is par-
ticularly challenging as the problem of handling missingness is often embedded within a more
complex framework, where outcome data typically present a series of complexities that need to
be simultaneously addressed to avoid biased results.
Trial-based routine analyses do not typically account for all these complexities, are conducted
on cross-sectional quantities based only on the complete cases and rarely assess the robustness
of the results to different assumptions about the missing values. The failure to appropriately
account for the uncertainty generated by missingness may have important consequences on the
results and, more importantly, on the approval or reimbursement of new health care technologies.
Bayesian methods are well-suited for addressing decision-making problems. By taking a prob-
abilistic approach, based on decision rules and available information, they can explicitly account
for relevant sources of uncertainty in the decision process and obtain an “optimal” decision out-
put. In addition, the flexibility of the Bayesian approach can handle the complexities of the data
in a relatively easy way and naturally allows the incorporation and assessment of transparent
assumptions about the missing data.
The aim of this research is to develop a full Bayesian approach to handle missingness in health
economic evaluations and compare its performance with respect to the standard approach used
by practitioners. We address the research question based on three key objectives: 1) to review
the missingness methods used in trial-based economic evaluations and evaluate the quality of
routine analyses with respect to the handling of missing data; 2) to identify potential limitations of
the standard approach in terms of unrealistic missing data assumptions and provide a Bayesian
approach that can improve the current practice and avoid biased results; 3) to develop a full
Bayesian approach to handle missingness in a principled way by combining a model for the data
and explicit assumptions about the missing values.
The rest of the thesis is structured as follows. Chapter 1 summarises the theoretical back-
ground related to the main topics of this thesis. First, we introduce the health economics evalua-
tion framework and purpose; then we provide a brief summary of some key concepts of Bayesian
analysis and its advantages in dealing with decision-making problems; finally, we present the topic
of missing data analysis and we review some of the most popular methods and approaches to
handle missingness. Chapter 2 shows the results from a literature review on missingness meth-
ods in trial-based analyses and provides recommendations to improve the current practice. In
addition, guidelines for assessing the quality of missing data analyses are provided in the form
of a structural framework, which is described and applied to the articles studied in the review
(objective 1). Chapter 3 presents the two case studies (MenSS and PBS trials) that will be anal-
ysed in this thesis and describes the standard approach for performing economic evaluations in
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routine analyses. Chapter 4 illustrates a pitfall related to the different missing data assumptions
associated with alternative implementations of the mean baseline adjustment methods used in
routine analyses. Data from both case studies are used to demonstrate the potential bias associ-
ated with this method (objective 2). Chapter 5 presents a general Bayesian analytic framework
that improves the standard approach and leads to more realistic imputations by jointly tackling
the typical complexities that affect the data. We demonstrate the benefits and flexibility of our
approach on the data from the two case studies (objective 2). Chapter 6 proposes a parametric
Bayesian longitudinal approach that extends the modelling framework of economic evaluations to
handle missingness more efficiently, while incorporating a sensitivity analysis to alternative miss-
ingness assumptions. We motivate and apply our approach using the data from the PBS trial
(objective 3). Finally, Chapter 7 summarises the main conclusions from this thesis and suggests
directions for future research.
3
Chapter 1
Background
We first introduce health economic evaluations, the type of data analysed and the decision-making
problem involved in the cost-effectiveness assessment. Next, we briefly review some key concepts
of Bayesian inference and describe the advantages of using a Bayesian approach to account for
multiple forms of uncertainty in economic evaluations. Finally, we present the topic of missing data
from a general statistical perspective, review some of the most popular methods used to handle
missingness and focus on a principled approach for conducting sensitivity analysis to plausible
missingness assumptions.
1.1 Health Economic Evaluation
Economic evaluations are applied in the field of healthcare with the principle aim of improving
the economic efficiency of resource allocation, i.e. help maximise benefits from available (and
constrained) resources. This has become an increasingly important problem in many countries
over the last decades due to a continuous increase in the costs associated with healthcare ser-
vices that now affect a great portion of the total economy expenditures (OECD, 2015). Naturally,
this is the result of an increase of the average life expectancy and the development of new and
more expensive technologies. A major consequence of this process is the need to balance the
total healthcare spending, i.e. to define what is the optimum expenditure level and specify how to
reach it. In countries where there is a predominant public funding of healthcare, such as the UK,
this is typically achieved by defining a governmental health scheme that can provide the highest
clinical benefit level for the patients and society, given the availability of limited resources.
In the UK, the National Institute for Health and Care Excellence (NICE) plays an important
role with regard to the approval of new healthcare technologies and uses economic evaluations
to inform decisions about a wide range of interventions: medical devices, diagnostic technolo-
gies, surgical procedures and pharmaceuticals (NICE, 2013). NICE provides evidence-based
guidelines on how a particular disease or condition should be treated and assesses whether new
treatments provide value for money as they become available in England and Wales (Meltzer,
2001).
The increasing use of economic evaluation for decision-making has placed requirements on
the type of evidence and analytic methods to be used in order to define an appropriate framework
for the analysis (Sculpher et al., 2005). NICE typically relies on decision models to evaluate the
cost-effectiveness of new treatment regimens. These models are based on information collected
from the literature, among which a key role is played by Randomised Controlled Trials (RCTs).
They provide individual patient data where the randomisation of patients to treatment acts to
reduce bias, and therefore can be used to perform head-to-head comparisons in controlled envi-
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ronments. As a result, RCTs are commonly used as a vehicle for economic evaluations. Many
funders, such as the UK National Institute for Health Research Health Technology Assessment
Programme, routinely request that assessments of cost effectiveness are incorporated in the de-
sign of randomised trials to inform policy makers about the feasibility of extending the treatment
to the overall target population.
Economic evaluations can be formally defined as the comparison of alternative options in
terms of both their costs and benefits (Drummond et al., 2005). The joint consideration of both
outcome measures represents a key element in determining whether a new treatment option
should be given priority in terms of resource allocation with respect to an alternative. The most
popular types of economic evaluation in healthcare are Cost-Effectiveness Analysis (CEA) and
Cost-Utility Analysis (CUA), which share a similar rationale but typically differ by the types of
measures used to describe the benefits.
In CEA, the benefits of an intervention are measured in terms of a pre-defined unit of health
outcome such as lives saved or life years gained and the task of an analyst performing the evalu-
ation is to estimate the cost per unit of health outcome achieved, i.e. the cost per life saved. CEA
does not permit a direct comparison of costs and benefits across interventions yielding different
outcomes (for instance, cases prevented vs. life years gained) but is restricted to the compar-
isons of interventions that use the same disease-specific outcome measures. However, health-
care providers, such as the National Health Service (NHS) in the UK, require the comparison of
interventions across different disease areas to inform resource allocation and prioritisation deci-
sions.
To avoid the problem of non-comparability, benefits in CUA are expressed in terms of utility or
quality of life. Among these non-monetary measures, one of the most popular is Quality Adjusted
Life Years (QALYs), an index comprising both length and quality of life. Although this has been
debated (Mooney, 1989; Neumann and Greenberg, 2009), it is generally assumed that the QALY
is a comprehensive measure of health that captures enough aspects of health to be considered
an appropriate instrument for measuring outcomes in the field of curative healthcare.
More specifically, QALYs measure the state of health of a person or group in which the ben-
efits, in terms of length of life, are adjusted to reflect the quality of life (one QALY is generally
associated with one year of life in perfect health). QALYs are calculated by estimating the years of
life remaining for a patient following a particular treatment or intervention and weighting each year
with a quality-of-life or utility score (see Section 1.2 for more details), which is often measured
in terms of the person’s ability to carry out the activities of daily life, and freedom from pain and
mental disturbance.
The result of a CUA is usually expressed in terms of total net cost per unit of utility or qual-
ity (e.g. cost per QALY gained). As in CEA, the value of measures is still implicitly defined as
part of the QALY component but has the general advantage of being used across many different
disease areas. This makes CUA very attractive because effectiveness, measured in terms of life
expectancy, is a straightforward concept for most clinicians and utilities are a quantitative mea-
sure about the strength of patients’ preferences for certain health states. However, issues arise
when calculating utility measures due to a variety of available statistical methodologies as well as
different types of patients’ data that could be used (Hunter et al., 2015). Although CUA is more
resource and time consuming than CEA, it is the recommended analytic framework for economic
evaluations in many jurisdictions such as the UK.
Due to an established practice, especially for analyses on individual-level data, practitioners
often use the term CEA to also indicate a cost-utility analysis. Throughout this thesis we will focus
on trial-based analyses and use the terms economic evaluations, cost-effectiveness analysis and
cost-utility analysis interchangeably, as is commonly done.
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1.2 Individual-Level Data
A multivariate outcome constitutes the main focus of economic evaluations: the costs and benefits
associated with the treatments under examination. We now present a brief description of how
these individual-level variables are typically computed and the features that characterise the data.
In a trial setting, e.g. RCTs, health benefit and resource use data are typically collected on
each individual in the study (i = 1, . . . , n) at baseline (j = 0) and at successive follow-up times
(j = 1, . . . , J) for each treatment group t. Data on some baseline demographic variables (e.g. age,
gender, ethnicity, etc.) are also typically collected. Table 1.1 displays an example of a typical trial-
based individual level dataset for economic evaluation.
Demographics utility data cost data
Individual t Gender Age . . . u0 u1 . . . uJ c0 c1 . . . cJ
1 1 M 23 . . . 0.32 0.66 . . . 0.44 £103 £241 . . . £80
2 1 M 21 . . . 0.12 0.16 . . . 0.38 £1204 £1808 . . . £877
3 2 F 19 . . . 0.49 0.55 . . . 0.88 £16 £12 . . . £22
4 1 F 20 . . . 0.23 0.37 . . . 0.52 £99 £150 . . . £85
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1.1: Example of a typical trial-based dataset used in economic evaluations.
Different types of effectiveness or benefit measures can be considered, even though decision-
making bodies typically favour outcomes that are comparable across as many different disease
areas as possible. Generic preference-based measures of health related quality of life are typically
used for economic evaluations, and are obtained from short health questionnaires that measure
patients’ health and well-being across a number of domains. The questionnaire most favoured in
the UK is the EuroQol 5D (EQ-5D, http://euroqol.org) and the variant currently most commonly
used is the 3-level version. The EQ-5D is constructed on the basis of five different domains
(mobility, self-care, usual activities, pain and anxiety/depression) for which patients are asked
whether they have no, some or extreme problems (three levels), for a total of 35 = 243 potential
distinct health states. For example, the health state (11223) is associated with an individual who
reports no problems (level 1) in the mobility and self-care domains, some problems (level 2) in
usual activities and pain, and extreme problems (level 3) in anxiety/depression.
Each health state is then associated with a country-specific utility score representing the pref-
erences of a sample of the general population for that specific health state. Utility scores are
calculated using preference-based algorithms which typically anchor the scores so that a value of
1 corresponds to perfect health and a value of 0 is equivalent to the state of death; sometimes,
depending on the specific method used, negative scores are possible, representing states that
are theoretically worse than death. For example, in the UK, the utility scores for the EQ-5D 3-
level version range from a value of 1 for perfect health to −0.594, which corresponds to the worst
possible health state. NICE’s recommended algorithm to calculate the utilities is the time-trade
off (Dolan and Gutex, 1995), in which the utility scores associated with health states considered
better or worse than death are valued using different approaches. Figure 1.1 shows how the al-
gorithm derives the utility scores associated with an hypothetical impaired health state h, which is
either valued better (panel a) or worse (panel b) than death.
For an impaired state h, which is considered better than death (panel a), the respondent faces
a choice between two hypothetical lives: one involving x years of healthy life, followed by death
(alternative 1); the other involving t years in state h (where x ≤ t), followed by death (alternative
2). If the respondent prefers alternative 2 to alternative 1, x is increased to make alternative
1 more attractive; if the respondent prefers alternative 1 to alternative 2, x is reduced to make
alternative 1 less attractive. This iterative procedure continues until the respondent is unable to
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Figure 1.1: Schematic representation of the time-trade off algorithm to derive the utility scores associated
with some impaired health state, which is either valued better (panel a) or worse (panel b) than death.
Legend: h impaired health state, u(h) utility score of state h, x time in full health, t time in state h.
choose between the two lives. The utility value of h, i.e. u(h), is calculated according to how much
healthy time the respondent is willing to forgo at this point of indifference, and is given by x/t. If
the state h is considered by the respondent to be worse than death (panel b), the respondent is
presented with a different choice: between a life involving t − x years in h, followed by x healthy
years and then death (alternative 1); and immediate death (alternative 2). The value of x is varied
until the respondent’s point of indifference is identified, where u(h) = −x/(t − x). Dolan and
Gutex (1995) validated the time-trade off algorithm on a representative sample of the general UK
population to derive a preference-based tariff which directly provides the utility scores associated
with each of the health states of the EQ-5D questionnaire. For example, using this tariff, the utility
score associated with the state (11223) is equal to 0.255.
The decision of which types of resource use are included in an economic analysis is usually
tailored to the requirements of the decision-makers, i.e. the target audience of the evaluation.
For a number of countries, healthcare decision-making bodies only consider healthcare costs
when assessing the cost-effectiveness of a new intervention. However, in principle, other costs
could be included, e.g. societal costs. In addition, the types of cost and resource data collected
can be different (patient questionnaires, clinic records, administrative records), depending on the
perspective of the decision-maker.
Aggregate measures of effectiveness (e.g. QALYs) and total costs for each individual and
treatment option are typically computed by combining the utilities uijt and costs cijt collected at
each time point into cross-sectional quantities (eit, cit)1 as
eit =
J∑
j=1
(uijt + uij−1t)
xj
2
and cit =
J∑
j=1
cijt, (1.1)
where xj =
Timej−Timej−1
Unit of time is the fraction of the time unit (e.g. 12 months) between consecutive
measurements, e.g. x2 =
(6 months−3 months)
12 months = 0.25. For the utilities, this approach is often referred
to as the area under the curve (Drummond et al., 2005).
Essentially, QALYs are calculated as a series of preference-weighted health states, where the
1We slightly abuse the notation and denote the longitudinal and aggregate cost variables with cijt and cit, respectively.
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weights (i.e. the utility scores at each time point) reflect the desirability of living in those states.
Once the weights are derived, they are multiplied by the time spent in the associated state and
these products are then summed to obtain the QALYs. Thus, the QALY values associated with
an individual, and their range, depend both on the utility scores at each time point j and the time
horizon J considered. For example, given a time duration of 1 year, the QALY value associated
with an individual who has always lived in perfect health (i.e. utility scores of 1 at each time point
j) is equal to 1. However, if a time duration of 2 years is considered, the QALY value associated
with the same individual living in perfect health throughout this period is equal to 2. Similarly, the
QALY value associated with an individual living in the worst possible health state (uj = −0.594
at each j) is equal to −0.594 when J = 1 year and −1.188 when J = 2 years. When the QALYs
and total cost outcomes are evaluated over a time period longer than 1 year, their values are
typically discounted using some yearly discount rate r to account for time preferences in the
receipt of costs and benefits, where the value for the discount rate currently recommended by
NICE is equal to 3.5% (NICE, 2013). Since for both the case studies analysed in this thesis the
time horizon is equal to 1 year, the range of the QALYs always coincides with that of the utility
scores, i.e. between −0.594 and 1, and no discounting is required for both QALYs and total costs.
In general, cost data can vary widely between individuals, are defined on the range [0,∞) and
tend to be positively skewed. The skewness of cost data is typically due to the fact that for many
evaluations a smaller number of patients will accrue substantially higher costs compared to other
patients. This may be due to, for example, long inpatient stays or expensive interventions. It is
also common to observe individuals who are associated with a null cost and that induces a spike
at 0 in the cost distribution.
In the UK, the utility scores for the EQ-5D 3-level version are defined on the range [−0.594, 1],
where negative values are associated with health states that are considered worse than death (Dolan
and Gutex, 1995). Among the general population, utility data tend to be negatively skewed, with
most of the values lying at the higher end of the measurement scale and some observations dis-
playing extremely low utility levels. Similarly to the costs, some individuals are typically associated
with a perfect health state that induces a spike at 1 in the utility distribution. Right-skewed distri-
butions of utilities are occasionally observed among certain groups of patients (e.g. terminally ill
patients or individuals with chronic conditions) where most of the individuals in the sample report
poor health states.
A typical feature of individual-level utility and cost data is that they can be either positively
or negatively correlated. The first case may arise, for example, when effective treatments are
innovative and are associated with higher unit costs. The second case, instead, may result when
more effective treatments reduce total care pathway costs e.g. by reducing hospitalisations, side
effects, etc. In addition, when the data are collected from different centres or clusters, utilities and
costs can be differently correlated at the individual and cluster level.
This typically occurs in cluster randomised trials, where the unit of randomization is the “clus-
ter” – for example, the hospital or primary care physician, not the individual. A cluster design
may be chosen because the intervention operates at a group rather than at an individual level
(e.g. changing incentives for providers) or if there is a high risk of “contamination” among the
individuals within clusters (e.g. evaluating different advertising strategies to encourage smoking
cessation). In cluster RCTs, individuals within a cluster are likely to be somewhat similar in their
characteristics and the care they receive, and therefore, individual utilities or costs within the same
cluster tend to be more homogeneous than those in different clusters (Gomes et al., 2012a). For
example, cost data based on process measures such as length of stay, typically have a rela-
tively high proportion of the variation at the cluster rather than at the individual level (Campbell
et al., 2005). Thus, in cluster RCTs, the size or direction of the correlation may differ according to
whether the focus is at the individual or the cluster level (Gomes et al., 2011). For example, within
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clusters, individuals with lower health status may incur higher costs (i.e. at the individual level,
there is a strong negative correlation), while clusters that have higher mean costs per patient may
have on average higher utilities.
Finally, some observations for either or both outcomes, are almost invariably missing. Reasons
for missingness may differ according to the context considered or the individuals’ characteristics
(e.g. age, sex, etc.) and outcome values. For example, when data for utilities and costs are derived
from similar types of sources throughout the trial, e.g. using self-reported questionnaires, then
missingness at a given time typically occurs in both outcomes, e.g. when an individual drops out
from the study. However, in trial-based analyses, outcome data may also be derived using different
types of sources, e.g. EQ-5D questionnaires for the utilities and a combination of observational
datasets and NHS average unit prices for the costs. In this case, reasons and patterns of missing
data may be different between utilities and costs and missingness in one outcome may imply or
be related to missingness in the other outcome. In addition, when utility and/or cost data for the
i−th individual in the study are not observed at all time points, then (eit, cit) cannot be directly
computed as in Equation 1.1 for those subjects and are recorded as missing. When the data are
partially-observed or “incomplete”, there are important implications for their analysis that cannot
be ignored (we address the implications of missing data analysis in Section 1.5).
1.3 Bayesian Analysis in Economic Evaluation
From the statistical point of view, trial-based CEAs have historically been performed using fre-
quentist methods: these include power calculations at the design stage and calculation of p-
values and confidence intervals (Briggs and Gray, 1998; Laska et al., 1999; Willan, 2001; Glick,
2011). However, the increasing sophistication of economic evaluations is highlighting the limita-
tions of this approach. For example, unlike standard statistical analyses, economic evaluations
do not just focus on estimation (e.g. the computation of point or interval estimation, or hypothesis
testing), but are used as a tool to aid decision making (Claxton, 1999). Thus, rather than relying
merely on statistical and clinical significance, economic evaluations need to quantify the impact
of the uncertainty in the evidence on the entire decision-making process (e.g. to what extent the
uncertainty in the estimation of effectiveness of a new intervention affects the decision about
whether it is paid for by the public provider). To this aim, much of the recent research has been
oriented towards building the economic evaluation on sound statistical decision-theoretic founda-
tions (Spiegelhalter et al., 2004; Briggs and Gray, 1999), and increasingly often under a Bayesian
statistical approach (O’Hagan and Stevens, 2001; Baio, 2012). In particular, NICE advocates the
use of this decision-theoretic framework as a standardised approach in health economic evalua-
tions to ensure the comparability of results and the consistency of decision-making (NICE, 2013).
Therefore, although alternative approaches to decision-making exist in other application areas,
the thesis discusses and focuses on the decision-theoretic approach recommended by NICE, to
which all economic evaluations in the UK are expected to adhere.
There are several reasons which make the use of the Bayesian approach in economic evalua-
tions particularly appealing. First, Bayesian methods are naturally embedded in the wider scheme
of decision theory; by taking a probabilistic approach, based on decision rules and available infor-
mation, they can explicitly account for relevant sources of uncertainty in the decision process and
obtain an “optimal” course of actions. Second, Bayesian modelling is characterised by extreme
flexibility, which allows to account for the typical complexities of the data (e.g. correlation, skew-
ness, spikes and missing data) in a relatively easy way. Third, the Bayesian approach naturally
allows the incorporation of evidence from different sources (e.g. expert opinion or multiple studies)
into the analysis, which may improve the estimation of the quantities of interest compared with us-
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ing the evidence from a single source (e.g. a single trial). Finally, under the Bayesian approach,
it is straightforward to assess and quantify the impact of uncertainty in all inputs of the decision
process; this is extremely relevant in economic evaluations as it is a required component in the
approval or reimbursement of a new intervention for many decision-making bodies, such as NICE
in the UK (Claxton et al., 2005).
We briefly introduce the main aspects of Bayesian inference and focus on how the economic
evaluation process is performed within a Bayesian framework. The concepts illustrated in this
chapter constitute only a limited insight into the more general and complex Bayesian statistical
theory. For a more comprehensive and exhaustive presentation of these topics we refer the
reader to Gelman et al. (2013), Jackman (2009) and Lee (2012).
1.3.1 Bayesian Inference and Computation
In contrast with the frequentist approach, which assumes a unique, correct or “true” value of
the probability attached to any uncertain event, the Bayesian approach interprets the probability
as a “subjective” degree of belief, which depends on the individual whose uncertainty is being
expressed and the information available to him/her. Under this perspective, each individual is
entitled to his/her own subjective probability, which can be updated according to the evidence that
becomes sequentially available.
From a modelling perspective, the Bayesian interpretation of probability allows to make prob-
abilistic statements directly on the quantities of interest, i.e. some unobservable feature of the
process under study, typically represented by a set of parameters. More specifically, a Bayesian
model specifies a full probability distribution to describe uncertainty in terms of the data, which
are subject to sampling variability, and unobserved quantities (e.g. parameters or future observa-
tions), which are not typically known to the experimenter. As a consequence, probability is used
in the Bayesian framework to assess any form of limited knowledge. The experimenter needs to
identify a suitable probability distribution to describe the overall uncertainty about the data y and
the unknown parameters θ, which we indicate with p(y,θ).
By the basic rules of probability we can re-express this joint distribution as the product of the
marginal distribution of the data p(y) and the conditional distribution of the parameters given the
data p(θ | y) or vice versa, i.e. p(y,θ) = p(y)p(θ | y) = p(θ)p(y | θ). From this, we can derive the
fundamental theorem of Bayesian inference known as Bayes theorem:
p(θ | y) = p(y | θ)p(θ)
p(y)
(1.2)
The basic idea underlying the theorem is that we can update our level of uncertainty about the pa-
rameters before observing the data, expressed through a prior distribution p(θ), with the evidence
from the data, expressed through the likelihood p(y | θ), into a posterior distribution p(θ | y). This
allows us to make inference in terms of direct probabilistic statements.
When little information is contained in the prior p(θ), which is then typically referred to as a
diffuse or vague prior, the resulting posterior will be mostly informed by the likelihood. Thus,
inference will be numerically similar to that achieved in a frequentist setting, where only informa-
tion from the data is considered. However, because of the different assumptions underlying the
Bayesian and frequentist statistical frameworks, the interpretation of the results between the two
approaches remains different.
Alternatively, we can use informative priors, i.e. distributions that represent some knowledge
about the model parameters before observing the data and that, together with the likelihood,
drives posterior inferences. The most serious issue with using informative priors is related to the
way information is elicited, i.e. brought into the model. More generally, the elicitation process
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implies that the people providing the information to be included in the model (e.g. clinical experts)
possess some kind of knowledge or beliefs “in their heads” and it is the analyst task to devise the
right kind of questions to “extract” this information from them (O’Hagan et al., 2006).
It is crucial to find an appropriate way to express the external information collected in order
to adequately inform the priors on the parameters of interest in the setting analysed. There is
a wide literature about the process of eliciting experts probabilities and alternative approaches
are available (Stevens and O’Hagan, 2002; Grigore et al., 2016; Mason et al., 2017). Elicited
probabilities may suffer from biases and non-coherence in practice, but the goal of the elicitation
is to represent the expert knowledge and beliefs as accurately as possible. We will not further
cover this subject as it falls outside the focus of this work and we refer to O’Hagan et al. (2006)
for a more comprehensive examination on the topic.
A Bayesian analysis can assess the level of uncertainty for any unobserved quantity, be it a
parameter or some future observation, given the information from the observed data and model
assumptions. For example, it is possible to evaluate probabilistically unobserved data y˜, assumed
to be of the same nature as those already observed, by means of the (posterior) predictive distri-
bution
p(y˜ | y) =
∫
p(y˜ | θ)p(θ | y)dθ. (1.3)
The expression indicates that, once the uncertainty regarding the unknown parameters has been
integrated out, p(y˜ | y) does not depend on θ anymore and indicates what we know about the
distribution of the (future) y. When only prior information is available, we replace p(θ | y) by
p(θ) in Equation 1.3. This yields the prior predictive distribution p(y˜) =
∫
p(y˜ | θ)p(θ)dθ, which
corresponds to the denominator of Equation 1.2.
While the posterior distribution might be known in closed form, it is often not analytically
tractable. Iterative approximation methods are typically used to approximate the posterior dis-
tribution and produce the required inference. Among these, one of the most popular techniques
is Monte Carlo Integration (Kroese et al., 2013), which uses a series of random values to numer-
ically compute a definite integral. More details on how Monte Carlo integration can be used to
derive posterior summaries is available in Appendix A.1.
When the posterior distribution is not available in closed form, a more general class of algo-
rithms which can be used to derive posterior inferences is provided by Markov Chain Monte Carlo
(MCMC) methods (Brooks et al., 2011). MCMC methods are a class of iterative algorithms for
sampling from generic probability distributions, which are based on the construction of a Markov
chain that converges to the desired target distribution, i.e. the joint posterior distribution of the
parameters we are interested in. Provided that some regularity conditions are satisfied (Jackman,
2009; Brooks et al., 2011), after a sufficiently large number of iterations the chain will forget its
initial state and will converge to the unique stationary target distribution, which does not depend
on time or the initial position.
There are different types of MCMC algorithms. One of the most popular is Gibbs sampling (Ge-
man and Geman, 1984), which samples sequentially from the full conditional distribution of each
parameter or block of parameters. For a detailed presentation of different types of MCMC meth-
ods we refer to Brooks et al. (2011). Over time, many software that are specifically designed for
the analysis of Bayesian analysis using MCMC techniques have been developed. Perhaps, the
software that have most proliferated among applied statisticians are those based on the model de-
scription language known as BUGS (Bayesian inference Using Gibbs Sampling; Gilks et al., 1994;
Lunn et al., 2012). Some examples are: WinBUGS, and its open source variant OpenBUGS; and
JAGS (Just Another Gibbs Sampler ; Plummer, 2010). Recently, another probabilistic programming
language, called STAN (Carpenter et al., 2017), has been developed for conducting Bayesian infer-
ence using a specific class of MCMC methods known as Hamiltonian Monte Carlo (Brooks et al.,
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2011).
Once the MCMC sampling has successfully been performed, for each parameter of interest we
can typically access a vector of S simulations (θ(1), . . . , θ(S)) from the posterior distribution. This
can then be summarised by computing a variety of quantities, such as the posterior mean or me-
dian, with uncertainty typically represented via “credible” intervals obtained from the percentiles
of the posterior. For example, we can compute the posterior mean E[θ | y] by averaging across
the simulated values θ(s) or derive an approximate 95% credible interval (CI) using the empirical
2.5% and 97.5% quantiles of the posterior distribution of θ. A slightly different type of interval is the
95% highest posterior density (HPD) interval. This corresponds to the CI that contains the values
of θ that are a posteriori more plausible, i.e. p(θ | y) is higher for all θs inside the interval than for
values outside the interval.
Generally speaking, there is no measure that can definitely assess whether the MCMC has
converged because the chain will reach the target distribution (forgetting its initial state) only
asymptotically. However, some diagnostic measures such as the potential scale reduction factor
and the effective sample size (Gelman et al., 2013) may provide some useful insights to detect
failures in convergence or high autocorrelation in the MCMC sampler. We do not go further into
details about MCMC methods as they are not the main focus of this work, and we refer to Brooks
et al. (2011) for a comprehensive text about MCMC methods and inference.
1.3.2 Model Checking
A crucial part of any statistical analysis is assessing the fit of the model. In Bayesian analysis
this includes checking for any sensitivity to the choice of the prior in addition to more “standard”
checks regarding, for example, residuals and predictions (Gelman et al., 2013). In particular,
when comparing models, it can be informative to evaluate their predictive accuracy and perform
model selection based on their fit to the data.
A typical approach to assess the predictive accuracy of a Bayesian model uses posterior pre-
dictive checks (Gelman et al., 2013). The basic technique is to draw simulated values from the
posterior predictive distribution (Equation 1.3), and compare these to the observed data, either
graphically or using discrepancy measures. If the model fit is reasonable, then the predictions
generated by the model should look similar to the observed data. Different types of graphical as-
sessments can be used, including a display of all the data, data summaries or residuals (Gelman
et al., 2013). A potential issue with using posterior predictive checks is that, since the data have
influenced the estimation of the parameters, they are in fact used twice, i.e. for model fitting and
checking. This is not optimal as, in principle, the fit of the models should be evaluated on some
external data that were not used for estimation. However, posterior predictive checks can provide
useful insights about potential failings of the model, provided that usage is limited to study model
adequacy, not for model comparison and inference (Meng, 1994).
Alternative measures of model checking, known as information criteria, have been proposed.
These measures evaluate the predictive ability of competing models in terms of the accuracy
of the models’ predictions based on the observed data and some bias correction terms. For a
comprehensive review of different types of criteria we refer to Gelman et al. (2014) and Vehtari
et al. (2017). For the analyses in this thesis, we specifically focus on the Deviance Information
Criterion (DIC; Spiegelhalter et al., 2002), which is the predictive measure of choice in many
Bayesian applications, in part because of its incorporation in the popular BUGS software. A detailed
description of how DIC can be computed and the potential pitfalls in its implementation is available
in Appendix A.2.
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1.4 Decision Modelling in Economic Evaluation
Health economic evaluations are a typical problem of decision-making under uncertainty. Their
main objective is to provide decision-makers with a useful tool that permits the comparison of
competing technologies in terms of the benefits they provide and the resource use required to
reach these benefits. This leads to the need of some methods to compare alternative options,
reflect uncertainty in the conclusions and choose which option should be applied to the whole
population, given the available evidence (e.g. coming from a RCT).
Figure 1.2 graphically represents the general process of doing a Bayesian analysis (with a
view of using the results of the model to perform an economic evaluation). Four steps form the
process:
Statistical Model. At the beginning of the process a statistical model is used to estimate some
relevant parameters, such as the population mean effectiveness and costs. The type of
statistical analysis varies with the nature of the underlying data (e.g. individual level versus
aggregated level data).
Economic Model. The estimates from the statistical model are then combined in the economic
model, with the objective of obtaining some relevant population parameters indicating the
average benefits and costs for a given intervention in comparison to another one. Depending
on the type of available data and statistical model used, this step may simply correspond
to using the parameters as derived from the statistical model or it may involve complex
combinations thereof (Baio, 2017).
Decision Analysis. Once appropriate outcome measures are obtained from the economic model,
these are used as the basis for the decision analysis, which aims at identifying the optimal
intervention that should be applied to the target population by computing suitable measures
of “cost-effectiveness".
Uncertainty Analysis. The final aspect is represented by the evaluation of how the uncertainty
(e.g. in parameters or model structure) impacts the final decision outcome and obtain the
best course of action given current evidence. However, when the available evidence is
limited, it is important to assess the impact of current uncertainty on decision-making.
Statistical Model Economic Model Decision Analysis
Uncertainty Analysis • Assesses the impact of uncertainty on economic results
• Estimates relevant
population parameters
• Combines the parameters to obtain
a population average measure for
costs and clinical benefits
• Summarises the economic
model by computing suitable
measures of cost-effectiveness
Figure 1.2: Economic evaluation process. The process is formed by four main steps, represented as
rectangles, connected to each other by arrows (indicating the dependency relationships). The flow of
the process is indicated by solid arrows, while dashed arrows link the steps subjected to uncertainty
assessments. Source: Baio et al. (2017).
The first two steps (Statistical and Economic Model) are related to the construction of appropri-
ate models to obtain inferences and their forms mainly depend on the available data and modeller
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approach. Conversely, the last two steps (Decision and Uncertainty Analysis) can be represented
in a more standardised way. Specifically, their purpose is to obtain summary CEA measures of
interest for decision makers and assess the current level of uncertainty in the decision problem.
We now focus on these steps and on the tools typically used to perform their tasks.
1.4.1 Comparing Health Interventions
As discussed earlier, the purpose of economic evaluations is to provide information to decision-
makers about the costs and benefits for each treatment under evaluation. Decision analysis has
been defined as a systematic approach to decision-making under uncertainty (Raiffa, 1968). In
the context of economic evaluation, a decision analytic model uses mathematical relationships to
define a series of possible consequences, each associated with specific costs and benefits, for the
set of alternative treatments being evaluated. These consequences are then used to inform the
best course of action and choose the “optimal” treatment given current evidence, where optimality
is defined in decision-theoretic terms (O’Hagan and Stevens, 2001; Briggs et al., 2006; Baio,
2012).
A simple and popular criterion to select an “optimal” strategy in the decision problem of eco-
nomic evaluation is the maximisation of the expected utility. The main idea is to choose, among
the set of available interventions, the option maximising the probability of the outcome preferred
by the decision-maker, i.e. in terms of benefits and costs. When certain conditions are satisfied
(Raiffa, 1968; Smiith, 1988), the decision-making can be performed by simply computing an av-
erage. In particular, we need to compute for each intervention the expectation of a utility function
with respect to both “population” (parameters) and “individual” (sampling) uncertainty/variability.
For simplicity, we consider the example where there are only two treatments being compared and
generically term the clinical benefits as “effectiveness”. In the following, we indicate the economic
outcome variables as (cit, eit), where t = 1, 2 denotes the treatment option (e.g. new intervention
vs control), and drop the individual index i to ease notation. Although the definition and type of
the variables (ct and et) may vary depending on the specific conditions considered (e.g. quality of
life or survival data), throughout the thesis we assume that they are always expressed in terms of
health care costs and QALYs, which are derived from the cost and utility data collected at different
time points in the trial using the formulae illustrated in Section 1.2.
As for the type of utility function, health economic evaluations are generally based on the Net
monetary Benefit (Stinnett and Mullahy, 1998)
Net Benefit = ket − ct, (1.4)
where k is a willingness-to-pay parameter used to put the outcomes on the same scale. Note
that the definition provided in Equation 1.4 is based on the standard representation of the net
benefit which is typically used in the health economic literature (Claxton, 1999) and that alternative
formulations exist (Willan et al., 2004).
The net benefit represents the budget that the decision-maker is willing to invest to increase the
benefits by one unit. The main advantage of using the net benefit framework is its fixed form, once
(et, ct) are defined, which provides easy guidance to the evaluation of the interventions. Moreover,
Equation 1.4 is linear in (et, ct), which facilitates interpretation and calculation tasks. However, the
use of the net benefit presupposes that the decision-maker is risk neutral, which is by no means
always appropriate in health policy problems (Koerkamp et al., 2007). For simplicity, we do not
focus on this aspect and we assume that the net benefit framework can adequately describe
the utility function of the decision-maker, in line with the vast majority of the health economics
literature (Briggs, 1999; O’Hagan and Stevens, 2001; Spiegelhalter et al., 2004; Grieve et al.,
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2005; Gomes et al., 2012b; Diaz-Ordaz et al., 2014b; Ng et al., 2016).
Since the net benefit is assumed to be linear in both outcomes, the focus of the analysis can
be moved to the estimation of the expected effectiveness and cost quantities, which can then be
used in Equation 1.4 to easily derive the expected net benefit associated with each treatment
t. In particular, a statistical model p(et, ct | θ) is typically applied to the cost and effectiveness
variables to derive some relevant parameters θ. The model is usually fitted to all treatments
under the assumption that some of the parameters θ are shared between treatment groups. In
principle, however, it is possible to separately fit a model to each treatment to derive treatment
specific estimates for all model parameters, i.e. θ = (θ1, θ2). The interest lies in the population
mean parameters
µet = E [et | θ] and µct = E [ct | θ] . (1.5)
The quantities µet and µct are then used in assessing the relative cost-effectiveness of the inter-
ventions. More specifically, resource allocation decisions are typically based on suitable economic
summaries that compare average differences in ct and et between options. For example, we can
re-express the parameters in Equation 1.5 in terms of the population average increments
∆e = E[e | θ2]− E[e | θ1] = µe2 − µe1
∆c = E[c | θ2]− E[c | θ1] = µc2 − µc1,
(1.6)
where ∆e and ∆c are respectively the average increment in the effectiveness and costs from
selecting t = 2 compared to t = 1. Once the measures in Equation 1.6 are obtained, using the
net benefit as the utility function, it is possible to obtain the Incremental Benefit (IB) of treatment
2 over treatment 1
IB = k∆e −∆c. (1.7)
Notice that, under the Bayesian framework, the quantities (∆e,∆c) in Equation 1.7 are random
variables because, while sampling variability is averaged out, these are defined as functions of
the parameters of the model θ = (θ1, θ2). The second layer of uncertainty (i.e. the population,
parameters domain) can be further averaged out. Thus, according to the net benefit framework,
decision-making can be effected by considering the so-called Expected Incremental Benefit (EIB)
EIB = E[k∆e −∆c] = kE[∆e]− E[∆c]. (1.8)
where, the increment in mean effectiveness and costs (E[∆e],E[∆c]) are actually pure numbers
E[∆e] = e2 − e1 = E[µe2]− E[µe1]
E[∆c] = c2 − c1 = E[µc2]− E[µc1].
(1.9)
In particular, c2 and e2 are the population averages of cost and benefit measures for the reference
treatment, to be assessed against those of the comparator (c1, e1). The quantities in Equation 1.8
and Equation 1.9, in turn, can be used to compute the Incremental Cost-Effectiveness Ratio
(ICER), defined as
ICER =
E [∆c]
E [∆e]
. (1.10)
The ICER represents the cost per incremental unit of effectiveness (e.g. cost per QALY gained)
and provides a ratio summary of the additional cost and benefit that result from one option com-
pared to another. From Equation 1.8 and Equation 1.10, we see that when EIB > 0 and so
k > ICER, then t = 2 is the optimal treatment (associated with the highest expected utility).
Thus, decision-making can be equivalently effected by comparing the ICER to the willingness-to-
pay threshold.
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1.4.2 Cost-Effectiveness Assessment
The two layers of uncertainty underlying the decision-making process, as well as the relation-
ships between benefits and costs, can be best appreciated through the inspection of the Cost-
Effectiveness Plane (CEP; see Black, 1990; Briggs and Gray, 1999; Baio, 2012), shown in Fig-
ure 1.3 which is taken from Baio (2012).
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Figure 1.3: Graphical representation of the CEP under different scenarios. Panels (a) and (b) show the
joint distribution for (∆e,∆c) and the position of the ICER, respectively. Panels (c) and (d) represent the
CEP and corresponding sustainability areas under two alternative choices for k. Source Baio (2012).
The CEP depicts the joint distribution of the random variables (∆e,∆c) on the x and y axis, re-
spectively, and is divided into four quadrants. Depending on where the point (E(∆e),E(∆c)), which
is related to the ICER through Equation 1.10 (i.e. the ICER corresponds to the slope of the line
joining the origin with the point), the CEP can provide a general idea about the cost-effectiveness
of the new intervention with respect to the comparator. For example, when the point associated
with the ICER falls in the north-east quadrant, the intervention generates more health gains but
is also more expensive. Other quadrants are relevant when the intervention generates poorer
health outcomes (north-west or south-west quadrants) or lower costs (south-west or south-east
quadrants). CEPs are also useful to show the uncertainty around model parameters and cost-
effectiveness outcomes, often represented as a cloud of points on the plane corresponding to
different iterations of an economic model, Figure 1.3 (a). Specifically, in the graphs, the samples
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are obtained from the joint posterior distribution of the expected mean effectiveness and costs
using a full Bayesian approach (through MCMC methods, see Section 1.3.1). Taking the expec-
tations over the marginal distributions for ∆e and ∆c, we then marginalise out the uncertainty and
obtain the point (E(∆e),E(∆c)) in the plane which is closely related to the ICER, Figure 1.3 (b).
Figure 1.3 (c) shows the “sustainability area” (Baio, 2012), i.e. the part of the CEP that lies
below the line E[∆c] = kE[∆e], for a given value of the willingness-to-pay k. Interventions for
which the point associated with the ICER is in the sustainability area are more cost-effective than
the comparator. Changing the value for the threshold can modify the decision as to whether t = 2
is the most cost-effective intervention. The target values for k, indicated by NICE for economic
evaluations, usually lie between £20, 000−40, 000 per QALY gain (NICE, 2008). Recently, Claxton
et al. (2015) have also suggested to reduce this generic threshold benchmark value. However, no
agreement has been reached yet as to whether this new threshold should be used and routine
analyses still use £20, 000− 40, 000 as the reference range.
Figure 1.3 (d) shows the sustainability area for a different choice of the parameter k. In this
case, because the ICER and, for that matter, most of the entire distribution of (∆e,∆c) lie outside
the sustainability area, the new intervention t = 2 is not cost-effective.
Theoretically, the identification of the expected utility with respect to both individual variations
and uncertainty in the value of the parameters is all that is needed to reach the best decision given
current evidence. However, when implementing an intervention, decision-makers are typically
faced with the problem of whether to make the decision based on the current evidence or to defer
the decision in order first to gather more evidence. Thus, the decision-process is also subject
to the uncertainty related to the trade-off between the collection of new data, with the aim at
resolving at least partially the current uncertainty about the model parameters, and the sampling
costs associated with the collection of the additional evidence. For these reasons, economic
evaluations are typically subjected to some form of uncertainty analysis to quantify and qualify the
uncertainty underlying the decision problem.
A particular class of analysis that is suited to assess this type of uncertainty is probabilistic
sensitivity analysis (Claxton et al., 2005; Baio, 2012; Baio and Dawid, 2015), which considers all
input parameters as random quantities and assigns them a probability distribution that describes
the associated state of knowledge. Very briefly, the idea behind probabilistic sensitivity analysis is
to compare the actual decision process to the ideal one, characterised by the (currently unknown)
quantities. This is done with a view to assessing whether the information provided by the current
evidence is sufficient to take a decision on the optimal treatment or it would be more effective to
defer the decision until after additional evidence is collected.
A common tool used to summarise the results of probabilistic sensitivity analysis is the Cost-
Effectiveness Acceptability Curve (CEAC; see Van Hout et al., 1994). Using the net benefit as the
utility function, the CEAC can be expressed as
CEAC = Pr(k∆e −∆c > 0) (1.11)
The CEAC depends on the willingness-to-pay parameter k. When Net benefit > 0, i.e. the optimal
decision is treatment t = 2, the CEAC is the probability that learning the value of θ (i.e. resolv-
ing the uncertainty on the parameters) would not change that decision. The main advantage of
Equation 1.11 is to allow a simple summary of the probability of cost-effectiveness upon varying
the willingness-to-pay parameter k. In particular, within a Bayesian approach, the CEAC can be
straightforwardly interpreted as the probability that the intervention t = 2 is cheaper, compared to
t = 1, as k is reduced, and that it is more effective as k increases.
Some limitations about the CEACs have been pointed out since they do not allow explicit for
any possible change in the payoffs. In particular, CEACs are only concerned with currently avail-
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able information, but do not consider explicitly the possibility of gathering additional evidence,
therefore providing only a partial evaluation of the overall decision process (Koerkamp et al.,
2007). Despite their limitations, however, CEACs represent the standard tools used by practition-
ers in trial-based analyses to report the economic results, particulalry for small and pilot trials,
where the objective is to provide a simple summarisation of the probability of cost-effectiveness
of the new interventions to inform the decision about the feasibility of conducting larger trials to
collect more evidence. Since the economic analyses in this thesis will only focus on realtively
small trials (Section 3.1), we will follow the current practice in trial-based analyses which uses
the CEACs as the main tool to summarise the uncertainty about the cost-effectiveness of a given
intervention (NICE, 2013; Ramsey et al., 2015).
Finally, an important and almost inevitable source of uncertainty in trial-based economic evalu-
ations is represented by missingness, as it induces a lower level of information in the data. Missing
data may seriously complicate the analysis due to a potential bias introduction that can affect all
treatment regimens and outcome measures. Handling missingness is a particularly well-suited
task for Bayesian analysis where any unknown quantity (e.g. missing data and parameters) is
attached to a probability distribution that can be used to incorporate in the model some external
information about that quantity which is not contained in the data.
It is therefore essential, within the decision model, to investigate and describe how uncertainty
in all model inputs or parameters (including the missing values) translates in terms of uncertainty
over the model outputs. Indeed, variations in posterior inferences will be an indication of the
impact that this uncertainty has on the inferences and on the decision-making process.
1.5 Missing Data Analysis
There is a large literature on handling missing data. For the purpose of this thesis, we only
introduce some key concepts for missingness analysis and present some of the most popular
methods to deal with missing outcome data in trial-based economic evaluations. For a more
comprehensive discussion on the topic we refer to the handbooks Rubin (1987); Schafer (1997);
Molenberghs and Kenward (2007); Daniels and Hogan (2008); Little et al. (2010); Carpenter and
Kenward (2013); Molenberghs et al. (2015).
The CEA setting is particularly challenging and worthwhile in terms of missing data handling.
First, due to its intrinsic characteristics, CEA deals with a bivariate outcome whose relationships
should be accounted for in the analysis. Thus, specifying and modelling the impact missing data
may have on both outcomes, their dependence structure, and how these are translated in terms of
changes in cost-effectiveness assessments is a major issue. Second, unlike standard statistical
analyses, CEA does not merely focus on estimation purposes but needs to quantify the impact of
missing data uncertainty both on the inferences and decision-making.
When nonrespondents are systematically different from respondents in terms of characteris-
tics or outcomes, biased estimates may result from the (often implicit) formulation of unrealistic
missingness assumptions (Molenberghs and Kenward, 2007). This is particularly likely when the
reasons for missingness are ignored or not properly recorded. As a result, the statistical and
economic analysis will be impaired because assumptions about unobserved data will be forced
by the lack of available information about the missing values. Inferences may be strongly affected
by the method chosen to deal with missingness, with the effect that decisions about the cost-
effectiveness of a new treatment may be totally or partially misrepresented (Manca and Palmer,
2005; Marshall et al., 2009).
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1.5.1 Full Data Models
We denote with yij = (uij , cij) the typical bivariate outcome of trial-based CEAs, formed by the
utility and cost pair collected at time j for subject i. Although, in principle, different groups of
subjects enrolled in a trial could be followed-up at different times, i.e. yij(i) , however, this is not
typically the case for trial-based economic evaluations, where a consistent follow-up is usually
scheduled to ensure that cost and utility data are collected at the same set of occasions for
all subjects in the analysis (Ramsey et al., 2015). Thus, in the following, we will assume that
both economic outcomes are collected at the same time points j = (1, . . . , J) for all subjects
i = (1, . . . , n).
When missingnes occurs at one or more occasions in the study, data are necessarily unbal-
anced over time since there are at least some individuals who have a different number of repeated
measurements at a common set of occasions. This poses a serious problem for the analysis be-
cause nonresponses may occur at any follow-up time and lead to distinct missingness patterns.
Dropout or attrition refers to the specific situation where subjects are observed uninterruptedly
from the beginning of the study until a given point in time, after which they are never observed
again. More generally, a missing data pattern is said to be monotone if missingness is all due
to dropout, i.e. given that yij is unobserved, then yij+1 is also unobserved. When this condition
does not hold, the missing data pattern is said to be nonmonotone or intermittent.
We denote with rij = (ruij , r
c
ij) a pair of indicator variables that take value 1 if the corre-
sponding outcome for subject i at time j is observed and 0 otherwise. Next, we denote with
ri = (ri1, . . . , riJ) the missingness pattern to which subject i belongs, where each pattern is
associated with different values for rij . For example, the pattern r = ((1, 1), . . . , (1, 1)) = 1 is
associated with the set of ones at each occasion and therefore corresponds to the completers
pattern.
Given the set of the responses y and missingness indicators r, the full data model describes
the joint distribution p(y, r | ω), indexed by a finite-dimensional parameter ω. In almost all practical
settings, interest typically lies in drawing inference about some parameters θ that are a subset of
ω and that index the full data response model p(y | θ). The relationship between the two full data
models is
p(y | θ) =
∑
r∈R
p(y, r | ω), (1.12)
where R denotes the sample space of r. Equation 1.12 shows that inference about θ will depend
crucially on choices made in specifying the full data model. These are distinguished between
the choices related to the model for the data and the choices about the missingness assump-
tions. However, while the observed data can be used to validate the modelling choices about the
observed responses, they offer no information to validate choices about the missing data assump-
tions. Thus, either explicit or implicit assumptions about the missing values are needed to identify
the full data model and will generally influence the final inferences about θ.
Before briefly reviewing some of the most commonly used techniques to handle missing data in
CEA, we introduce the key concept of the missing data mechanism, which provides a convenient
setting for the understanding and addressing of missingness.
1.5.2 Missing data mechanism
When analysing partially observed data it is essential to investigate the possible reasons behind
the missingness, which translates into an assumed missing data mechanism that is linked to the
data generating process. An analysis that is able to express and explicitly model this relationship
can address missingness in a “principled way”. We specifically refer to principled methods for
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missing data as those based on a well-defined statistical model for the complete data, and explicit
assumptions about the missing value mechanism.
More formally, we use the term missing data mechanism to refer to the conditional distribution
of the missing data indicators given the full data response p(r | y,ψ), where the parameter ψ is
a subset of ω. Any full data model can be factored as the product of a full data response model
and the associated missing data mechanism
p(y, r | ω) = p(y | θ)p(r | y,ψ). (1.13)
The characterisation of the missing data mechanism through the factorisation in Equation 1.13,
which is commonly referred to as a selection model factorisation, is only one possible representa-
tion. The implied missing data mechanism can, in principle, be derived from any specification of
the full data model, but it may not always take a closed form.
The most accepted classification of missing data mechanisms is given by Rubin (1987) and
is based on three classes, distinguished according to how the probability of missingness in the
missing data mechanism is modelled.
Definition 3.1 Missing Completely At Random (MCAR).
Missing responses are missing completely at random (MCAR) if, for all ψ
p(r | yobs,ymis,ψ) = p(r | ψ), (1.14)
where yobs and ymis indicate the subsets of the response data that are observed and missing,
respectively. Under MCAR there is no systematic difference between partially and fully observed
individuals in terms of the outcome y. In other words, Equation 1.14 assumes that the observed
cases are a representative sample of the full sample. MCAR is a strong assumption that ensures
the validity of any fully-observed data method to any case of partially-observed data. An example
of MCAR is when a sample of patient questionnaires is lost and therefore no data is recorded.
Definition 3.2 Missing At Random (MAR).
Missing responses are missing at random (MAR) if, for all yobs and ψ
p(r | yobs,ymis,ψ) = p(r | yobs,ψ). (1.15)
Under MAR, the partially observed cases are systematically different from the fully observed
cases; crucially, however, the difference is fully captured by yobs. Equation 1.15 is less restrictive
than Equation 1.14 and is therefore considered a more plausible assumption in many situations.
For this reason, MAR is normally considered as the reference assumption for the analysis of
partially observed data. An example of MAR is when an individual is removed from a study as
soon as the value of a specific observed variable falls outside a certain range. Missingness is
therefore under the control of the investigator and is related to some observed components.
The MAR assumption is one component of the ignorability condition, which allows to draw
valid inference about θ in the full data response model based on the likelihood for yobs. More
specifically, missingness is said to be ignorable if the following three conditions hold (Little and
Rubin, 2002): (1) the missing data mechanism is MAR; (2) the parameter ω of the full data model
p(y, r | ω) can be decomposed as (θ,ψ), with p(y | θ) and p(r | y,ψ); (3) the parameters of the
full data response model and missing data mechanism are a priori independent, that is p(ω) =
p(θ)p(ψ) (only required for a Bayesian analysis). When any of the conditions for ignorability is not
satisfied, missingness is said to be nonignorable or informative. Often, this is due to the failure of
the first condition, known as Missing Not At Random (MNAR).
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Definition 3.3 Missing Not At Random (MNAR).
Missing responses are missing not at random (MNAR) if, for some ymis 6= y′mis and ψ
p(r | yobs,ymis,ψ) 6= p(r | yobs,y′mis,ψ), (1.16)
that is, if r depends on some part of the unobserved data, say y′mis, even after conditioning on
yobs. Since we cannot definitely distinguish between MAR and MNAR from the data at hand, the
full data model p(y, r) always requires untestable assumptions about the missing data mechanism
in order to be identified. Thus, model assumptions about p(r | y,ψ) become crucial in that
any assumption on the missingness process cannot be tested from the observed data. The
impossibility of testing Equation 1.16 based on the observed data leads to an extremely important
role played by sensitivity analysis in assessing the robustness of the results across a range of
plausible assumptions about the missingness mechanism. Some examples of these types of
models, typically referred to as “nonignorable models”, will be discussed in Section 1.6.
Since the scope of this section is to provide a broad overview for Rubin’s classification, we
assumed the simplest case where there are no covariate variables x. If these covariates are
fully observed, they can be incorporated in either or both the response and missingness model
in a relatively easy way. However, when there are missing values in x, the task of modelling
missingness becomes more complex as there are potentially as many missingness mechanisms
as the number of partially observed variables considered.
1.5.3 Missing data methods
This section briefly summarises some of the most commonly used methods to handle missing
data in CEA. A review of the methods used in trial-based economic evaluations is presented and
discussed in Chapter 2. Here, we focus our attention on three popular approaches: Complete
Case Analysis, Single Imputation and Multiple Imputation. These are quite well-known methods
used in the CEA literature to deal with missingness.
Complete Case Analysis
One of the popular methods for handling missing data in trial-based CEAs is Complete Case
Analysis (CCA), as shown in recent reviews (Eekhout et al., 2012; Noble et al., 2012; Diaz-Ordaz
et al., 2014a; Hughes et al., 2016; Gabrio et al., 2017; Leurent et al., 2018a). This approach in-
cludes in the analysis only individuals in the completers pattern (i.e. r = 1) and is straightforward
to implement. However, estimates under CCA are inefficient because some of the observations
are discarded and the predictive information contained in the partially observed cases is com-
pletely ignored. In addition, non-negligible rates of missingness on a few variables of interest may
cause large portions of the sample to be discarded and induce a greater loss of efficiency. When
missingness occurs only in y, the condition of validity of CCA corresponds to the MAR condition.
However, the condition for validity of CCA does not fit neatly into Rubin’s classes (White and Car-
lin, 2010) in the important cases when: some covariates in the analysis are partially-observed; or
the outcome is longitudinal. For example, when the focus of the analysis is in some aspect of the
conditional distribution of the response y given some covariate x (e.g. regression coefficients),
then CCA will lead unbiased estimates as long as the distribution of y | x in the completers is
the same as in the target population. This condition does not match exactly the definition of the
Rubin’s classes since it holds when the missingness mechanism is MCAR, but also under certain
MAR and MNAR mechanisms (White and Carlin, 2010). In general, the condition for the validity
of CCA is that missingness is (conditionally) independent of response y. Appendix A.3 provides a
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simple example to show the validity of the estimates derived from CCA under different scenarios
when the interest of the analysis is in some aspect of the conditional distribution of the response
given some partially-observed covariates.
Single Imputation
Single Imputation (SI) methods replace the missing values with a single imputed value. The most
attractive feature of these methods is that, once the imputation is performed, standard methods
for complete data can be used. However, a serious drawback is that they always fail to account
for the uncertainty associated with the missing data. Two of the most popular SI methods are
marginal or conditional mean imputation (Buck, 1960) and Last Value Carried Forward (LVCF;
Kenward and Molenberghs, 2010; Shao and Zhong, 2010).
Likelihood-Based Methods
Under MAR, the marginal distribution of the observed data yobs, also called the observed data
likelihood and denoted with L(θ,yobs), provides the correct likelihood for the parameters θ when
the model fitted to the complete data p(y | θ) is realistic, where y = (yobs,ymis). The logarithm of
this function, called the observed-data log-likelihood
logL(θ,yobs) (1.17)
has a crucial role in estimation. In particular, the maximum likelihood estimate θˆ which maximises
logL(θ,y) tends to be approximately unbiased and highly efficient in large samples (Cox and
Hinkley, 1974). Confidence intervals and regions are often computed by appealing to the fact
that, in regular problems with large samples, θˆ is approximately normally distributed about the
true parameter θ with approximate covariance matrix given by
V (θˆ) ≈ [− logL′(θˆ)]−1, (1.18)
where logL
′
(θˆ) is the matrix of second partial derivatives of Equation 1.17 with respect to the
elements of θ. The matrix − logL′(θˆ) in Equation 1.18, which is often called the “observed in-
formation”, describes how quickly the log likelihood function drops as we move away from the
maximum likelihood estimate.
When the expressions for the maximum likelihood estimates cannot be written down in closed,
iterative computation methods are typically required for estimation. A general method for maxi-
mum likelihood in missing data problems is the so called expectation-maximisation algorithm (Demp-
ster et al., 1977), which proceeds by “filling in the missing data” with a best guess at what it might
be under the current estimate of the unknown parameters, then re-estimate the parameters from
the observed and filled-in data. The process is reiterated until the changes in parameter estimates
between iterations are less than a pre-specified threshold at which point the algorithm is stopped.
In theory, likelihood methods are more attractive than CCA or SI methods as they provide esti-
mates that are generally valid under MAR (Little and Rubin, 2002; Schafer and Graham, 2002).
However, they still rest on a few crucial assumptions. First, they assume that the sample is large
enough for the ML estimates to be approximately unbiased and normally distributed. Second,
the likelihood function comes from an assumed parametric model for the complete data (both
observed and missing).
22
Multiple Imputation
Multiple Imputation (MI) overcomes the problems of single imputation by replacing missing data
with a set of H plausible values, thereby taking into account the uncertainty about the imputa-
tions (Rubin, 1987, 1988, 1996). A common way to represent how MI works is based on three
steps. The first is the Imputation step, where H completed datasets (observed and imputed data)
are created to express the uncertainty about the imputed values. Then, in the Analysis step, the
H completed datasets are analysed with some statistical method to produce H different sets of
parameter estimates. Finally, in the Combination step, the results from the H different analyses
are combined into a single estimate.
The main idea behind MI is that each imputed data set is not considered as the true completion
of the actual data, as in SI, but instead they are used jointly to produce valid inferences. Rubin’s
rules (Rubin, 1987) are typically used to obtain an estimate of the mean (θMI) and variance (VMI)
of the parameters of interest across the H imputed datasets. These are typically computed as
θMI =
1
H
H∑
h=1
θh and VMI = V¯ +
(
1 +
1
H
)
B, (1.19)
where the mean estimate θMI is obtained as a simple average of the H separate parameter
estimates θh, while the variance estimate VMI is derived as a specific combination of two com-
ponents. The first component, V¯ =
∑K
h=1
Vh
H , is the average of the within-imputation variance
estimates for all the H imputed data sets. V¯ does not account for the implied correlation in the im-
puted data. The second component, B =
∑H
h=1
(θh−θMI)2
(H−1) , is the overall between-imputation vari-
ance estimate, reflecting the uncertainty due to missing data captured by the imputation process.
The more we expect the imputed data sets to differ from each other, the greater the between-
imputation variance estimate should be.
Originally, a small number of imputations (roughly 10) was recommended to achieve suffi-
ciently realistic estimates for the quantities in Equation 1.19 (Rubin, 1987), but nowadays this
number can be greatly increased at a limited computational cost. The increased availability of
functions that allow the implementation of MI in standard software packages (e.g. STATA or R;
see Van Buuren and Groothuis-Oudshoorn, 2011), with limited customisation from the user, in
combination with the lack of expertise and understanding about MI may have lead to some un-
supervised used of these methods, as noted by Molenberghs et al. (2015). Recently, guidelines
and recommendations have started to appear in the CEA literature to move practitioners towards
a more critical approach to the implementation of MI and other imputation methods (Faria et al.,
2014; Diaz-Ordaz et al., 2014a; Leurent et al., 2018a), but these require further development in
order to be incorporated into the current practice.
On the one hand, MI generally allows the inclusion of a larger number of variables/predictors
in the imputation model than used in the analysis model, which potentially makes the assumption
of MAR more plausible and thus the overall analysis less likely to be biased. On the other, the
performance of MI depends on the correct specification of the imputation model (i.e. complexity
in the analysis model is reflected in the imputation model) and care is required in its construction.
When there is a mismatch between the imputation model and the analysis model, often referred
to as “non-congeniality”, the final results may be biased (Van Buuren and Groothuis-Oudshoorn,
2011; Carpenter and Kenward, 2013). This situation occurs when modelling choices made in
performing imputation are not compatible with those that will be made in the ultimate analysis of
interest. Examples include the use of inappropriate distributions for the imputation of the data
and omission of covariates or random effect terms in the imputation models which, instead, are
included in the analysis model. In all these cases the relationships between the variables in the
analysis are misrepresent and may lead to biases in the estimates of association, e.g. Rubin’s
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variance rules in Equation 1.19 (Molenberghs et al., 2015)
MI is commonly available in many statistical software packages using different approaches.
Perhaps, the most popular version of MI is the one known as chained equations, which imputes
missingness using appropriate univariate regression specifications for each variable included in
the imputation model. Multiple imputation using chained equations can simultaneously handle
issues about an appropriate scaling and modelling of the data distributions together with the in-
corporation of non-linear terms in the univariate models. An alternative version of MI is known
as joint modelling and is based on the construction of a joint model for the complete data where
missing values are iteratively sampled from proper conditional distributions. In CEA, an example
of multiple imputation using joint modelling has been recently proposed to handle multilevel struc-
tures in the data through a flexible parametric approach (Gomes et al., 2013; Diaz-Ordaz et al.,
2016).
1.6 Nonignorable Models
In the presence of missingness, identification of a full data response model p(y | θ) requires
making unverifiable assumptions about the full data model p(y, r | ω), with θ a subset of ω.
When the assumptions for ignorability are believed to be unrealistic, a more general class of
models that allow missing data indicators to depend on the missing responses themselves can be
used. These models are called nonignorable models and allow to parameterise the conditional
dependence between r and ymis given yobs. This association structure can only be identified
through some untestable assumptions about ymis.
The Bayesian approach is well-suited to handle missingness, particularly under a nonignor-
able modelling framework. More specifically, assumptions about the missing values can be easily
incorporated in a Bayesian model using informative prior distributions, which can be elicited using
sources external to the data. Inferences are derived based on the information from the avail-
able data and the missingness assumptions specified, with uncertainty that is fully propagated
throughout the model. Then, the sensitivity of the results to alternative assumptions (i.e. using
different priors) and their impact on the final results can be easily assessed in terms of variations
in the posterior quantities of interest.
There are different types of nonignorable models, typically distinguished based on the fac-
torisation used to identify the full data model. Three popular techniques are the Selection Mod-
els (Heckman, 1979; Diggle and Kenward, 1994; Mason et al., 2012b), Shared Parameters Mod-
els (Wu and Carroll, 1994; Hogan and Laird, 1997) and Pattern Mixture Models (Little, 1993, 1994;
Daniels and Hogan, 2008). The general intuition and a summary of the potential advantages and
disadvantages of each of these nonignorable approaches are now briefly presented.
Selection Models
The selection model approach factors the full-data distribution as
p(y, r | ω) = p(y,θ)p(r | y,ψ), (1.20)
so that the full-data response model p(y,θ) and the missing data mechanism p(r | y,ψ) must
be specified by the analyst. Equation 1.20 can be attractive because it directly specifies the full-
data response distribution and because its factorisation appeals to the missing data taxonomy
described in Section 1.5.2, which allows an easy characterization of the missing data mecha-
nism. However, an important downside of selection models is that identification of the missing
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data distribution is accomplished primarily through parametric assumptions about the full-data re-
sponse model p(y,θ) and the explicit form of the missing data mechanism (e.g. linear in y). This
could lead to the situation where selection models allow the parameters indexing the association
between r and the partially-observed y (i.e. ψ) to be identified from the observed data. Thus, this
feature of the models places considerable importance on assumptions that cannot be verified,
and has the potential to make sensitivity analysis problematic.
Shared Parameter Models
Shared parameter models specify the full data distribution using an explicitly multilevel formulation,
where some random effects b are modelled jointly with y and r. The general form of the full-data
model using a shared parameter approach is
p(y, r | ω) =
∫
p(y, r, b,ω)db, (1.21)
Alternative specifications are formulated by making different assumptions about the joint distribu-
tion under the integral sign. Notice that in Equation 1.21 the full-data parameter ω also includes
parameters indexing the distribution of the random effects. The main advantage of shared param-
eter models is their simplified specification for the response and missingness components and
the possibility of handling multilevel response data in a relatively easy way. However, a critical
disadvantage is that the underlying missing data mechanism can be difficult to understand and
may not even have a closed form (i.e. it requires the integration over b).
Pattern Mixture Models
Pattern mixture models factor the full data model as
p(y, r | ω) = p(y | r,η)p(r | λ), (1.22)
where η and λ respectively index the two factors in Equation 1.22. To notice that, the decompo-
sition of ω = (θ,ψ) used in Section 1.5.2 refers to a selection model factorisation of the full-data
model (Equation 1.20), while the partition ω = (η,λ) is based on the pattern mixture model fac-
torisation and the two are therefore not equivalent.
The full data response model can be derived as a mixture
p(y | η,λ) =
∑
r∈R
p(y | r,η)p(r | λ). (1.23)
Pattern mixture models essentially specify a different distribution for each missing data pattern
and retrieve the full data response model by marginalising over r. The main advantage of these
models is to make explicit the parameters that cannot be identified by the observed data. There
are two potential downsides of pattern mixture models. First, the full data response model is not
directly available and must be retrieved through Equation 1.23. Second, the implementation of
these models may become cumbersome: as the dimension of y increases, so will the dimension
of the unidentified parameters.
Although all three types of nonignorable models can be used to explicitly handle missingness
under MNAR, the choice of which approach to use is typically guided by the specific objective
of the analysis and context analysed. In particular, the focus of this thesis is on the factorisation
of pattern mixture models and how it can be used to assess the sensitivity of the inferences to
alternative nonignorable assumptions. Specifying a different distribution for each missing data
pattern may seem cumbersome, but it has the advantage of making explicit the parameters that
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cannot be identified by the observed data. These parameters, often called “sensitivity parameters”
(see Section 1.6.3) make a suitable basis for formulating sensitivity analysis and for identifying
the conditional distribution of missing responses using informative prior distributions; in general,
mixture models lend themselves well to parameterisations having these properties.
When missingness is monotone it is possible to summarise the patterns by dropout time and
directly model the dropout process (Daniels and Hogan, 2008; Gaskins et al., 2016). In addition,
for monotone patterns, a precise definition of the MAR condition exists, requiring that that the
marginal probability of dropping out at a specific time j cannot depend on measurements at or
beyond j (Molenberghs et al., 1997). However, when missingness is non-monotone, the plausi-
bility and appropriateness of the MAR/ignorability assumption has been debated in the literature.
Robins and Gill (1997) and Vansteelandt et al. (2007) argued that a specific MAR condition for
non-monotone missingness patterns implies the existence of MAR missingness mechanisms in
different portions of the data. Nevertheless, due to the precise way in which this must occur in
order for the MAR condition to jointly hold for all patterns, the “natural missing data processes”
for non-monotone missingness patterns, especially within a longitudinal framework, will typically
be MNAR. The general definition of the MAR condition and the ignorability assumption provided
in Section 1.5.2 offer a natural starting point for an analysis of partially-observed data even if, es-
pecially for non-monotone patterns, they are unlikely to hold precisely. This is why in longitudinal
applications, precise discussions over the MAR mechanism are usually of secondary interest with
respect to including appropriate (relatively) fully observed variables which can be used to improve
the estimate of the distribution of the missing data given the observed data (Molenberghs et al.,
2015).
When missingness is non-monotone and the data are sparse, alternative strategies for identi-
fying the distribution of the missing data can be used. Linero and Daniels (2018) provide a review
of these approaches, which are now briefly presented.
Permutation missingness. A first approach, proposed by Robins and Gill (1997), is the class
of permutation missingness models. Let yj = (y1, . . . ,yj) and y˜j = (yj+1, . . . ,yJ) denote
the history of the response up to time j and the future of the response strictly after time
j, respectively. Thus, the full response data vector can be expressed as y = (yj , y˜j), and
similarly for the missingness indicator vector r = (rj , r˜j). Let also oj and o˜j denote the
observed data (including the rj) up to time j and the observed data strictly after time j. The
permutation missingness model assumes:
p(rj | y, r˜j) = p(rj | yj−1, o˜j),
possibly after applying an a priori known permutation to y. In words, these models assume
that missingness at time j can depend on the “past” and the “observed future”, but not on
the present, where the notion of time is determined by the given permutation.
Sequential explainability. Vansteelandt et al. (2007) proposed the sequential explainability re-
striction, which assumes
p(yj | oj , rj = 0) = p(yj | oj , rj = 1),
that is, it assumes that the observed responses prior to time j are sufficient to predict
whether or not a subject will be measured at time j, while the outcome at time j is not
predictive.
Nearest identified pattern. Linero (2017) introduced the nearest identified pattern restriction,
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which assumes
p(yj | rj ,y) = p(yj | r?j ,y),
where, r?j corresponds to rj but with the j−th component fixed at 1. The model assumes
that, conditional on all other observed quantities being equal, missingness at time j is not
predictive of the response at time j.
Itemwise conditional independence. Sadinle and Reiter (2017) proposed the itemwise condi-
tional independence assumption
p(yj | rj = 0, r−j ,y−j) = p(yj | rj = 1, r−j ,y−j),
where, r−j and y−j denote the full vectors r and y with the j−th component removed. The
model assumes that, conditional on all other quantities (both observed and unobserved)
being equal, missingness at time j is not predictive of the response at time j.
Pairwise missing at random. Tchetgen Tchetgen et al. (2016) introduced the pairwise missing
at random restriction
p(yj | rj = 0,y) = p(yj | r = 1,y),
which assumes that the distribution of the missing values of a subject at each time j can be
approximated using the observed response at time j of an equivalent subject who was ob-
served at all measurement times (i.e. a completer). Linero and Daniels (2018) showed that
pairwise missing at random is an extension of the complete case missing value restriction
(defined for monotone missingness) to non-monotone missingness.
All these classes of restrictions are phrased in terms of conditional independence relation-
ships which, however, are not themselves particularly plausible when yj is thought to directly
influence rj . Indeed, these assumptions are not used because the conditional independences
they suggest are believed to hold, but rather they are only used as benchmark assumptions from
which alternative non-ignorable departures can be explored in sensitivity analysis. Because of
this, an alternative and more intuitive modelling strategy which can handle both monotone and
non-monotone missingness patterns, based on the so-called extrapolation factorisation, is now
introduced.
1.6.1 Extrapolation Factorisation
The full data model p(y, r | ω) can be expressed as
p(y, r | ω) = p(yrobs, r | ωO)p(yrmis | yrobs, r,ωE), (1.24)
where ωE and ωO are (possibly overlapping) subsets of ω, while yrobs and y
r
mis indicate the ob-
served and missing responses within pattern r, respectively. Equation 1.24 (Linero and Daniels,
2015) is often called the extrapolation factorisation and factors the joint distribution in two com-
ponents. The observed data distribution p(yrobs, r | ωO) is completely identified by the data, while
the extrapolation distribution p(yrmis | yrobs, r,ωE) remains unidentified by the data in the absence
of unverifiable assumptions about the full data (Daniels and Hogan, 2008).
To specify the observed data distribution p(yrobs, r | ωO) a possible strategy is to use a working
model p? (Linero and Daniels, 2015) for the joint distribution of the response and missingness
p(yrobs, r | ωO) =
∫
p?(y, r | ω)dymis. (1.25)
27
Since p? is used only to obtain a model for p(yrobs, r | ωO) and not as a basis for inference,
the extrapolation distribution is left unidentified. Thus, any inference depending on the observed
data distribution may be obtained using Equation 1.25 as the true model, with the advantage that
it is often easier to specify a model for the full data compared with a model for the observed
data. In principle, any factorisation can be used to specify p(yrobs, r | ωO). For example, we
can use the factorisation of pattern mixture models, which lend themselves particularly well to
parameterisations based on the extrapolation factorisation.
This modelling approach is particularly appealing for handling missingness because the pa-
rameters of the extrapolation distribution cannot be identified from data and make therefore a
suitable basis for conducting sensitivity analysis. Typically, the values of these parameters are ar-
bitrarily set or informative priors (under a Bayesian framework) are used to assess the robustness
of the inferences to plausible variations.
1.6.2 Sensitivity Analysis
Exploring the sensitivity of the results with respect to different missingness assumptions is a
crucial task in any analysis that deals with partially-observed data.
Sensitivity analysis represents an extremely valuable tool to deal with the uncertainty induced
by missingness. Formally, sensitivity analysis is a technique used to determine how different in-
put values in a model will impact the output, under a given set of assumptions. When applied
to missing data, sensitivity analysis corresponds to exploring plausible missing data assumptions
and assessing how consistent results are across different scenarios. The degree to which con-
clusions (inferences) are stable across these scenarios provides an indication of the confidence
that can be placed in the results.
Bayesian methods are particularly well-suited for conducting sensitivity analysis by specifying
alternative prior distributions to encode different assumptions about missingness. In addition, the
full propagation of the uncertainty in a Bayesian model allows to easily assess and quantify the
impact of these assumptions on the posterior results.
In principle, sensitivity analysis can be implemented in any type of nonignorable models, but
the nature and interpretation of the assessment changes according to the specific features of
each approach. Here, we focus on the extrapolation factorisation, where the separation between
the parameters that are identified and those that cannot be identified by the observed data offers
a convenient framework for conducting sensitivity analysis.
1.6.3 Identifying Restrictions and Sensitivity Parameters
Recall that the full data distribution can be factored into an extrapolation distribution p(yrmis |
yrobs, r,ωE) and an observed data distribution p(y
r
obs, r | ωO), where ωE and ωO denote the pa-
rameters indexing the two distributions. In general, the extrapolation distribution can be identified
through identifying restrictions and informative priors on the parameters of the distribution of the
missing responses, typically called sensitivity parameters.
Identifying restrictions correspond to assumptions about p(y, r), which link the observed data
distribution p(yrobs, r | ωO) to the extrapolation distribution p(yrmis | yrobs, r,ωE). According to
the way the two factors are linked, different types of restrictions can be used. For example,
the complete case missing value restriction identifies the full data distribution by equating the
extrapolation distribution to the distributions of the completers p(y | r = 1,ωC), indexed by the
parameters ωC ⊂ ωO. We refer to Daniels and Hogan (2008) for a comprehensive review of the
most popular classes of identifying restrictions.
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It is common practice to specify a single identifying restriction as a benchmark assumption and
consider interpretable deviations from that benchmark to assess how inferences are driven by our
assumptions (Wang and Daniels, 2011). When identification of the joint p(y, r) is not required,
e.g. if the interest lies only on some parameters rather than the entire distribution, then partial
identifying restrictions (Linero and Daniels, 2018) can be used to identify the distribution only up
to the specific parameters of interest.
Identifying restrictions are often combined with sensitivity parameters to conduct sensitivity
analysis to MNAR assumptions. These parameters are generally not identifiable from the ob-
served data but, when their values are fixed, the full data model is identified. To illustrate this
nonignorable strategy we consider the example of the mixture model p(y | r) ∼ Normal(µr,Σr),
where µr and Σr are the mean vector and the variance matrix of y in each pattern r, respec-
tively. For the purpose of this example, we assume that the variance matrix is common across the
patterns Σr = Σ and that it can be identified from the data.
We assume that only dropout missingness occurs and that the only missing responses are
those at the last follow-up, i.e. ymis = y
r 6=1
J . Within this setting, ωO = (µ
r
1 , . . . ,µ
r
J−1,µ
r=1
J ,Σ) and
ωE = µ
r 6=1
J are the sets of parameters indexing the observed data and extrapolation distributions,
respectively. Using the complete case missing value restriction, we identify ωE using the subset of
ωO related to the corresponding parameters that index the completers ωC = µr=1J . This amounts
to assuming a very informative (point mass) prior:
p(ωE | ωO) = I{ωE = ωC}, (1.26)
where ωC ⊂ ωO. Identifying restrictions typically impose very restrictive assumptions about the
parameters of the extrapolation distribution and fail to characterise the missingness uncertainty.
However, Equation 1.26 provides a useful framework for incorporating some sensitivity parame-
ters.
More generally, we can reparameterise the model in terms of ξ(ω) = (ξS, ξM), where ξM are
the parameters fully identified from the data while ξS are the sensitivity parameters. Daniels and
Hogan (2008) provide a formal definition of sensitivity parameters, which must satisfy specific
conditions. Consider a full data model p(y, r | ω) and its extrapolation factorisation as in Equa-
tion 1.24. Let ξ(ω) = (ξS, ξM) denote a reparameterisation of the full data parameter ω such that:
1) ξS is a nonconstant function of ωE; 2) the observed data distribution is a constant function of
ξS; 3) at a fixed value of ξS, the observed data distribution is a nonconstant function of ξM. Then,
when all these three conditions are satisfied, ξS is a sensitivity parameter.
The use of a pattern mixture approach allows a straightforward incorporation of ξS through
the reparameterisation of the full data parameter ω = (ωO,ωE) as ξ(ω) = (ξS, ξM). For example,
in the mixture model considered before, the parameters indexing the observed data distribution
correspond to those fully identified from the data (ωO = ξM) while the parameters indexing the
extrapolation distribution can be identified using the sensitivity parameters (ωE = ξS). Then,
within the framework of Equation 1.26, ξS can be expressed as a function of ωC ∈ ωO and some
redundant parameters δ
ωE = ξS = ωC + δ, (1.27)
whose value must be specified according to the specific missingness assumptions made in the
given context. Thus, Equation 1.27 provides a convenient framework to incorporate ξS into the
model, where the robustness of the results to departures from a benchmark assumption, e.g. ξS =
ωC, can be easily assessed through the specification of alternative values of δ. Essentially, ξS are
parameters that index the extrapolation distribution which cannot be identified by the observed
data and provide a framework for assessing sensitivity of model-based inferences to assumptions
29
about the missing data mechanism.
In a frequentist setting, a possible approach to incorporate ξS into the model is the so-called
“delta-shift” method, which corresponds to adding/subtracting a constant value to the imputed
data (for example obtained through MI) under a benchmark missingness assumption, typically
MAR (Leurent et al., 2018b). This approach approximately corresponds to a degenerate Bayesian
analysis which assumes a point mass prior on ξS, with uncertainty about the sensitivity param-
eters that can be captured by repeating the analysis for a fixed set of values for the sensitivity
parameters. By contrast, in a Bayesian framework, uncertainty about ξS is typically captured us-
ing proper probability distributions, whose impact on the inferences is available in terms of the
variations observed in the posterior quantities of interest. This would allow to specify a joint prior
on the sensitivity parameters to account for the possible dependence among ξS while explor-
ing some plausible missingness departures, which should be defined according to the available
information (e.g. expert opinion).
1.6.4 Specifying Priors on the Sensitivity Parameters
Prior distributions on the sensitivity parameters should be constructed in order to reflect uncer-
tainty about the missing data assumptions within the context analysed. A common approach is
to anchor full data models at a benchmark assumption (e.g. MAR), which typically coincides with
a fixed point in the range of plausible values of the sensitivity parameters ξS. Inference under
MNAR is then assessed in terms of departures from this benchmark scenario.
Given the reparameterisation ξ(ω) = (ξS, ξM), the priors on ξS are typically specified in terms
of the parameters identified by the observed data ξM and some redundant parameters δ that ex-
plicitly capture the departures from the benchmark. More specifically, given a one-to-one function
h(ξM, δ), the sensitivity parameters can be re-expressed as (Daniels and Hogan, 2008)
ξS = h(ξM, δ), (1.28)
where δ captures the information about the missing data mechanism. The quantity in Equa-
tion 1.28 is typically anchored to a benchmark by setting δ equal to some value δ0 (e.g. δ0 = 0).
This corresponds to assuming a point mass prior at δ0 which encodes a particular missingness
assumption with certainty.
Alternatively, priors that convey uncertainty about the missing data mechanism δ ∼ p(δ?) can
be specified, where δ? are the hyperparameters of the non-degenerate priors on δ. Typically,
values for δ? are informed by a credible source of external information, such as expert opinion if
available, or calibrated on the observed data to obtain a range of plausible departures from the
benchmark. The Bayesian framework is ideal for this task as it allows to quantify uncertainty about
missing data assumptions through these priors.
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Key points of this chapter:
• Trial-based economic evaluations are an important source of evidence for
decision-makers to inform the decision about the funding or reimbursement of new
healthcare technologies. Analyses typically compare alternative options in terms
of some measures of effectiveness and costs that are collected for each partici-
pant at different time points in the study. These measures are then summarised
into cross-sectional quantities (e.g. QALYs) on which the analysis is performed.
• Bayesian methods are well-suited to addressing decision-making problems, such
as that in economic evaluations. By taking a probabilistic approach, based on
decision rules and available information, they can explicitly account for both sam-
pling and parameter uncertainty in the decision process and obtain an “optimal”
decision output.
• Trial-based outcome data are almost invariably affected by missingness, which
considerably complicates the task of the analyst as assumptions about the unob-
served values cannot be checked from the data. Most of the missing data methods
in the CEA literature typically rely on ignorability of the missing data mechanism as
the default assumption when drawing inference. However, this cannot be verified
from the observed data and plausible nonignorable departures should be explored.
• Nonignorable models are typically specified using some factorisation of the full
data model. Pattern mixture models can be used in combination with the extrap-
olation factorisation as a particularly appealing way to model nonignorable miss-
ingness. It allows to separately fit a model to the observed data and identify the
distribution of the missing data through suitably-defined identifying restrictions and
sensitivity parameters. The Bayesian approach naturally allows the implementa-
tion of sensitivity analysis through the incorporation of external information into the
model though informative priors on the sensitivity parameters.
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Chapter 2
Literature Review
In this section we present the results of a focused 2 literature review that assesses the quality
of the information reported and type of methods used to handle missing outcome data in trial-
based economic evaluations. Recent reviews on missing data methods in within-trial CEAs (Noble
et al., 2012; Diaz-Ordaz et al., 2014a; Hughes et al., 2016; Leurent et al., 2018a) concluded
that CCA has historically represented the standard approach, but transparent information about
missingness has rarely been provided to justify its use.
The purpose of this review is to critically appraise the current literature in within-trial CEAs with
respect to the quality of the information reported and the methods used to deal with missingness
for both effectiveness and costs. The review complements previous work (Noble et al., 2012),
covering 2003-2009 (88 articles) with a new review, covering 2009-2015 (81 articles) and focuses
on two perspectives.
First, we provide guidelines on how the information about missingness and related methods
should be presented to improve the reporting and handling of missing data. We propose to ad-
dress this issue by means of a quality evaluation scheme, providing a structured approach that
can be used to guide the collection of information, formulation of the assumptions, choice of meth-
ods, and considerations of possible limitations for the given missingness problem. Second, we
review the description of the missing data, the statistical methods used to deal with them and the
quality of the judgement underpinning the choice of these methods. A synthesised version of this
chapter in the form of a research article is published in PharmacoEconomics-Open.
2.1 Quality Evaluation Scheme
In order to judge whether missing data in CEAs have been adequately handled, we assembled
guidelines from previous review articles (Wood et al., 2004; Noble et al., 2012; Faria et al., 2014;
Diaz-Ordaz et al., 2014a) on how information relating to the missing data should be reported (Ta-
ble 2.1). In particular, we defined three broad components of the analysis that are related to the
description of the missingness problem (Description), details of the methods used to address it
(Methods) and a discussion on the uncertainty in the conclusions resulting from the missingness
(Limitations). For each component, information that is considered to be vital for transparency is
listed under “key considerations”, while other details that could usefully be provided as supple-
mentary material are suggested under “optimal considerations”.
2A focused or trageted review is similar to a systematic literature review in that it uses explicit methods to identify,
select, critically appraise some key relevant research question. However, this approach is less comprehensive than a
systematic review since the focus is on key (rather than exhaustive) research questions, and is typically performed by a
single reviewer (Moher et al., 2015; Huelin et al., 2015)
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Description
Key considerations
1. Report the number of individuals
with missing data for each variable
in the reported analysis by
treatment group.
2. Describe the missing data patterns
for all variables included in the
economic analysis (is missingness
on one variable associated with
missingness on another variable?,
is there a longitudinal aspect to the
data?)
3. Discuss plausible reasons why
values are missing (e.g. death).
Optimal considerations
1. Provide supplementary material
about the preliminary analysis on
missingness (e.g. descriptive plots
and tables)
?For example, in Multiple Imputation, state the imputation model specification and variables included, the number of imputations,
post imputation checks.
Method
Key considerations
1. Identify a plausible missingness
assumption for the specific patterns
and setting analysed.
2. State the method and software
used in the base-case analysis.
3. For more general methods provide
details about their implementation ?
4. Perform a plausible robustness
analysis; provide and discuss the
results.
Optimal considerations
1. Provide supplementary material
about the method implementation
in the base-case and robustness
analysis (e.g. software
implementation code)
Limitations
Key considerations
1. Acknowledge and quantify the
impact of the missing data on the
results.
2. State possible weaknesses and
issues with respect to the method
and assumptions.
Table 2.1: List of the information content for each of the three components that we would like to observe
in the studies in order to achieve a full reporting of the missing data analysis. The contents are divided
into two subgroups: key and optimal considerations. The former are mandatory for transparency in the
presence of missing data while the latter are additional considerations that can be provided.
Using the list of key considerations in Table 2.1, we determine whether null (all key consid-
erations absent), partial (one or more key considerations absent) or full (all key considerations
present) information has been provided for each component. The set of key considerations is
defined to ensure a full assessment of the impact that missingness may have on the final con-
clusions of the analysis with respect to all three components. However, providing a certain level
of information on one component (e.g. full information on Description) typically has a different im-
pact on the results with respect to providing the same level of information on another component
(e.g. full information on Limitations).
Based on this, we suggest computing a numerical score that weights each component by
the impact that it may have on the final results to summarise the overall information provided on
missingness. Table 2.2 shows the proposed scores for each of the three components by level of
the information content.
XXXXXXXXXXContent
Score Description Method Limitations
Full (F) 6 4 2
Partial (P) 3 2 1
Null (N) 0 0 0
Table 2.2: Numerical scores associated with the level of the information content (Full, Partial or Null)
provided in each of the three components (Description, Method and Limitations). The level of information
content is defined according to the number of key considerations satisfied for each component (Table 2.1).
The scores are computed by weighting the components using a ratio 3:2:1 (Description, Method and
Limitations).
Different score values are calculated based on whether full, partial or null information content
is provided in each component and by weighting the three components in a ratio of 3:2:1 (De-
scription: Method: Limitations). This weighting scheme has been chosen according to the impact
that each component is likely to have on the final conclusions based on assumptions that we
deemed to be reasonable. Specifically, the Limitations component typically has the least impor-
tance among the three because of its limited impact on the conclusions. In the same way, the
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Description component has potentially a higher impact on the results than the Method component
as it generally drives the choice for the initial assumptions about the missingness.
Finally, the relevance of the scores in terms of decision analysis is mainly associated with a
qualitative assessment of the articles. Therefore, we suggest converting the scores into ordered
grades (A-E) to evaluate the studies based on the overall information reported on the handling of
the missing data. Studies that are graded in the top categories should be associated with a higher
degree of confidence in their results, whereas more caution should be given in the consideration
of results coming from studies that are graded in the bottom categories. When qualitatively as-
sessing the articles, the different grading assigned to each of them could be an indication of a
lack in the robustness of the conclusions provided due to missingness uncertainty. The complete
list of the grades (and the associated scores) can be interpreted as follows:
A (12) The highest quality judgement, identified by the upper thicker blue path in Fig-
ure 2.1, including only those studies that simultaneously provide all the key con-
siderations for all the components. It is the benchmark for a comprehensive expla-
nation and justification of the adopted missing data method.
B (9-11) Includes studies providing full details for either the description or the method and
at least partial information for the other components. Studies with no information
about the limitations are only included in this category if full detail is provided for
both the other components.
C (6-8) Studies for which information about missingness is not well-spread across the
components. All key considerations are provided either for the description or the
method, but with only a partial or no content in the other components. Alternatively,
we can have partial content for description and method, and partial or full content
for limitations.
D (3-5) Indicates a greater lack of relevant information about missingness. Despite pos-
sibly including key considerations on any of the components, the information pro-
vided will at most be partial for the description in which case it will be combined
with a total lack of content on either the method or the limitations.
E (0-2) The worst scenario where the overall information about the missing data is con-
sidered to be totally unsatisfactory. No description is given and we can observe at
most only some of the key considerations for the method.
With respect to the quality assessment of the studies, the aggregation of the quality scores on
the components of the analysis (Description, Method and Limitations) into ordered grades could
lead to some loss of information compared with the direct use of the quality scores on each
component. However, merging the scores into a fewer number of categories ensures a relatively
easy comparison of the quality of the information provided across the three analysis components
and provides a useful indication about the different degree of confidence to assign to the results
obtained by each study.
Figure 2.1 shows a visual representation of the grade (and score) assignment in the quality
evaluation scheme. Although the importance between the different components is subjective, the
chosen structure represents a reasonable and relatively straightforward assessment scheme.
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Figure 2.1: Diagram representation for the quality score grades (E-A) based on final scores (0 - 12).
Branches colour represents the different way information can be provided: Red=Null information (N),
Light Blue=Partial information (P), Blue=Full information (F).
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2.2 Review
Noble et al. (2012), reviewed the methods used to handle missing cost measures in 88 articles
published during the period 2003-2009. The review is extended to include missing effects, while
using the same strategy to identify papers in the subsequent period, 1 April 2009 to 31 December
2015. A list of all the articles reviewed is available in Appendix E.
The choice of the on-line databases from which to extract the articles and the eligibility criteria
used to select the studies to include in the review for the period 2009-2015 were based on those
used by Noble et al. (2012). This would ensure a fair comparison of the conclusions based on the
articles between the two periods of the review. The search engines of three on-line full-text journal
repositories were used: 1) Science-Direct.com, 2) bmj.com, and 3) The Database of Abstracts
of Reviews of Effects and NHS Economic Evaluation Database. The searches of the databases
identified 1129 articles most of which were duplicates. After abstract review, 128 articles were
considered, of which 81 fulfilled the eligibility criteria.
Articles were considered eligible for the review only if they were cost-effectiveness analyses
within RCTs, used individual patient-level data and mentioned missing data in the text. The key
words used in the search strategy were (cost effectiveness OR economic evaluation) AND
missing data AND trial AND (randomised OR randomized). One author examined the abstract
of each article and any article that was not an economic evaluation of a randomised controlled
trial was excluded, as were articles that did not use individual patient data. Data were recorded
on an Excel spreadsheet by one author. Data were extracted on type of economic evaluation.
The following information was also extracted for those articles, which were cost-effectiveness
analyses of randomised controlled trials that used individual patient data: the methods of dealing
with missing cost and effect data, the year of publication, the number of complete cases used in
the cost-effectiveness analysis and the overall sample size.
The articles reviewed for the two periods are presented and compared by type of analysis
performed. First, the base-case methods are considered, i.e. those used in the main analysis.
Second, any alternative methods in these analyses are discussed; when present, these assess
the robustness of the results obtained in the main analysis against departures from the initial
assumptions on missingness.
2.2.1 Base-case Analysis
The numbers of reviewed articles using a different base-case method are displayed in Figure 2.2.
In the graphs, the methods associated with the largest number of articles for both outcomes
between 2003-2009 and 2009-2015 are denoted with red (CCA) and blue (MI) bars, respectively.
As shown in Figure 2.2 (a), Noble et al. (2012) found that CCA was the most popular base-
case method, used in 31% of the papers; 23% were unclear about the technique adopted. Different
single imputation methods were adopted; among the most popular, mean imputation and condi-
tional imputation were used in 10% and 9% of the articles respectively. MI was found in 9% of the
articles. Our analysis of the methods for missing effectiveness measures shows a similar pattern
in Figure 2.2 (c). CCA was used in 27% of the cases and with a sizeable proportion of papers
unclear about the technique adopted (24%). Single imputation methods are here dominated by
last value carried forward (10%), while a slightly higher proportion uses MI (15%).
In 2009-2015, MI replaces CCA as the most frequently used base-case method in both costs
and effects, at 33% and 34% respectively – Figures 2.2 (b) and 2.2 (d). However, CCA is still the
method of choice in many papers (15% for costs and 21% for effects). The proportion of papers
that are unclear about the chosen method is similar over the two time periods for costs, but it
is reduced by 50% in the later period for effects. This may be due to the fact that, in general,
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clinical effectiveness measures and the estimate of treatment effect are typically the main focus
of the analyses, whereas costs are less frequently included as a primary outcome in the study
research questions. This will in turn translate into a more careful and reasoned examination of
the missingness problem in the effect compared to the cost analysis.
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Figure 2.2: Review of the base-case methods used to handle missing cost and effect data between 2003-
2009 and 2009-2015. Legend: Complete Case Analysis (CCA), Last Value Carried Forward (LVCF), Lin-
ear Extrapolation (Lin Ext), Mean Imputation (Mean), Conditional Imputation (Cond), Multiple Imputation
(MI), any other method present in less than 4 articles (Others), unspecified method (Unclear). The num-
bers to the right of the bars in the graphs are the number of papers including the corresponding method
in the base-case analysis.
2.2.2 Robustness Analysis
With the term “robustness analysis” we refer to any analysis using different missing data methods
compared to those in the base-case analysis, which is implemented without an appropriate justifi-
cation, and which therefore is unlikely to provide a plausible approach to handle missingness in the
context considered. By contrast, with the term “sensitivity analysis” we refer to the concept intro-
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duced in Section 1.6.2 and which can be thought of as structurally varying the assumptions about
the missingness model, whose plausibility is justified in light of known information. The difference
between the two types of analysis consists in whether the additional methods implemented to
assess the robustness of the results to the missing data assumptions can be considered plausi-
ble (sensitivity analysis) or not (robustness analysis) in the given context based on the available
information.
However, in practice, even robustness analyses are rarely performed in CEAs. This poses
an important question related to the reliability of the findings, as they may be affected by the
specific assumptions about the missing data. From both review periods it seems that a robustness
analysis is infrequently used and typically involves only one alternative scenario. This is not likely
to be an optimal choice as the main objective of this analysis is to explore as many plausible
alternative missing data assumptions as possible.
Noble et al. (2012) found that 75% of the articles did not include any robustness analysis,
with the remaining papers typically performing an analysis by comparing CCA and MI. Similar
findings apply to missing effects, with about 76% of the studies lacking any alternative missing
data method. Similarly in the 2009-2015 review, we observe no robustness analysis in the majority
of the articles for both costs (75%) and effects (70%).
Figure 2.3 provides a pictorial overview of the alternative methods used for cost and effect
data. For costs, shown in Figure 2.3 (a) and Figure 2.3 (b), most articles describe no alternative
analysis. In the earlier period, the choice of alternative missingness methods seems well-spread
across CCA (4 cases), MI (7 cases) and the use of more than one method (5 cases), with a slightly
more frequent adoption of MI. By contrast, in the later period, CCA (9 cases) is by far the most
used robustness method, followed by more than one method (3 cases). Figures 2.3 (c) and 2.3
(d) describe the effects, with most of the articles not reporting any robustness analysis and with a
decrease in MI (from 6 to 2 cases) used for robustness, opposed to an increase in CCA (from 4
to 7 cases), between the two periods.
Finally, the costs and effects graphs show a similar change with respect to the methods used
in combination between the base-case and robustness analyses in the two periods. Specifically,
in the earlier period, MI is the most used robustness method in combination with CCA as the
most used base-case method (4 cases for the costs and 3 for the effects); conversely, in the later
period, the situation is reversed, with CCA being used as the robustness method in combination
with MI as the base-case method (8 cases for the costs and 7 cases for the effects). Two-way
frequency tables are included in Appendix C to provide detailed information about the number
of the studies that belong to each combination of base-case and robustness methods shown in
Figure 2.3 for costs and effects in both periods.
2.3 Application of the quality evaluation scheme to the re-
viewed articles
Comparing the information provided in the reviewed articles to the list of considerations given in
Table 2.1 allows to assess the quality of the missingness handling in the studies. More specifi-
cally, the articles are classified from the perspective of the strength of the assumptions about the
missingness mechanism. This is related to the choice of method, since each is underpinned by
some specific missing data assumption. It is possible to view the quality judgement and strength
of assumptions as two dimensions providing a general mapping of how the missingness problem
is handled. This applies to both the level of knowledge about the implications of a given miss-
ingness assumption on the results and how these are translated into the chosen method. Details
about the evaluation of both aspects are provided next, starting with the strength of assumptions.
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Figure 2.3: Comparison of methods used in the base-case analysis (x axis) and those used as alterna-
tives in a robustness analysis (y axis) for the articles between 2003-2009 and 2009-2015 for missing costs
and effects. Legend: unspecified methods (Unclear), other methods (Others), Linear Extrapolation (Lin
Ext), Last Value Carried Forward (LVCF), Mean Imputation (Mean), Conditional Imputation (Cond), Com-
plete Case Analysis (CCA), Multiple Imputation (MI). Jittering is used in all graphs to avoid overplotting
and visualise all the points.
Methods are grouped into five categories, broadly ordered according to the strength of the as-
sociated missingness assumptions. These are: Single Imputation (SI); Complete Case Analysis
(CCA); Multiple Imputation (MI); and Unknown (UNK), a residual group in which we classify stud-
ies that do not explicitly mention the method used. We associate this class with the strongest level
of assumptions, since the lack of any method description may implicitly suggest (over)confidence
in a small effect of missingness on the results. By contrast, we define Sensitivity Analysis (SA) as
the least restrictive approach, which can assess the robustness of the results to different alterna-
tive missing data assumptions.
The suitability of each method to handle missigness is very dependent on the specific problem
considered and the available information. For example, as noted in Section 1.5.3, when partially-
observed covariates are included in the analysis, the validity of CCA does not fit neatly into Rubin’s
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categories as it is not only valid under MCAR but also under MAR and MNAR under certain con-
ditions (see Appendix A.3). Thus, the broad distinction between the methods in terms of their
strength about the missing data assumptions is based on some simplifying assumptions. Specif-
ically, we assume that SI methods are valid only under very restrictive missing data assumptions
(e.g. some implausible MNAR scenarios such as that of LVCF) and that there are no covariates in
the analysis model, which makes CCA valid only under MCAR. By contrast, the possible inclusion
of auxiliary variables in the imputation model allows MI to be valid under MAR.
Figure 2.4 gives a graphical representation of both aspects for the articles reviewed between
2009-2015 in terms of the assumptions and justifications (quality scores) on missingness. In both
graphs, more studies lie in the lower than in the upper part, indicating that fewer studies can be
classified as high quality in terms of the considerations about missingness. This is highlighted by
a greater concentration of points at the bottom of the figures (grade E). As we move along the
vertical axis, this tends to reduce up to the top level (grade A), where there are only 4 and 5 cases
for the cost and effect analyses, respectively. Of particular interest is the (almost) total absence of
articles that performed a sensitivity analysis, clearly indicating very slow uptake of this technique.
Detailed information about the number of the studies that belong to each combination of quality
score and missing data assumption categories for both the costs and effects shown in Figure 2.4
is provided using two-way frequency tables, which are available in Appendix C.
A shift along the vertical axis in the graphs indicates an increase in the level of understanding
about the implications on the results for different choices of the missing data assumptions. There-
fore, an upward movement in the plot will always improve the justification of a specific assumption.
However, to be able to follow this path we may have to rely on more sophisticated methods that
can match the given missingness assumption, i.e. if we think our data are MNAR, then CCA as-
sumptions are less likely to hold. The aim of an optimal analysis should be to select a method that
can be fully justified by matching the description of the missing data problem to the assumptions
underpinning the chosen method, i.e. map onto the upper section of the graphs.
As a concrete example about the importance of exploring different missingness assumptions
in terms of the impact they may have on the CEA, we consider one of the reviewed studies that
has been graded as “A” by our scheme (Pickard et al., 2015). The authors provide an assessment
of the probability of accepting a given treatment against a comparator (CEAC) for different willing-
ness to pay thresholds and missingness methods. For all the thresholds considered, substantial
uncertainty is reflected by significant variations in the CEAC values according to the different
missing data methods used. Specifically, the incorporation of external information leads to miss-
ingness assumptions that significantly affect the uncertainty in the results, producing a decrease
in the value of the CEAC, at the target willingness to pay threshold, from 71% in the base-case
(CCA) to 53% in one alternative scenario (MI). This example should encourage authors to recog-
nise the importance that a comprehensive examination of missingness via sensitivity analysis may
have on the uncertainty around CEA conclusions.
2.4 Summary of the Findings
Our review is based on a sample of recently published studies and should therefore provide a
picture of current missing data handling in within-trial CEAs. However, the quality assessment of
the articles is based on the information reported in the articles. It is possible that authors had
assessed the robustness of their conclusions to the missing data using alternative approaches
that were not reported in the published version because of space limitations in journals. In these
cases, it is important that on-line appendices and supplementary material are used to report
these alternatives. In our literature review, information about missing data information and meth-
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(b) Missing Effect Analyses (2009-2015)
Figure 2.4: Joint assessment, in the reviewed articles between 2009-2015, for missing costs and effects,
of two components. The x-axis is the missingness method assumptions: Unknown (UNK), Single Impu-
tation (SI), Complete Case Analysis (CCA), Multiple Imputation (MI) and Sensitivity Analysis (SA). The
y-axis is the ordered classification for the quality judgement (grades) to support these assumptions: E, D,
C, B, A. Jittering is used in all graphs to avoid overplotting and visualise all the points.
ods was available from 4 and 9 on-line supplementary materials for the period 2003-2009 and
2009-2015, respectively. Both the larger number of on-line materials and more detailed informa-
tion reported about missingness handling in the analyses indicate an increased use of this tool in
the later period (2009-2015) compared to the first period (2003-2009).
2.4.1 Descriptive review
From the comparison of the base-case methods used for the costs and effects between 2009 and
2015 (Figure 2.2), a marked reduction is observed in the number of methods not clearly described
for the effects, compared to those for the costs. A possible reason for this is that, while clinical
effectiveness measures are often collected through self-reported questionnaires, which are natu-
rally prone to missingness, cost measures rely more on clinical patient files which may ensure a
higher completeness rate. It was not possible to confirm this interpretation in the reviewed studies
due to the high proportions of articles not clearly reporting the missing rates in both 2003-2009
and 2009-2015 periods, for effects (≈ 45% and ≈ 38%) and costs ( ≈ 50% and ≈ 62%). In addi-
tion, clinical outcomes are almost invariably the main objective of RCTs and are usually subject
to more advanced and standardised analyses. Arguably, costs are often considered as an add-on
to the standard trial: for instance, sample size calculations are almost always performed with the
effectiveness measure as the only outcome of interest. Consequently, missing data methods are
less frequently well thought through for the analysis of the costs. However, this situation is likely to
change as cost data from different perspectives (e.g. caregivers, patients, society, etc.) are being
increasingly used in trials, leading to the more frequent adoption of self-report cost data which
may start to exhibit similar missingness characteristics to effect data.
The review identified only a few articles using more than one alternative method (Figure 2.3).
In addition, these analyses are typically conducted without any clear justification about their un-
derlying missing data assumptions and may therefore not provide a concrete assessment of the
impact of missingness uncertainty. This situation indicates a gap in the literature associated with
an under-implementation of sensitivity analysis, which may significantly affect the whole decision-
making process outcome, under the perspective of a body who is responsible for providing rec-
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ommendations about the implementation of alternative interventions for health care matters.
To assess whether the number and type of missing data methods used in the reviewed papers
vary across the years in the most recent period (2009-2015), an additional analysis by year of pub-
lication is performed. The results from this analysis for the different types of base-case methods,
grouped into four classes (UNK, SI, CCA and MI) are displayed in Figure 2.5. The proportions of
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Figure 2.5: Proportions of base-case methods used to handle missing cost and effect data between 2009-
2015, presented by type of method and year of publication. Legend: Multiple Imputation (MI), Complete
Case Analysis (CCA), Single Imputation (SI) and unspecified method (UNK).
the different types of base-case methods show a similar pattern over the years between missing
costs (panel a) and effects (panel b). The proportions of unclear (UNK) and single imputation
(SI) methods remain roughly constant over time, with an exception in 2015 for the missing effects
for which the proportion of UNK methods disappear while SI methods are substantially reduced
(especially for the missing costs). The proportions of CCA methods are generally the highest until
2012 for both outcomes (with the exception of the missing costs in 2010), after which they are
halved while those of MI raise and achieve their highest in 2015 (above 0.5 for both outcomes).
The results suggest that up to 2012 CCA was the reference base-case method, but is then re-
placed by MI, whose frequency of implementation has rapidly increased and achieved its highest
in 2015 for both missing costs and effects. Figure 2.6 shows the results for the proportions of any
robustness methods used in the reviewed articles by year of publication. No robustness method
was found for the articles in 2011 (for both costs and effects) and 2012 (only for the costs), possi-
bly due to the low number of articles that were reviewed from those years (3 and 8, respectively).
Across almost all the years the proportion of robustness methods is low and generally below 0.3.
In 2015, however, the proportions show an marked increase for both missing costs (6/14) and,
especially, for missing effects (8/14). These results suggest a general lack of implementation of
robustness analyses for most of the articles until 2014, with a an uptake of this technique for the
articles in 2015.
Limiting the assessment of missingness assumptions to a single case is unlikely to provide
a reliable picture of the underlying mechanism. This, in turn, may have a significant impact on
the CEA and mislead its conclusions, suggesting the implementation of non-cost-effective treat-
ments. Robustness analyses assess the sensitivity of the results to alternative missing data
methods but do not justify the choice of these methods and their underlying assumptions about
missingness which may therefore be inappropriate in the specific context analysed. By contrast,
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Figure 2.6: Proportions of articles using robustness methods to handle missing cost and effect data
between 2009-2015 by year of publications. The numbers at the top of the bars in the graphs are the
absolute numbers of papers performing robustness analysis.
sensitivity analyses, which rely on external information to explore plausible alternative methods
and missingness assumptions, represent an important and more appropriate tool to provide real-
istic assessments of the impact of missing data uncertainty on the final conclusions.
2.4.2 Quality assessment
Generally speaking, most of the reviewed papers achieved an unsatisfactory quality score under
the Quality Evaluation Scheme (Figure 2.4). Indeed, the benchmark area on the top-right corner
of the graphs is barely reached by less than 7% of the articles, both for cost and effect data.
Figure 2.7 shows the results from the application of the Quality Evaluation Scheme to the reviewed
studies, disaggregated by year of publication. Overall, the proportions of the studies associated
with the lowest category (E) prevails in the majority of the years, with a similar pattern over time
between missing costs and effects. All the articles that are associated with the top category (A)
belong to the period 2013-2015, with the highest proportions of articles falling in this category
being observed in 2015 for both outcomes. The opportunity of reaching such a target might be
precluded by the choice of the method adopted, which may not be able to support less restrictive
assumptions about missingness, even when this would be desirable. As a result, when simple
methods cannot be fully justified it is necessary to replace them with more flexible ones that can
relax assumptions and incorporate more alternatives. In settings such as those involving MNAR,
sensitivity analysis might represent the only possible approach to account for the uncertainty due
to the missingness in a principled way. However, due to the lack of studies either performing
a sensitivity analysis or providing high quality scores on the assumptions, missingness is not
adequately addressed in most studies. This could have the serious consequence of imposing too
restrictive assumptions about missingness and affect the outcome of decision making.
Table 2.1 provides a convenient tool to check that all relevant information on missing data
is taken into account in determining the assumptions in the analysis. All the key considerations
should be fully satisfied, if possible. These criteria are grouped by type of components in the anal-
ysis and summarise previously published missing data recommendations from various settings,
drawing them together within a general, simple and easy-to-read checklist table.
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Figure 2.7: Proportions of articles across the categories of the quality evaluation scheme (from E to A)
for both missing cost and effect data between 2009-2015, divided by year of publication.
The assignment of scores, based on the weighting of the components, is an appealing feature
of the Quality Evaluation Scheme which allows a ranking of the studies based on the quality of
the analysis in terms of missing data methods used and information reported. The robustness of
the scheme to two different weight choices has been tested on the review’s articles to assess the
sensitivity of the score assignment and articles’ classification across the quality scores (A-E). In
one version all components (Description: Method: Limitations) are given exactly the same weight
using a ratio 1:1:1, while in the other version the difference in weights between the components
is increased using a ratio 6:3:1. The results of these comparisons in terms of weight allocation,
scoring system, and articles’ classification are provided in Appendix C.1.1. In general, the results
do not show any substantial changes in the classification of the articles between the three versions
and suggest a general robustness of the scheme to alternative weight allocations.
Finally, the grouping of the studies into ordered categories (Figure 2.1) is potentially a valu-
able tool for meta-analysis. The proposed quality evaluation scheme could be used by analysts
to assign scores and grade individual studies based on their overall quality level in terms of miss-
ingness handling. These grades could then be taken into account in assigning different weights
to the individual studies within the meta-analysis framework in order to reflect a different degree
of confidence in their results.
2.5 Conclusions
Our review shows, over time, a significant change from more to less restrictive methods in terms
of the assumptions on the missingness mechanism. This is an encouraging movement towards
a more suitable and careful missing data analysis. The results from the disaggregated analysis
by year of publication in the later period (2009-2015) indicates the rise of a better and more
transparent approach to handle missingness in the latest years of the review, especially in 2015.
In particular, compared to the previous years, the articles reviewed from 2015 are associated with
a higher proportion of MI methods used in the base-case analysis, a substantial increase in the
number of robustness methods implemented, and a better quality score assignment.
Nevertheless, improvements are still needed as, overall, only a small number of articles pro-
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vide transparent information about the missing data and almost no study performs a sensitiv-
ity analysis. These failings are probably due to the fact that the implications of using methods
that do not handle missingness in a principled way are not well-known among practitioners. In
addition, the choice of the missing data methods may also be guided by their ease of implemen-
tation in standard software packages rather than methodological reasons. This is a potentially
serious issue for bodies such as the NICE who use these evaluations in their decision making,
thus possibly leading to incorrect policy decisions about the cost-effectiveness of new treatment
options.
The Quality Evaluation Scheme represents a valuable tool to improve missing data handling.
By carefully thinking about each component in the analysis we are forced to explicitly consider
all the assumptions we make about missingness and assess the impact of their variation on final
conclusions. The main advantage is a more comparable formalisation of the uncertainty as well
as a better indication of possible issues in assessing the cost-effectiveness of new treatments.
In the next chapter, we present the CEA data from the two case studies analysed in this thesis
and describe the limitations of the “standard” statistical approach used by practitioners in routine
analyses. In the rest of the thesis we then present our missing data strategy, which overcomes
the limitations of the standard approach and can be implemented in a relatively easy way using
freely available software.
Key points of this chapter:
• The Quality Evaluation Scheme assembles guidelines of best practice about miss-
ing data handling. These recommendations are summarised in terms of three di-
mensions associated with the task of analysing missing data: description, method
and limitations. For each dimension we define a list of considerations that should
be satisfied. According to the number of considerations satisfied and the impor-
tance given to each dimension, quantitative scores can be assigned. These scores
are then grouped into categories that reflect the amount and quality of information
about missingness provided in a given analysis.
• The review summarises the types of methods used to handle missing effect and
cost data in trial-based CEAs between 2003-2015. MI seems to have replaced
CCA as the reference method in base-case analyses. A general drop in the use
of more restrictive SI methods is also observed. However, in many cases, the lack
of information about the details of method implementation or the absence of any
robustness analysis severely undermines the confidence that can be attributed to
the results of the studies.
• The application of the Quality Evaluation Scheme to the reviewed studies reveals
a generally poor picture about the quality of missingness handling in CEA. Most
of the studies fall in the categories associated with the lowest scores with only a
single article performing a sensitivity analysis.
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Chapter 3
Case Studies and Standard
Approach
After having summarised the current situation in terms of the missing data handling in trial-based
CEAs in Chapter 2, in this chapter we present two case studies to illustrate the characteristics
of the typical dataset in CEA. The two studies are: the Men’s Safer Sex (MenSS; Bailey et al.,
2016) and the Positive Behaviour Support (PBS; Hassiotis et al., 2018) trials. We also describe
the “standard” statistical approach used in routine analyses and highlight some of its pitfalls and
limitations that may lead to some bias in the results or mislead the final cost-effectiveness assess-
ment.
3.1 Case Studies
3.1.1 The MenSS trial
The MenSS trial is a pilot RCT whose purpose was to establish the feasibility and optimal design
of a full-scale RCT to test the effect of the Men’s Safer Sex (MenSS) intervention website. The
MenSS website is an interactive digital intervention which provides information and tailored advice
on sexual well-being and barriers to condom use. The website was offered to heterosexual men
in the waiting rooms of NHS sexual health clinics, with the aim of increasing condom use and
reducing the acquisition of sexually transmitted infections.
The aim of the health economic evaluation was to assess the feasibility of the economic anal-
ysis and to inform the methods for the collection of future cost and outcome data alongside a
full-scale RCT and to indicate whether or not the intervention seems promising with regard to
cost-effectiveness. Given the pilot nature of the trial, results and cost-effectiveness conclusions
derived from the analysis of these data should be treated very cautiously and only provide a pre-
liminary economic assessment about the new intervention. Specifically, both the design and the
methods used to collect the data could be modified in a future full-scale trial, which has implica-
tions on the economic assessment. For example, the length of the follow-up period of one year
in the pilot trial may be considered insufficient to assess the true cost-effectiveness of the new
intervention. Nevertheless, the findings from the MenSS trial provide preliminary evidence about
the potential cost-effectiveness of the website intervention, which could be used to guide further
research.
Individuals enrolled in the study (n = 159) were men aged 16 or over who reported female
sexual partners and recent unprotected sex or suspected acute sexually transmitted infections.
Participants were randomised to receive the MenSS website plus usual clinic care (reference
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intervention, n1 = 84), or usual clinic care only (comparator, n2 = 75). Sexual health related
utilities uij were calculated for all participants at baseline (j = 0) and at 3, 6 and 12 months
follow-ups (j = 1, 2, 3) using the EQ-5D 3 level in combination with the preference-based tariff
system of Dolan and Gutex (1995), which provides the utility scores for each possible health state
from the EQ-5D based on the implementation of the time-trade off algorithm (Section 1.2) to a
representative sample of the general UK population. Sexual health related costs cij (in £) were
collected for each participant via responses to resource use questionnaires at the three follow-ups
(not collected at j = 0).
Table 3.1 shows the number and proportion of available case (AC) at each time point in the
trial, i.e. the set of cases comprising the complete cases (CC) and any other observed value
at that time point, for both utilities and costs by treatment group. The number of CC in each
treatment t = 1, 2 is also reported at the bottom of the table. Baseline costs were not collected,
Time Type of outcome Control (n1 = 75) Intervention (n2 = 84)
observed (%) observed (%)
j = 0 utilities 72 (96%) 72 (86%)
j = 1 utilities and costs 34 (45%) 23 (27%)
j = 2 utilities and costs 35 (47%) 23 (27%)
j = 3 utilities and costs 43 (57%) 36 (43%)
complete cases utilities and costs ncc1 = 27 (36%) ncc2 = 19 (23%)
Table 3.1: Number and proportion of observed cases at each time point for the utility and cost data (self-
recorded questionnaires), presented by trial group (baseline data only related to the utilities). The number
of individuals having valid data at each time point (complete cases) is also reported at the bottom of the
table. Over the trial period both drop-out and intermittent missingness occur; at each time point only
unit-nonresponse is observed.
while across the other follow-ups utility and cost data were either both observed or both missing.
The average proportion of missing responses across follow-ups is 50% for the control (t = 1) and
32% for the intervention (t = 2). The proportions of observed data are systematically lower in
the intervention compared with the control group at each time point. This pattern could indicate
the existence of an informative missingness mechanism in which individuals in the intervention
are less likely to report their utility and cost data with respect to those in the control. Specifically,
given the relatively high QALYs values associated with the individuals in the trial (Figure 3.2), it
is plausible that individuals in the intervention group would experience health states closer to full-
health compared with those in the control and decide not to report these. The sensitivity of the
cost-effectiveness conclusions from the trial to alternative informative missingness assumptions
is assessed in Section 5.3.1.
Baseline utilities have the largest number of observed values. Specifically, the proportion of
AC for ui0 is 96% (nac1 = 72) in the control and 86% (nac2 = 72) in the intervention. Figure 3.1
compares the empirical distributions of CC and AC baseline utilities in the MenSS trial.
The empirical distribution of the CC is systematically different from that of the AC. Specifically,
the utilities show mean differences of −0.038 in the control (panel a) and of 0.037 in the interven-
tion (panel b) group between the AC and the CC. Although these changes are relatively small,
when adjusting the estimates of the QALYs for the potential imbalance between treatments in
the baseline utilities (e.g. using regression methods – see Section 3.3), their magnitude is large
enough to have substantial implications on the estimation of the mean QALYs differentials. This
can be seen by looking at the distribution and mean values of the QALYs (eit) and total cost (cit)
variables in the MenSS trial, which are shown in Figure 3.2. Since the time horizon of the trial is 1
year, the range of the QALYs coincide with that of the utilities and is defined between [−0.594; 1],
so that variations in the two variables are directly comparable. The empirical QALY means in the
control (0.904) and intervention (0.902) group of the trial are almost identical with a mean differ-
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Figure 3.1: Empirical distributions for the baseline utilities in the control (panel a) and intervention (panel
b) of the MenSS trial computed either on the AC or CC. A dashed line is drawn in correspondence of the
mean for each variable and the value reported in the plots.
ential of −0.002. Therefore, when the potential imbalance in the baseline utilities is accounted for
in the estimation of mean QALYs differential, even small variations in the mean baseline utilities
between the CC and AC can lead to QALY differentials of different sign with opposite implications
in terms of cost-effectiveness conclusions.
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Figure 3.2: QALYs and total cost distributions for the control (panel a) and intervention (panel b) groups
in the MenSS trial. A dashed line is drawn in correspondence of the mean for each variable and the value
reported in the plots. Costs are expressed in £.
Both outcome data shown in Figure 3.2 clearly present some of the features described in
Section 1.2. A relatively high degree of skewness characterises the empirical distributions of
QALYs and total costs in both treatment groups. In particular, the substantial proportion of in-
dividuals incurring a perfect health status (“structural ones”) observed in both the control (33%)
and intervention (42%) effectively induces spikes at 1 in the QALYs. Finally, a large proportion of
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missingness characterises both variables.
In addition to the outcomes, at baseline, data on three fully-observed covariates were collected
for each individual in the study. These are age, ethnicity and employment status, which are briefly
summarised in Table 3.2 The main target population in the MenSS trial was represented by young
name description details
age age at baseline continuous – median = 27, range = (16, 67)
ethn ethnicity categorical – 14 levels
empl employment categorical – 6 levels
Table 3.2: Description of the available covariates in the MenSS trial
men ≥ 16 attending sexual health clinics in England which serve a diverse range of patients in
terms of age, socio-economic status and ethnicity but who were all at risk of sexually transmitted
infections. However, no upper bound for the age of the participants was imposed in the inclusion
criteria defined in the protocol of the trial (Bailey et al., 2016) and one middle-aged individual in the
control (51 years-old) and two individuals in the intervention (59 and 67-years old) were recruited
in the trial.
In the original analysis (Bailey et al., 2016), the economic evaluation was carried out using
independent linear regressions for the QALYs and cost data, adjusting for differences in base-
line utilities using a regression approach, to derive the mean incremental cost per QALY gained
(i.e. ICER) of the website intervention compared with the control over the 12-month duration of
the trial. The analysis was repeated 1000 times using bootstrap sampling from the data collected
and the results of the bootstrap were used to construct CEACs for a range of values of the willing-
ness to pat for a QALY gained. The results reported indicate a 88% probability that the website is
cost-effective compared with current practice at a threshold of £20, 000 per QALY gained.
3.1.2 The PBS trial
The PBS trial is a cluster RCT involving community intellectual disability services and service
users with mild to severe intellectual disability and challenging behaviour. The purpose of the trial
is to evaluate the clinical outcomes of adults with challenging behaviour and intellectual disabilities
(e.g. carer-reported ratings of challenging behaviour), who are treated by staff who have received
manual-assisted face-to-face staff training in Positive Behaviour Support (PBS). PBS is a multi-
component intervention which is designed to foster prosocial actions and enhance the person’s
quality of life and his/her integration within the local community.
The primary aim of the economic evaluation was to assess the cost-effectiveness of the inter-
vention compared with the control from a health care perspective. Cluster RCTs raise additional
challenges for statistical methods for cost-effectiveness analysis, which should address the spe-
cific characteristics of the trials. More specifically, in cluster RCTs the unit of randomization is the
cluster (the community intellectual disability service in the PBS), not the patient. Thus, individuals
within a cluster are likely to be somewhat similar in their characteristics and the care they receive,
and therefore, individual outcomes or costs within the same cluster tend to be more homogeneous
than those in different clusters. Thus, statistical methods are required to allow for both individual
and cluster level correlations between QALYs and costs to avoid biased results.
Participants (n = 244) were enrolled from a total of S = 23 sites. 12 sites were allocated to staff
teams trained to deliver PBS in addition to treatment as usual (reference intervention, n2 = 208),
and 11 sites to staff teams trained to deliver treatment as usual alone (comparator, n1 = 136).
Utilities uij were derived for all participants at baseline (j = 0) and at 6 and 12 months follow-ups
(j = 1, 2) using the EQ-5D 3 level in combination with the utility scores associated with each
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health state that were obtained from the tariff system of Dolan and Gutex (1995) (Section 1.2).
Health related costs cij (in £) were collected for each participant via family and paid carer records
at each time point. Among the objectives of the study there was an economic evaluation aimed at
examining the costs and effectiveness of staff training in PBS.
Table 3.3 reports the missingness patterns in each treatment group as well as the number of
individuals and the observed mean responses within each pattern. In the table, r = (r0; r1; r2)
denotes the observed missingness patterns in the study, where each pattern is associated with
different values for the pairs of missing utility and cost indicators rj = (ruj , r
c
j) . For example, the
pattern r = 1 corresponds to the completers pattern.
control (t = 1) intervention (t = 2)
ui0 ci0 ui1 ci1 ui2 ci2 nr1 ui0 ci0 ui1 ci1 ui2 ci2 nr2
r = 1 1 1 1 1 1 1 108 1 1 1 1 1 1 96mean 0.678 1546 0.684 1527 0.680 1520 0.726 2818 0.771 2833 0.759 2878
r = 2 0 1 1 1 1 1 7 0 1 1 1 1 1 5mean – 1310 0.704 1440 0.644 1858 – 2573 0.780 2939 0.849 2113
r = 3 1 1 0 1 1 1 4 1 1 0 1 1 1 1mean 0.709 1620 – 1087 0.737 851 0.467 9649 – 4828 0.259 4930
r = 4 1 1 1 1 0 1 2 1 1 1 1 0 1 1mean 0.564 640 0.648 512 – 286 0.817 3788 0.884 0 – 0
r = 5 1 1 0 0 1 1 4 1 1 0 0 1 1 1mean 0.716 2834 – – 0.634 679 0.501 3608 – – 0.872 4781
r = 6 1 1 0 0 0 0 4 1 1 0 0 0 0 4mean 0.434 1528 – – – – 0.760 3086 – – – –
r = 7 0 1 0 1 1 1 2 0 1 0 1 1 1 0mean – 595 – 397 0.483 69 – – – – – –
r = 8 1 1 1 1 0 0 2 1 1 1 1 0 0 0mean 0.743 1434 0.705 1606 – – – – – – – –
r = 9 1 1 0 1 0 1 3 1 1 0 1 0 1 0mean 0.726 1510 – 432 – 976 – – – – – –
Table 3.3: Missingness patterns for the outcome yij = (uij , cij) in the PBS study. For each pattern and
treatment group, the number of subjects (nrt) and the observed mean responses at each time j = 0, 1, 2
are reported. We denote the absence of response values or individuals within each pattern with –.
The number of observed patterns is relatively small in both the control (R1 = 9) and inter-
vention (R2 = 6) groups. Missingness is mostly nonmonotone and, with the exception of the
completers (r = 1), the patterns are quite sparse. At each time point, when the costs are missing,
the utilities are always observed; but, when the utilities are missing, the costs may or may not be
observed. Table 3.4 shows the number and proportion of AC at each time point in the trial for both
utility and cost data by treatment group. The number of CC is also reported at the bottom of the
table.
Time Control (n1=136) Intervention (n2=108)
observed (%) observed (%)
utilities costs utilities costs
j = 0 127 (93%) 136 (100%) 103 (95%) 108 (100%)
j = 1 119 (86%) 128 (94%) 102 (94%) 103 (95%)
j = 2 125 (92%) 130 (96%) 103 (95%) 104 (96%)
complete cases ncc1 = 108 (79%) ncc2 = 96 (89%)
Table 3.4: Number and proportion of observed cases at each time point for the utility (self-recorded
questionnaires) and cost (clinic records) PBS data, presented by trial group. The number of individuals
having valid data at each time point (complete cases) is also reported at the bottom of the table. Over the
trial period both drop-out and intermittent missingness occur.
The average proportions of missing utilities and costs across the follow-ups are 11% and 5%
for the control (t = 1) and 5% and 6% for the intervention (t = 2) group respectively. While
the proportions of observed costs between the two treatment groups are roughly equal at each
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time point, the proportions of observed utilities are systematically lower in the control compared
with the intervention group. This may be due an informative missingness mechanism where
the individuals in the control are associated with worse health states with respect to those in
the intervention, which also seems to be supported by the generally lower mean QALY value
in the control compared with the intervention (Figure 3.4). The impact of alternative informative
missingness assumptions on the cost-effectiveness conclusions of the PBS trial is assessed in
Section 6.3.2.
Baseline costs are the only fully observed variables, while for the baseline utilities the propor-
tion of AC is 93% (nac1 = 127) in the control and 95% (nac2 = 103) in the intervention. Figure 3.3
compares the empirical distributions of CC and AC baseline utilities and costs in the PBS trial.
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Figure 3.3: Empirical distributions for the baseline utilities and costs in the control (panels a and c) and
intervention (panels b and d) group of the PBS trial computed either on the AC or CC. A dashed line is
drawn in correspondence of the mean for each variable and the value reported in the plots.
The baseline utilities show a mean variation of 0.054 and 0.004 between the AC and the CC
in the control and intervention group, respectively (Figure 3.3, panel a-b). These differences
are relatively small in terms of both baseline utility scores and QALYs, which share the same
range of [−0.594; 1] due to the 1 year time horizon of the PBS trial. However, compared with
the MenSS trial, the magnitude of these changes is less likely to have a substantial impact on the
estimation of the adjusted mean QALYs differentials. This is due to the fact that the empirical mean
QALYs differential between the two groups in the PBS trial is equal to 0.117, which is substantially
larger compared with the differences between the AC and CC in the baseline utilities. Similar
considerations hold for the baseline cost variables which show variations of £28 and £78 between
the AC and the CC in the control and intervention (Figure 3.3, panels c-d), against a mean total
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cost differential of £1463 between the two groups. The distribution and mean values of the QALYs
(eit) and total cost (cit) variables in both groups of the PBS trial are shown in Figure 3.4.
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Figure 3.4: QALYs and total cost distributions for the control (panel a) and intervention (panel b) groups
in the PBS trial. A dashed line is drawn in correspondence of the mean for each variable and the value
reported in the plots. Costs are expressed in £.
Few individuals are associated with a perfect health status in both treatment groups, i.e. unit
QALYs, while cost distributions show a relatively high degree of skewness, especially in the con-
trol. The dataset also includes a few fully-observed covariates that were collected at baseline.
These variables are summarised in Table 3.5.
name description details
age age at baseline continuous – median = 37, range = (18, 76)
ethn ethnicity categorical – 6 levels
liv living condition categorical – 3 levels (1 = with others, 2 = alone, 3 = with parents)
dis level of disability categorical – 3 levels (1 = mild, 2 = moderate, 3 = severe)
carer type of carer categorical – 2 levels (1 = family, 2 = paid)
gender sex categorical – 2 levels (1 = male, 2 = female)
marital marital status categorical – 3 levels (1 = single, 2 = married, 3 = widow)
site site categorical – 23 levels
Table 3.5: Description of the available covariates in the PBS trial.
The economic evaluation in the original analysis (Hassiotis et al., 2018) was carried out using
independent linear regressions for the QALYs and cost data, adjusting for differences in baseline
utilities/costs using a regression approach and accounting for clustering using site-specific inter-
cept terms. The mean incremental QALYs, cost and ICER of the new intervention compared with
the control were then computed over the 12-month duration of the trial. Bootstrapping methods
were used to construct CEACs for a range of values of the willingness to pat for a QALY gained.
The results reported indicate a 60% probability that the website is cost-effective compared with
current practice at a threshold of £20, 000 per QALY gained.
3.2 Standard Approach to Economic Evaluation
Trial-based routine analyses typically rely on a “standard” approach to perform the economic eval-
uation and assess the cost-effectiveness of the treatment options being compared. The methods
that belong to this class are identified by reviewing the methods used in the trial-based economic
evaluations for the articles included in the literature review in Chapter 2 and the approach used in
the original analyses of the MenSS and PBS studies (see Section 3.1.1 and Section 3.1.2).
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The statistical approaches used in the primary CEA analysis (and their frequency of use)
across the 81 studies included in the review between 2009-2015 are summarised in Table C.10,
which is provided in Appendix C.1.3. In particular, across the 81 articles included in the review for
the period 2009-2015, the majority of studies (53) used independent linear regression methods to
derive the mean incremental cost and effectiveness parameters between the intervention groups
(30 of these used bootstrap methods to account for parameter uncertainty). Of the remaining 28
studies,15 do not clearly report the methods used in the economic analysis, while the use of other
methods is uniformly distributed across 13 studies.
The majority of the reviewed studies used a frequentist statistical framework, where individual
QALYs and total costs are modelled independently (often implicitly) assuming normality and lin-
earity, and by controlling for baseline values (Manca et al., 2005; Van Asselt et al., 2009; Hunter
et al., 2015). Using ei and ci to indicate the QALYs and total costs as before, the model is
ei = α0 + α1ui0 + α2ti + εei [+ . . .], εie ∼ Normal(0, σe)
ci = β0 + β1ci0 + β2ti + εci [+ . . .], εic ∼ Normal(0, σc),
(3.1)
where ti is a treatment indicator variable, and εie and εic are independent error terms associ-
ated with the QALYs and total costs, respectively. The notation [+ . . .] indicates that other terms
(e.g. quantifying the effect of relevant baseline covariates) may or may not be included in the
model. Common examples are demographic factors, e.g. age, gender, ethnicity or some other
prognostic factors, e.g. stage, size or location of the disease (Hoch et al., 2002; Willan et al.,
2004; Vazquez Polo et al., 2005; Nixon and Thompson, 2005). For simplicity, here we assume
that only the baseline utilities/costs are included in the regression models.
Once the parameter estimates αˆ = (αˆ0, αˆ1, αˆ2) and βˆ = (βˆ0, βˆ1, βˆ2) from Equation 3.1 are
derived, e.g. using maximum likelihood estimates, then the population means are estimated as
µˆet = αˆ0 + αˆ1t+ αˆ2u0
µˆct = βˆ0 + βˆ1t+ βˆ2c0,
(3.2)
where u0 and c0 are the sample means for the baseline utility and cost variables, respectively.
Nonparametric bootstrapping techniques are typically used to quantify the uncertainty around
the estimates of Equation 3.2 (Rascati et al., 2001; Thompson and Nixon, 2005). A large number
of samples are usually drawn with replacement from the original data and confidence intervals
for (µˆet, µˆct) are then computed based on the distribution of average costs and QALYs across the
repeated samples (Briggs et al., 2003; Willan and Briggs, 2006; Ng et al., 2013).
When confronted with a multilevel structure, e.g. when utilities and costs are collected from
s = 1, . . . , S different sites, some structured or random effects are typically incorporated into the
regression models in Equation 3.1 to account for clustering (Grieve et al., 2010; Gomes et al.,
2012b; Ng et al., 2016). For example, site-specific intercept terms α0s and β0s can be included,
which are typically assumed to be normally distributed with zero means and variances estimated
from the data, i.e. α0s ∼ Normal(0, σ2α) and β0s ∼ Normal(0, σ2β). In this way, the precision of the
site-specific estimates is improved since information is “borrowed” from other sites.
The popularity of the “standard” approach is mostly due to its ease of implementation in pop-
ular statistical software, such as STATA or R, through some built-in functions with only a limited
customisation from the user. While this may favour the spread and accessibility of this method
to a wider audience, it can also lead to some careless use of the method, especially when the
underlying assumptions are likely to be unrealistic in the context analysed.
The original analyses for both the MenSS and PBS studies were performed using the approach
described above (Bailey et al., 2016; Hassiotis et al., 2018). In the MenSS trial, since baseline
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costs were not collected, the baseline regression adjustment was implemented only for the QALYs.
In the PBS trial, the multilevel structure of the data was taken into account by including site-specific
random intercepts in both the QALYs and cost regression models.
3.3 Pitfalls and Issues of the Standard Approach
In this section we first describe a pitfall of the “standard” approach which may lead to an incor-
rect computation of the population mean QALYs and cost parameters. Then, we discuss how
the “basic” modelling framework described in Section 3.2 can be extended to deal with the typ-
ical complexities of CEA data. These are: correlation, skewness, spikes at the boundaries and
missing data.
Complete and Available Cases Adjustment
Since baseline data (ui0, ci0) are often available for all or most of the individuals in the study, the
adjusted estimates (µˆet, µˆct) can be computed using the baseline means (u0, c0) from either the
CC or the AC. This introduces an ambiguity in the way the adjustment is performed and can lead
to potentially different cost-effectiveness conclusions.
There are no available guidelines in the literature about which approach to use, with standard
software implementations often implicitly selecting one of the two. We demonstrate the poten-
tial consequences of this pitfall in terms of both inferences and cost-effectiveness conclusions
in Chapter 4.
Correlation
The assumption of independence between costs and QALYs is often questionable. This is a
recognised problem in the CEA literature and alternative methods to deal with correlation have
been proposed (O’Hagan et al., 2006; Nixon and Thompson, 2005; Baio, 2012; Gomes et al.,
2012b). One approach is to specify a joint bivariate normal distribution. For example, the models
in Equation 3.1 can be extended by allowing the regression residuals to be correlated.(
εie
εic
)
∼ Normal
[(
0
0
)
,
(
σ2e ρσeσc
ρσcσe σ
2
c
)]
(3.3)
where ρ is a parameter capturing the correlation between the variables. Within a frequentist
paradigm, this approach is typically referred to as seemingly unrelated regression (Gomes et al.,
2012b). Seemingly unrelated regressions consist in a system of equations that can provide es-
timates that are more efficient that those obtained, for example, from equation-by-equation ordi-
nary least squares methods, because they recognise the correlation between individual costs and
health outcomes in the parameter estimation (Green, 2003).
Sometimes it is more convenient to represent Equation 3.3 using conditional probabilities and
factor the joint distribution p(e, c) into the product of a marginal and conditional distribution (Nixon
and Thompson, 2005; Baio, 2012). In this case, we can specify the model as
ei = α0 + α1ui0 + α2ti + εei [+ . . .], εie ∼ Normal(0, σe)
ci = β0 + β1ci0 + β2ti + β3ei + εci [+ . . .], εic ∼ Normal(0, σc),
(3.4)
where the regression coefficient β3 quantifies the association between costs and QALYs. Equa-
tion 3.4 re-expresses the joint model by keeping the regression framework of Equation 3.1 and
including ei into the cost model. Although the models in Equation 3.3 and Equation 3.4 assume
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Normal distributions, alternative bivariate specifications could be considered for the joint modelling
of the QALYs and costs. For example, Nixon and Thompson (2005) and Thompson and Nixon
(2005) use either Normal-Gamma or Normal-LogNormal models, Diaz-Ordaz et al. (2014b) and
Ng et al. (2016) consider either Normal-Gamma or Normal-Inverse Gaussian models, while Baio
(2014) use Beta-Gamma and Beta-LogNormal models.
When the data have a multilevel structure, e.g. they are collected from s = 1, . . . , S different
centers or clusters, methods that account only for the individual-level correlation between QALYs
and costs are not adequate and can lead to biased results (Gomes et al., 2012c,b). Multivariate
mixed effects models can overcome this problem by explicitly recognising the clustering in the
parameter estimation through cluster-level random effects, either or both for the intercept and
slope terms in the regressions in Equation 3.4, while also allowing for the incorporation of cluster
and/or individual-level covariates (Nixon and Thompson, 2005). For example, assuming that only
random intercepts (α0s, β0s) are included in the regression models in Equation 3.4, these are
typically modelled as (
α0s
β0s
)
∼ Normal
[(
0
0
)
,
(
σ2α ψσασβ
ρσβσα σ
2
β
)]
(3.5)
where σα and σβ are the cluster-specific variances for the random effects in the QALYs and cost
regressions, while ψ is the parameter that captures the cluster-level correlations. Multivariate
mixed effects models acknowledge separately individual and cluster-level correlations between
the outcomes through Equation 3.3 and Equation 3.5 and can be implemented either under a
frequentist or Bayesian framework, e.g. using maximum likelihood or MCMC methods (Nixon and
Thompson, 2005; Gomes et al., 2012b).
Skewness
In general, when the sample size is relatively large or the degree of skewness in the data is not
high, inferences about the population means are not strongly affected even if the model does
not explicitly account for skewness. In trial-based economic evaluations, however, since both
outcomes are typically characterised by a large degree of skewness and relatively small sample
sizes, either the the normality assumption encoded in Equation 3.1 or the use of nonparamet-
ric bootstrapping (Rascati et al., 2001) is not an optimal modelling approach. More specifically,
both methods rely on asymptotic assumptions which require a relatively large sample size to pro-
duce correct inferences if the data are highly skewed (O’Hagan and Stevens, 2003; Nixon and
Thompson, 2004).
Alternative approaches have been proposed in the literature to account for skewness in both
variables, particularly within a Bayesian approach, through the use of more appropriate skewed
parametric distributions, such as Gamma, LogNormal or Inverse-Gaussian distributions for the
costs Nixon and Thompson (2005); Thompson and Nixon (2005); Diaz-Ordaz et al. (2014b) or
Beta distributions for the QALYs (Basu and Manca, 2012). These distributions often allow im-
provements in the model fit to the observed data and appropriately capture skewness (Baio,
2014).
Spikes at the Boundaries
Fourth, data may exhibit spikes at one or both of the boundaries of the range for the underly-
ing distribution. For example, some patients may not accrue any cost at all (i.e. cit = 0), thus
invalidating the assumptions for the Gamma distribution, which is defined on the range (0,+∞).
Similarly, we may observe individuals who are associated with perfect health, i.e. unit QALY (Basu
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and Manca, 2012), which makes it difficult to use a Beta distribution, defined on the open interval
(0, 1). A possible solution to avoid this problem is to add/subtract a small constant  from the
entire set of observed values, artificially re-scaling it in the desired interval. However, no clear
guideline exists about the value to use for  (e.g. 0.1, 0.01, . . .) to minimise its influence on the
economic results (Cooper et al., 2003; Basu and Manca, 2012). In addition, this approach fails
to recognise that the underlying data generating process which characterise the individuals with
observed boundary values is different from that of the others, e.g. those associated with a perfect
health state may be associated with lower costs with respect to those with an impaired state.
A more efficient solution is the application of hurdle models (Ntzoufras, 2009; Mihaylova et al.,
2011; Baio, 2014). These are mixture models defined by two components: the first one is a mass
distribution at the spike, while the second is a parametric model applied to the natural range of
the relevant variable. Usually, a logistic regression is used to estimate the probability of incurring
a “structural” value (e.g. 0 for the costs, or 1 for the QALYs); this is then used to weight the
mean of the “non-structural” values estimated in the second component. Hurdle models have
been discussed and applied in CEA mainly for handling zero costs (Tooze et al., 2002; Harkanen
et al., 2013). In particular, Baio (2014) uses bivariate CEA models that combine hurdle models to
handle structural zeros with alternative parametric specifications for the distribution of the QALYs
(Beta distributions) and costs (Gamma or LogNormal distributions) to account for skewness in the
empirical distributions (the authors also provide an R package (Baio, 2013) to implement these
methods). We show how to incorporate and extend these approaches within a flexible Bayesian
modelling framework that jointly accounts for correlation, skewness and spikes, while also dealing
with missing data, in both QALYs and costs in Chapter 5.
Missing Data
Finally, routine analyses are conducted on (eit, cit), which are typically derived using the data
from the completers in the study. This, however, is an inefficient approach that discards some
observations and is also likely biased unless the completers are a random sample of all study
participants. Alternative approaches that account for missing data uncertainty (e.g. MI) have
become increasingly popular in trial-based CEAs, as shown by our review in Chapter 2. However,
these analyses typically assume that the missing data mechanism is ignorable and do not conduct
any sensitivity analysis to alternative missingness assumptions. In Chapter 6, we propose a
Bayesian longitudinal model that extends the standard approach using all observed values in the
study, accounts for the complexities of the data and facilitates a sensitivity analysis to plausible
nonignorable missing data assumptions.
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Key points of this chapter:
• Data from two RCTs are analysed in this thesis: The MenSS and PBS trials.
The motivating question in both studies is to assess the cost-effectiveness of new
treatment interventions compared with the standard of care.
• In both studies utility and cost data are derived from self-reported questionnaires
or patient records and show the typical complexities that affect individual-level
CEA data: skewed empirical distributions, spikes at one for the utility and at zero
for costs, and missingness in both outcomes.
• The original analyses of the studies were performed using a “standard approach”
that could lead to biased results. Potential pitfalls and issues involve the ambigu-
ity with respect to the way mean baseline adjustment is implemented, the failure
to account for most of the complexities of the data and the assumption that the
missingness mechanism is MAR.
• Sensitivity analysis to assess the impact of plausible nonignorable missing data
departures is typically not conducted. This undermines the confidence we may
place on both the inferences and cost-effectiveness conclusions derived from the
analysis.
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Chapter 4
A Pitfall in Mean Baseline
Utility/Cost Adjustment
Having introduced our data and the “standard” approach in CEA, we use the two studies as mo-
tivating examples to demonstrate a drawback in the implementation of mean baseline utility/cost
regression adjustment. Specifically, when dealing with partially-observed data, mean baseline
values can be computed in alternative ways, which have distinct implications in terms of missing
data assumptions. This, in turn, can lead to different estimates and impact the cost-effectiveness
assessment. A synthesised version of this chapter in the form of a research article has been
submitted for publication in Health Economics.
4.1 Complete versus Available Cases
Routine CEAs conducted alongside RCTs are typically performed using the statistical approach
described in Section 3.2, where the target estimates are derived using the baseline variables eval-
uated at their sample means. When some individuals fail to follow-up and have missing outcome
values at some time points, analyses are typically performed using only the completers (CCA).
However, since baseline values are often available for all or most of the individuals, the mean
values u¯0 and c¯0 can be effectively calculated using either the CC or the AC.
To our knowledge, there is no current guideline about which approach to use and standard
software implementations often implicitly select one of the two. This is problematic as analysts
may be unaware of how the adjustment is calculated and that alternatives exist. For example, in
STATA, adjusting for baseline utilities at means can be performed using the following commands:
reg QALY treatment_group baseline_utility
margins treatment_group, atmeans
The first line specifies a linear regression with QALY as the response variable and treatment_group
and baseline_utility as covariates. The second line uses the margins function to apply the ad-
justment by treatment group at the mean of the baseline variable in the model. In R, a similar
implementation of the regression adjustment can be performed using the commands:
reg = lm(QALY ∼ treatment_group + baseline_utility)
predict(reg)
The first line computes the linear regression, while the second line uses the function predict to
obtain the adjusted QALYs estimates by treatment group, evaluated at the mean of the baseline
variable in the model. By default both functions discard all missing values when fitting the re-
gression and make the adjustment by calculating the mean of the baseline variables on the AC.
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However, analysts may be unaware of the fact that if only the subset of the complete cases is
retained for the variables, then the adjustment will be computed using the mean of the CC.
The inferences under both approaches are obtained from the information contained in the ob-
served data, i.e. under MAR (Section 1.5.2). However, the appropriateness of the assumptions
about the missing data mechanism may differ according to which set of observed values is used
in the adjustment. When the additional observations from the AC are systematically different from
the CC, then the MAR assumption based on the complete case dataset is untrue and potentially
biased values for the population mean QALYs and total costs can be estimated. Thus, the applica-
tion of mean regression adjustment is characterised by some ambiguity and can lead to different
cost-effectiveness conclusions depending on how the mean baseline values are computed. This
pitfall holds even when model complexity is increased to account for framework-specific issues
such as the multilevel structure in the data or the correlation between outcomes.
4.2 Implementation
We demonstrate the potential issue associated with the implementation of mean baseline adjust-
ment using the data from the MenSS and PBS trials. In both studies, differences between the
empirical distributions of the CC and AC for the baseline variables (see Figure 3.1 and Figure 3.3)
suggest a potential impact on the final cost-effectiveness assessment depending on whether the
mean of the CC or AC is used to derive the target quantities. We compare the two approaches
for a set of models of varying complexity. We fit these models using a Bayesian approach, which
allows to extend the model structure in a relatively easy way to account for the issues that are
relevant to each dataset.
4.2.1 Models
Table 4.1 summarises the different types of models implemented for the economic analysis of the
MenSS and PBS studies in this work (Bayesian approach), comparing their structures with those
from the models used in the original analyses (frequentist approach).
For the MenSS trial, we compare the model of Bailey et al. (2016) with an analysis based on
both the CC and AC for the baseline utility adjustment, assessing the results under independent
and joint models. For the PBS study, we compare the model of Hassiotis et al. (2018) with a set of
models of increasing complexity. First, the CC and AC baseline utility/cost regression adjustment
are considered. The model is then extended to incorporate three additional baseline covariates:
living condition, level of disability and type of carer (see Section 3). Finally, the multilevel structure
is accounted for by assuming structured regression coefficients for the baseline utility/cost and for
the intercept terms (varying-intercept/slope model). For each of these models we compare the im-
pact on the inferences of independence/joint assumptions about the QALYs and cost distributions
and the use of the CC or AC in the calculation of the mean baseline utilities/costs.
For all Bayesian models, we specify vague priors on the parameters so that inferences are
based on the observed data alone (numerically similar to a frequentist approach). Specifically,
we choose normal priors centred at 0 with a standard deviation of 1000 for all the regression
coefficients α and β. Uniform distributions between (−5, 10) are assigned to standard devia-
tion parameters on the log scale. Prior sensitivity to alternative specifications for all parameters
(e.g. vague Half-Cauchy or Half-Normal priors for the standard deviations on the natural scale)
suggested that these choices were adequate in this setting.
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Study model baseline utilities/costs baseline multilevel correlation(CC) (AC) covariates structure
MenSS
Bailey et al. (2016) 7 3 — — 7
Utility model CC (ind) 3 7 — — 7
Utility model CC (joint) 3 7 — — 3
Utility model AC (ind) 7 3 — — 7
Utility model AC (joint) 7 3 — — 3
PBS
Hassiotis et al. (2018) 3 3 7 3 7
Utility/cost model CC (ind) 3 7 7 7 7
Utility/cost model CC (joint) 3 7 7 7 3
Utility/cost model AC (ind) 7 3 7 7 7
Utility/cost model AC (joint) 7 3 7 7 3
Covariate model CC (ind) 3 7 3 7 7
Covariate model CC (joint) 3 7 3 7 3
Covariate model AC (ind) 7 3 3 7 7
Covariate model AC (joint) 7 3 3 7 3
Multilevel model CC (ind) 3 7 3 3 7
Multilevel model CC (joint) 3 7 3 3 3
Multilevel model AC (ind) 7 3 3 3 7
Multilevel model AC (joint) 7 3 3 3 3
Table 4.1: List of the different models compared in the analysis of the MenSS and PBS data. The models
used in the original analyses are indicated with the author’s papers, while specific names are assigned to
the models implemented in this work according to the different types of complexities that are accounted for.
Different symbols are used to indicate whether the corresponding complexity is addressed (3), ignored
(7) or not relevant (–).
4.2.2 Software
We fitted the models using JAGS, which is interfaced with the freely available statistical software
R using the package R2jags (Su and Yajima, 2015). Samples from the posterior distribution of
the parameters of interest are then saved to the R workspace and used for producing relevant
statistics and plots. We ran two chains with 30,000 iterations per chain, using a burn-in of 15,000,
for a total sample of 30,000 iterations for posterior inference.
For each variable in the model, convergence of the MCMC sampler was assessed using diag-
nostic measures, such as the potential scale reduction factor and visual inspection of the density,
trace and autocorrelation plots, as well as measures to assess the adequacy of the posterior sam-
ple, such as the effective sample size. In particular, all the runs discussed in this chapter were
assumed to have converged when the value of the potential scale reduction factor was below 1.05
and the effective sample size was at least 20,000 for all model parameters. The JAGS code used
to implement the model for the MenSS trial is available in Appendix B.1.
4.3 Results
Results are reported and compared for all models in Table 4.1 in terms of the estimates and credi-
ble intervals of key parameters of interest for assessing the cost-effectiveness of the interventions
(Section 1.4.1). These include the mean QALYs and total costs in both intervention groups of the
trials (µet, µct) and the mean QALY and total cost increments (∆e,∆c). The latter are also used
to compute summary incremental measures, such as the incremental net benefit and the ICER,
which provide information about the relative cost-effectiveness of the two interventions compared.
In particular, the results associated with the net benefits (evaluated at the NICE’s recommended
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willingness to pay value of k = £20, 000) have been included for all the analysis scenarios ex-
plored for both the MenSS and PBS studies.
4.3.1 The MenSS study
Table 4.2 shows the posterior results for the two treatment groups of the MenSS trial. In this
particular case, small variations in the inferences are observed with respect to using a joint model,
and therefore only the results under the latter are presented. Since the time horizon of the trial is
Parameter
Utility model CC (joint) Utility model AC (joint)
Mean 95% interval Mean 95% interval
Control (t = 1)
mean QALY (µe1) 0.904 (0.873;0.935) 0.874 (0.841;0.907)
mean cost (µc1) 207 (104;307) 207 (104;307)
Intervention (t = 2)
mean QALY (µe2) 0.902 (0.859;0.943) 0.915 (0.873;0.959)
mean cost (µc2) 189 (111;266) 189 (111;266)
Incremental
QALY differential (∆e) -0.002 (-0.054;0.05) 0.041 (-0.013;0.094)
Cost differential (∆c) -18 (-146;110) -18 (-146;110)
IB (at k = 20000) -23 (-1063;1042) 835 (-241;1928)
ICER 8822 -449
Table 4.2: Posterior means and 95% credible intervals of the mean QALYs and cost parameters for the
control (t = 1) and intervention (t = 2) group in the MenSS trial. Mean QALYs and cost differentials, the
incremental benefits at k = 20000 and the ICERs are also reported. Two models are considered: Utility
model CC (joint) and Utility model AC (joint). Cost values are expressed in £.
one year, the theoretical range of the QALYs coincide with that of the utility scores, i.e. between
−0.594 and 1 (see Section 1.2). Thus, for example, the mean QALYs under both the Utility model
CC (joint) and Utility model AC (joint) are approximately 0.9, which is close to the upper bound of
full health (corresponding to 1 QALY) and indicates that individuals in both treatment groups have
on average a relatively good health status.
Changes in the QALYs estimates are observed between the two types of baseline adjustment.
In particular, going from the CC to the AC, the mean QALYs has an average decrease of 0.03
in the control group and an average increase of 0.013 in the intervention group. Although these
differences are relatively small in absolute terms, they have a substantial impact on the estimate
of the QALYs differential which, at the average value, changes its sign from negative to positive.
Because the cost differential is on average negative, this implies that the intervention dominates
the control, i.e. lower costs and higher QALYs.
Figure 4.1 shows a graphical representation of the CEP and CEAC based on the posterior
samples of the mean parameters from the models shown in Table 4.2. Results related to the CC
and AC are respectively indicated with red and blue dots and lines. The graphs provide a clear
picture about the impact of the two approaches on the final cost-effectiveness conclusions. At a
willingness to pay threshold of k = £20, 000, the CEP (panel a) shows a much larger proportion of
samples that fall in the sustainability area for the model based on the AC (Utility model AC (ind))
compared with the model based on the CC (Utility model CC (joint)). In the CEAC (panel b), the
CC are associated with a low probability of cost-effectiveness for almost all k values (red line),
while the AC shows a curve which consistently settles at values close to certainty (blue line).
Similar cost-effectiveness conclusions are obtained by considering the Expected Incremental
Benefit and Incremental Benefit distribution for the models based on the CC and AC, displayed
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Figure 4.1: CEP (panel a) and CEAC (panel b) associated with the Utility model CC (ind) (red dots and
lines) and Utility model AC (ind) (blue dots and lines) in the MenSS study.
in Figure 4.2. For most values of k, the EIB (panel a) for the Utility model CC (red solid line) is
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Figure 4.2: Expected Incremental Benefit (panel a) and Incremental Benefit distribution at k = 20000
(panel b) associated with the Utility model CC (joint) (red solid and dashed lines) and Utility model AC
(joint) (blue solid and dashed lines) in the MenSS study.
approximately 0 with a substantial degree of uncertainty indicated by the inclusion of both negative
and positive values within the lower and upper bound estimates (dashed red lines). Conversely,
for all values of k the EIB for the Utility model CC (blue solid line) is above 0 (with a positive slope)
as well as most of the values falling between the lower and upper bound estimates (dashed blue
lines). These results are reflected in the distribution of the IB (panel b), evaluated at k = £20, 000,
with a probability of cost-effectiveness for the Utility model AC (blue shaded area) that is almost
twice that of the Utility model CC (red shaded area).
4.3.2 The PBS study
Table 4.3 shows the posterior results for the two treatment groups of the PBS trial. Like the MenSS
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study, the time horizon in the PBS study is one year, which means that QALYs are defined on the
same range of the utility scores, i.e. between −0.594 and 1. Therefore, compared with the MenSS
trial, the individuals in the PBS study are on average associated with worse health states (mean
QALYs approximately equal to 0.5 compared with 0.9 in the MenSS study).
Changing the model structure produces variations in the economic results. More specifically,
incorporating the covariates (Covariate model) leads to an average decrease in the mean QALYs
of 0.033 in the intervention group with respect to the simpler baseline utility/cost adjustment (Util-
ity/cost model). This discrepancy is similar for both the independent and joint models based on
the CC and AC. Given that all the other quantities barely change, this induces a reduction in the
QALYs differential and a less favourable cost-effectiveness assessment for the new intervention.
When the multilevel structure is accounted for (Multilevel model), a substantial average increase
of £800 is observed in the mean cost estimates of the intervention group for both the CC and AC
versions compared with the other models. Relatively smaller differences are observed in the mean
cost incremental estimates between the AC and CC versions of Multilevel model (≈ 7) compared
with those of Utility/cost or Covariate models (≈ 50). These are due to the different assumptions
about the impact that the baseline costs have on the mean total costs, which is modelled either by
accounting for clustering (Multilevel model CC/AC) or ignoring it (Utility/cost model CC/AC or Co-
variate model CC/AC). Correlation assumptions have a limited impact on mean QALYs estimates,
which remain almost unchanged across all models. Conversely, mean cost estimates are lower
for the Utility/cost model (ind) and Covariate model (ind) compared to the Utility/cost model (joint)
and Covariate model (joint).
Compared with the other models, the results associated with the multilevel models are more
robust to correlation assumptions. This may be due to the fact that, in the PBS trial, the magnitude
of the correlations between QALYs and costs at the cluster level (Spearman correlations of −0.55
and −0.65 in the control and intervention group) is substantially greater than that at the individual
level (Spearman correlations of −0.37 and −0.28 in the control and intervention group). Thus, it is
possible that, by accounting for both levels of correlations, the discrepancy between the joint and
independent version of the model is different for the multilevel models compared with those that
ignore clustering. Finally, the multilevel models are only slightly less sensitive (for the mean cost
estimates) to the use of the CC or AC in the baseline adjustment. This is again due to the impact
of accounting for both individual and cluster level correlations, even though differences compared
with those from the models that ignore clustering are relatively small (mean cost differences of
£52 and £59 between the Covariate CC/AC models against £7 and £7 between the Multilevel
CC/AC models).
Figure 4.3 shows the CEP and CEAC based on the inferences for all the models described in
Table 4.3. The graphs distinguish between the results from using the CC (red) and AC (blue), as
well as between independence (dashed lines) and joint (solid lines) models. CEPs are reported
only for their joint versions for simplicity.
At a willingness to pay threshold of k = £20, 000 the ICERs for all the models indicate a more
cost-effective intervention compared to the control. However, the magnitude of the assessment
substantially changes between the models. When the multilevel structure is ignored (panels a-d),
inferences are sensitive to correlation assumptions. Both the Utility/cost model (ind) and Covari-
ate model (ind) are characterised by CEACs that are shifted upwards by 10% compared to the
Utility/cost model (joint) and Covariate model (joint). A substantial decrease of the curves is ob-
served for the Multilevel model (panel f) compared to the others for values of k below £20, 000.
In this case, however, differences between the independent and joint models almost disappear,
which suggests that adjusting for the clustering in the data may also substantially capture the
correlation at the individual level.
Finally, we focus on the multilevel models, and look at the differences in terms of Expected
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(c) Covariate model CC and AC
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(d) Covariate model CC and AC
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(e) Multilevel model CC and AC
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(f) Multilevel model CC and AC
Figure 4.3: CEPs (panels a, c, e) and CEACs (panels b, d, f) associated with the models shown in
Table 4.3 for the PBS study. The results based on the CC (red dots and lines) and the AC (blue dots and
lines) are indicated with different colours while correlation assumptions are associated with different line
types (solid and dashed lines for joint and independence models). In the CEPs only the results from the
joint models are shown.
Incremental Benefit and Incremental Benefit distribution between the models estimated using the
CC and AC baseline utilities/costs, shown in Figure 4.4. For almost all values of the willingness
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Figure 4.4: Expected Incremental Benefit (panel a) and Incremental Benefit distribution at k = 20000
(panel b) associated with the Multilevel model CC (joint) (red solid and dashed lines) and Multilevel model
AC (joint) (blue solid and dashed lines) in the PBS study.
to pay k the EIB for both the CC and AC models is negative (red and blue solid lines, panel a),
therefore indicating a poor cost-effectiveness assessment for the intervention compared with the
control. The Multilevel model CC is associated with a higher slope of the EIB compared with
the Multilevel model AC and a higher proportion of positive EIB values, as also indicated by the
lower and upper bound estimates (dashed lines). The incremental benefit distribution, evaluated
at k = £20, 000, is mostly below 0 for both models, with a probability of cost-effectiveness that is
approximately 0.3 for Multilevel model CC and 0.1 for Multilevel model AC (shaded red and blue
areas).
The results between the CC and AC show discrepancies that persist almost regardless of the
complexity of the model. This is indicated by the stable gap between the CEACs associated with
the two approaches for all models. More specifically, results based on the CC indicate a more
cost-effective intervention compared with those based on the AC for most values of k. Similarly,
in the CEPs, the largest proportion of samples falling in the sustainability area is associated with
the use of the CC for all models.
4.4 Discussion
Baseline regression adjustment is considered the reference approach to deal with baseline util-
ity/cost imbalance in trial-based CEA. However, when some of the participants fail to follow-up
and the economic evaluation is performed using a CCA, this method is subject to the pitfall of
whether the mean of the CC or the AC should be computed for the baseline variables in the
procedure. Many statistical software packages have built-in functions that by default perform the
adjustment using one of two approaches. This is undesirable as analysts may be unaware of
the type of adjustment the software implements, which in turn may affect the inferences and the
decision-making.
We compared the results from the baseline CC and AC adjustment obtained under the Bayesian
framework implemented in this chapter with those obtained from other frequentist methods that
allow for either the individual-level correlation (seemingly unrelated regressions – Section 3.3) or
both the individual and cluster level correlation (multivariate linear mixed effects models – Sec-
tion 3.3) for the analysis of the MenSS and PBS trials, respectively. For each treatment group in
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both case studies, the estimates for the mean outcome parameters and other incremental quanti-
ties (e.g. net benefit) are almost identical between the Bayesian and frequentist methods for both
the CC and AC baseline adjustment. Inferences from these methods are also compared in terms
of mean QALYs, mean costs and key incremental quantities (e.g. net benefit) with those derived
from the original analyses of the two trials. These comparisons are reported in Figure C.2 and
Table C.11 (for the MenSS study) and in Figure C.3, Figure C.3 and Table C.12 (for the PBS study)
in Appendix C.2.
In the MenSS trial, accounting for the individual-level correlation between QALYs and costs
does not lead to sizeable differences in the estimates compared with assuming independence
(i.e. with respect to the results from the “standard approach” – only performed using the AC).
In the PBS trial, accounting for both levels of correlation (either under a Bayesian or frequentist
approach) leads to substantially different estimates for both mean QALYs and costs compared
with those from the “standard approach” . These results suggest that, regardless of whether the
CC or AC baseline adjustment is used, failure to account for the relevant levels of correlations in
the data may lead to incorrect inferences.
While the two baseline adjustment approaches could lead to similar results, our two motivating
examples demonstrate that this is not always the case. For the MenSS trial, the cost-effectiveness
conclusions derived from the two types of adjustments are completely opposite; for the PBS trial,
the differences in the results based on the CC and AC are almost unaltered regardless of the
complexity of the model considered. In both studies baseline variables show considerably different
mean values between the CC and AC, which lead to different model estimates and, crucially, cost-
effectiveness conclusions.
When this occurs, there is a clear indication that the MAR assumption, when using the com-
plete case dataset, is implausible and the results based on CCA are likely to be biased. By
including the additional data contained in the AC, rather than just the subset of the CC, may pro-
vide sufficient information to eliminate the bias associated with a CCA and obtain valid inferences.
However, it is possible that neither the CC nor the AC lead to valid inferences as MAR can never be
verified from the data at hand. Thus, it should be more reasonable to avoid CCA and use a method
that retains the full sample by imputing the missing values, while also assessing the robustness
of the results to different missing data assumptions (including MNAR). Bayesian methods are
well-suited to accomplish this task through the specification of suitably-defined (informative) prior
distributions, which allow to incorporate external evidence about missingness (e.g. expert opin-
ion) into the analysis. However, the lack of a sensitivity analysis to missingness is only one of
the issues that question the validity of the conclusions derived from routine analyses. As we dis-
cussed in Section 3.3, both outcome data are typically affected by a series of complexities, such
as skewness and spikes, that are ignored by the standard approach and that may bias the results.
In the next chapter we present a flexible Bayesian framework that improves the standard ap-
proach by jointly accounting for these complexities, while simultaneously imputing the missing
values. In addition, the framework accommodates a sensitivity analysis to MNAR assumptions
that can be implemented in a relatively easy way.
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Key points of this chapter:
• In routine analyses mean baseline regression adjustment can be implemented
either using the mean of the CC or AC for the baseline variables. Standardised
functions in popular statistical software (often implicitly) perform the adjustment
using one of the two approaches. This is potentially dangerous as analysts may
not be aware that the two approaches could lead to different results.
• Using the data from two case studies, we showed that, when there are systematic
differences between the CC and AC for the baseline utilities/costs, mean baseline
regression adjustment under the two approaches can lead to substantially different
cost-effectiveness conclusions. In addition, for both studies, the discrepancy be-
tween the inferences associated with the two methods was generally unaffected by
the level of complexity of the model, i.e. differences between the CC and AC sce-
narios remained roughly constant after accounting for correlation (for the MenSS
trial) or for correlation, covariates and multilevel structure (for the PBS trial).
• Discrepancies between the empirical distributions of the baseline CC and AC indi-
cate that those individuals whose follow-up values are missing are associated with
systematically different baseline utility/cost values compared with the completers.
Therefore, even when missingness is MAR, computing the mean utility/costs in
the regression adjustment using only the CC is inefficient (i.e. it discards the ad-
ditional information contained in the AC) and is also more likely to lead to biased
results than using the AC because the adjusted QALYs/total cost estimates do not
account for the systematic difference between completers and non-completers in
the baseline variables. However, in general, both approaches can lead to biased
results since assumptions on the missing values can never be checked from the
data at hand; thus, methods that explicitly account for missingness uncertainty
by retaining the full sample should be preferred to assess the robustness of the
results to departures from MAR.
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Chapter 5
A General Bayesian Framework for
Health Economic Evaluation
In this chapter we propose a unified Bayesian framework that jointly accounts for the typical com-
plexities of the data discussed in Section 3.3 (i.e. correlation, skewness, spikes at the boundaries
and missingness), and that can be implemented in a relatively easy way. We demonstrate the
benefit of using our approach using the MenSS trial as motivating example (Section 3.1.1). We
then show how the framework can be flexibly adapted to accommodate the characteristics of the
data in the PBS trial (Section 3.1.2). A simplified version of this chapter in the form of a research
article is published in Statistics in Medicine.
5.1 Modelling Framework
Consider the usual cross-sectional bivariate outcome formed by the QALYs and total cost vari-
ables (eit, cit) calculated for the i−th person in group t of the trial. To simplify the notation, unless
necessary, we suppress the treatment indicator t. Following Nixon and Thompson (2005), we
specify the joint distribution p(ei, ci) as
p(ei, ci) = p(ci)p(ei | ci) = p(ei)p(ci | ei), (5.1)
where, for example, p(ei) is the marginal distribution of the QALYs and p(ci | ei) is the conditional
distribution of the costs given the QALYs. Note that, although the two factorisations shown in
Equation 5.1 are mathematically equivalent, the choice of which to use has different practical im-
plications. From a statistical point of view, the factorisations require the specifications of different
statistical models, e.g. p(ei) or p(ei | ci), which may have different approximation errors. From a
clinical point of view, the two versions make different assumptions about the casual relationships
between the outcomes, i.e. either ei determines ci or vice versa. We describe our analysis un-
der the assumption that the costs are determined by the effectiveness measures and therefore
we specify the joint distribution p(ei, ci) in terms of a marginal distribution for the QALYs and a
conditional distribution for the costs.
For each individual we consider a marginal distribution p(ei | θe) indexed by a set of param-
eters θe comprising a location φie and a set of ancillary parameters ψe typically including some
measure of marginal variance σ2e . We can model the location parameter using a generalised
linear structure, e.g.
ge(φie) = α0 [+ . . .], (5.2)
where α0 is the intercept and the notation [+ . . .] indicates that other terms (e.g. quantifying the
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effect of relevant covariates) may or may not be included in Equation 5.2. In the absence of
covariates or assuming that a centered version x∗i = (xi− x¯) is used, the parameter µe = g−1e (α0)
represents the population average QALYs.
For the costs, we consider a conditional model p(ci | ei,θc), which explicitly depends on the
QALYs, as well as on a set of quantities θc, again comprising a location φic and ancillary parame-
ters ψc. For example, when normal distributions are assumed for both p(ei | θe) and p(ci | ei,θc),
i.e. bivariate normal on both outcomes, the ancillary parameters ψc include a conditional variance
τ2c , which can be expressed as a function of the marginal variance σ2c (Nixon and Thompson,
2005; Baio, 2012). More specifically, the conditional variance of p(ci | ei,θc) is a function of the
marginal effectiveness and cost variances and has the closed form τ2c = σ2c−σ2eβ2, where β = ρσcσe
and ρ is the parameter capturing the correlation between the variables (see Equation 3.3).
The location can be modelled as a function of the QALYs as
gc(φic) = β0 + β1(ei − µe) [+ . . .]. (5.3)
Here, (ei − µe) is the centered version of the QALYs, while β1 quantifies the correlation between
costs and QALYs. Assuming other covariates are either also centered or absent in Equation 5.3,
µc = g
−1
c (β0) is the estimated population average cost.
Figure 5.1 shows a graphical representation of the general modelling framework described
above. The QALYs and cost distributions are represented in terms of combined “modules” — the
ci
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Figure 5.1: Joint distribution p(ei, ci), expressed in terms of a marginal distribution for the QALYs and a
conditional distribution for the costs, respectively indicated with a solid red and blue line. The solid black
and magenta arrows show the dependence relationships between the parameters within and between the
two models, respectively. The dashed magenta arrow indicates that the ancillary parameters of the cost
model may be expressed as a function of the corresponding QALYs parameters. The dots enclosed in the
square brackets indicate the potential inclusion of other covariates at the mean level for both modules.
blue and the red boxes — in which the random quantities are linked through logical relationships.
This ensures the full characterisation of the uncertainty for each variable in the model. Notably,
this is general enough to be extended to any suitable distributional assumption, as well as to
handle covariates in either or both the modules.
The proposed framework allows jointly tackling of the different complexities that affect the data
in a relatively easy way by means of its modular structure and flexible choice for the distributions
of the QALYs and cost variables. Using the MenSS trial as motivating example, we start from the
original analysis and expand the model using alternative specifications that progressively account
for an increasing number of complexities in the outcomes. We specifically focus on appropriately
modelling spikes at the boundary and missingness, as they have substantial implications in terms
of inferences and, crucially, cost-effectiveness results.
Three model specifications are considered: 1) Normal marginal for the QALYs and Normal
conditional for the costs (which is identical to a Bivariate Normal distribution for the two outcomes);
2) Beta marginal for the QALYs and Gamma conditional for the costs; and 3) Hurdle Model. The
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choice of the Beta distribution for modelling the QALYs is considered reasonable given the specific
characteristics of the MenSS trial: individuals are associated with relatively high utility and QALY
values (always above 0) and the time horizon of the evaluation is 1 year, which ensures that the
maximum QALYs value is equal to 1 (see Section 1.2). However, in general, QALYs may be
either negative or above 1, for example when the individuals are associated with very poor health
states (utilities below 0) or the time horizon of the analysis is longer than 1 year, respectively. In
these situations, the choice of the Beta distribution may be inadequate and alternative approaches
should be considered; these include the rescaling of the QALYs to ensure they fall in the range
[0, 1] (see Section 5.7) or the choice of alternative parametric distributions which explicitly allow
for these values, e.g. Normal distributions (Ng et al., 2016).
First, we present each assuming a “complete cases” scenario and then extend the structure
to an “all cases” scenario. The latter includes the complete cases and additionally imputes the
outcome values for all the remaining individuals in the trial, either under MAR (for all models) or
alternative MNAR scenarios (for the Hurdle Model only). In particular, the sensitivity of the results
to MNAR is not assessed using a proper nonignorable model (see Section 1.6). This is due to
the fact that a cross-sectional framework is not ideal to handle missingness in trial-based CEAs
because it does not allow to incorporate the information from all partially-observed utility and cost
data into the model, which instead is likely to provide at least some information for imputing the
missing values. However, for all analyses in this chapter, we use a cross-sectional framework
because it represents the standard framework practitioners are familiar with in routine analyses
and which is currently recommended by NICE for trial-based economic evaluations (NICE, 2013).
We overcome the limitations associated with this framework for handling missingness in Chap-
ter 6, where a longitudinal modelling framework is used to efficiently incorporate the information
from all partially-observed data to impute the missing values and a pattern mixture approach is
implemented to conduct sensitivity analysis to MNAR (see Chapter 6).
For the analyses in this chapter, the alternative MNAR scenarios (Section 5.3.1) are chosen
according to the specific features of the QALY data in the MenSS study, where some of the
individuals in both groups are associated with a perfect health status at one or more time points
(uij = 1) but have unobserved measurements at some other time points. Thus, it is plausible to
assume that at least some of these individuals are associated with a perfect utility score at all time
points, which would result in a perfect health status over the trial period (i.e. ei = 1). We exploit
the modelling structure of the Hurdle Model to assess the robustness of the results to differing
assumptions about the proportions of these individuals that could be potentially observed in both
treatment groups and the impact that these assumptions may have on the final conclusions.
5.2 Complete Cases Scenario
5.2.1 Bivariate Normal
The first specification jointly models the two outcomes assuming bivariate normality, which in
our framework is factorised into marginal and conditional Normal distributions for ei and ci | ei.
The model is similar to the “standard” approach described in Section 3.2 with the difference that
correlation between the variables is explicitly captured.
In line with the original analysis of the MenSS trial, we adjust for the baseline utilities — using
a centered version u?i0 = ui0 − u¯0. We model ei | θe ∼ Normal(φie, σ2e), using an identity link
function for the location parameter
ge(φie) = φie = α0 + α1u
?
i0. (5.4)
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Here, the parameter α1 quantifies the impact of the centered baseline utilities on the QALYs, while
µe = α0 and σ2e represent the marginal (population level) mean and variance, respectively.
As for the costs, we model ci | ei,θc ∼ Normal(φic, τ2c ), where the conditional mean and
variance are defined as
gc(φic) = φic = β0 + β1(ei − µe) and τ2c = σ2c − σ2eβ21 . (5.5)
This conditional specification of the model corresponds to the multivariate structure in Equa-
tion 3.3 (Nixon and Thompson, 2005; Baio, 2012), where the parameters indexing the distribution
of the costs can be re-expressed as β1 = σcσe ρ and τ
2
c = σ
2
c (1− ρ2).
The sets of the QALYs and cost parameters from the models specified in Equation 5.4 and
Equation 5.5 are thus θe = (α0, α1, σ2e) and θc = (β0, β1, µe, σ2c , σ2e) — note that the marginal
mean and variance of the QALYs link the two modules and therefore feature in both sets of pa-
rameters. The model is completed by assigning suitable prior distributions to the elements of
θ = (θe,θc). We specify independent Normal(0, 1000) priors for the regression parameters, while
Uniform(0, 1000) priors are assigned on the scale of the standard deviations.
A limitation of the Bivariate Normal model is that it fails to capture skewness in both outcomes.
This may introduce some bias in the estimates, especially when the sample size is small and the
degree of asymmetry in the data is relatively high.
5.2.2 Beta-Gamma
The second model assumes a Beta marginal for the QALYs and a Gamma conditional for the
costs. We choose this specification as, in addition to the correlation between ei and ci, it allows
to capture skewness in both outcome variables.
We parameterise the Beta distribution in terms of the mean φie and the precision parameter
τie =
(
φie(1−φie)
σ2e
− 1
)
as ei | θe ∼ Beta (φieτie, (1− φie)τie). We model the location using a logit
link function and include u?i0 in the QALYs regression
ge(φie) = logit(φie) = α0 + α1u?i0. (5.6)
The costs are modelled as ci | ei,θc ∼ Gamma (φicτic, τic), where the shape parameter is defined
as the product of the location φic and the rate τic. We use a logarithmic link function for the
location and include the centered QALYs in the cost regression
gc(φic) = log(φic) = β0 + β1(ei − µe). (5.7)
The marginal means for the QALYs and total costs can then be obtained using the respective
inverse link functions
µe =
exp(α0)
1 + exp(α0)
and µc = exp(β0). (5.8)
The model is again completed using Normal(0, 1000) priors on the regression coefficients (α,β)
and a Uniform(0, 1000) prior on the standard deviation σc. As for σe, a little more care is needed in
defining suitable prior distributions. In fact, by the mathematical properties of the Beta distribution,
the variance is bounded by a function of the mean such that σ2e ≤ µe(1− µe) = υ. Consequently,
we can place an informative prior on the standard deviation σe ∼ Uniform(0,
√
υ), which coupled
with a prior for µe induces a suitable prior for τie as well. We choose this parameterisation of the
Beta distribution because it is generally easier from an interpretation perspective to specify priors
on the standard deviations rather than on the precision or variance parameters, for which different
types of weakly informative priors may have different impacts on σ2e .
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Notice that, in comparison to the Bivariate Normal, the Beta-Gamma model reflects more
closely the range of the observed data, i.e. between (0, 1) for ei and between (0,+∞) for ci.
Nevertheless, the model fails to directly account for the structural values, e.g. unit QALYs or zero
costs, which do not belong to the support of the Beta and Gamma distributions. Since in the
MenSS trial, some individuals are associated with ei = 1 and ci = 0, it is necessary to rescale the
observed data before fitting the model. We therefore apply the Beta and Gamma distributions to
e∗i = ei −  and c∗i = ci +  and we assessed the sensitivity of the results to different choices of .
The mean QALYs and costs in both intervention groups remain almost unaffected by the choice
of  and suggest a general robustness of the posterior estimates (Figure C.4 in Appendix C).
5.2.3 Hurdle Model
To overcome the limitations of the Beta-Gamma model in terms of the structural ones, we expand
it to a hurdle version. This is achieved through the incorporation of a new module into the frame-
work, which is linked to the marginal model for ei and allows to explicitly handle the values at the
boundary of the QALYs range.
Specifically, for each subject in the trial we define an indicator variable die taking value 1 if the
i−th individual is associated with a unit QALYs (ei = 1) and 0 otherwise (ei < 1). This variable
defines the module for the structural ones into the framework and is modelled as
die := I(ei = 1) ∼ Bernoulli(piie)
logit(piie) = γ0 + γ1u?i0 [+ . . .],
(5.9)
where piie is the individual probability of unit QALYs, which is estimated on the logit scale as a func-
tion of a baseline parameter γ0 and the centred baseline utilities u?i0, whose effect is quantified
by the parameter γ1. Similarly to the QALYs and cost models, other covariates can be additively
included in the model of die. We specifically distinguish the baseline utilities from any other covari-
ate as they are likely to be particularly informative in predicting whether an individual is associated
with a structural one in the QALYs. All the logistic regression parameters in Equation 5.9 are given
vague Normal(0, 1000) priors.
Within this module, we can apply the inverse logit function on γ0 to retrieve the quantity
p¯ie =
exp(γ0)
1 + exp(γ0)
, (5.10)
which represents the estimated marginal probability of unit QALYs. Depending on the value of
die, we can partition the observed data on the QALYs into two subsets. In the first subset, defined
as the n1 subjects for whom die = 1, we define a variable e1i = 1. Conversely, the second subset
consists of the n<1 = (n − n1) subjects for whom die = 0 and for these individuals we define a
variable e<1i .
Because the individuals associated with e<1i have QALY values that are less than 1, we can
model this variable directly using a Beta distribution, which is characterised by an overall mean
µ<1e . Next, using the estimated value for p¯ie from Equation 5.10, we can compute the overall
population average QALYs measure µe as the linear combination
µe = (1− p¯ie)µ<1e + p¯ie, (5.11)
where the parameters p¯ie and (1 − p¯ie) in effect represent the weights used to mix the means of
the two components µ1e = 1 and µ<1.
It is also possible to extend the cost model to account for the individuals associated with a zero
cost. However, because of the small number of ci = 0 in the MenSS trial, the inclusion of a hurdle
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module for the structural zeros has almost no impact on the posterior results for ci compared
with the Beta-Gamma model. We therefore keep the same specification for the cost model as
described in Equations 5.7 and 5.8.
Figure 5.2 shows a graphical representation of the Hurdle Model. In addition to the modules
ci
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Figure 5.2: Three modules form the framework. The first two are the marginal distribution of ei and the
conditional distribution of ci | ei, respectively indicated by the blue and red box. The third, indicated
by a green box, is the Hurdle module for die, which separates the structural (e1i ) and non-structural (e
<1
i )
values in ei. The solid black arrows show the dependence relationships between the parameters within the
modules, while the magenta (green) arrows show the dependence between the parameters of the QALYs
and costs (hurdle) modules. The dots enclosed in the square brackets indicate the potential inclusion of
other covariates at the mean level in the model for piie.
associated with the QALYs (blue box) and cost (red box) variables, the Hurdle Model is formed
by a third module related to the structural ones (green box), which allows to split ei into the two
components e1i and e
<1
i . Using the modular structure of the framework it is possible to increase
model complexity in a relatively easy way to account for the presence of structural values in either
or both the outcomes, while simultaneously capturing both correlation and skewness.
5.3 All Cases Scenario
Each of the three models specified under the “complete cases” scenario can be easily extended
to what we term the “all cases” scenario by additionally imputing the values for all individuals with
unobserved data.
Specifically, when missingness occurs in the QALYs and/or cost variables, no change to the
models is required under a MAR assumption for both the Bivariate Normal and Beta-Gamma
specifications. For the Hurdle Model, when ei is missing, it is not possible to directly define the
value for die. However, unit QALYs can only be observed if uij = 1 for all time points j = 0, . . . , J .
Consequently, we can use the observed values for uij to inform the corresponding value for die; if
an individual i is such that uij is missing at some time point j and uij 6= 1 at any other time point,
then by necessity die = 0. Notice that for all individuals having uij = 1 at all observed time points,
but with at least one missing value at some other time point, die is unknown.
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When present in the analysis, incomplete covariates need to be explicitly modelled to impute
their missing values. Within the framework, this corresponds to adding a new module for each
of these variables. In the MenSS trial, the only partially-observed covariates are the baseline
utilities ui0, which are linked to ei (all models) and die (only Hurdle Model) to account for their
impact on the inferences. The missing values in ui0 under the Bivariate Normal and the Beta-
Gamma formulations are handle by assuming the same distribution of the outcome ei, i.e. Normal
and Beta, respectively. In general, if other partially-observed covariates are available, the same
approach can be extended to handle the missing values in those variables.
As for the Hurdle model, it is possible to apply the same approach used for ei to handle the
structural ones in the baseline utilities through the inclusion of a module for ui0 = 1. First, a model
for the individuals with a non-unit utility value u<1i0 is specified. Again, a simple solution is to base
this on the same distribution assumed for e<1i , i.e. Beta. Second, the probability of observing a
structural one in the baseline utilities piiu is estimated as
diu := I(ui0 = 1) ∼ Bernoulli(piiu)
logit(piiu) = κ0 [+ . . .],
(5.12)
where diu is the indicator variable for observing u1i0 in the baseline utilities and κ0 is the intercept
term of the logistic regression of piiu. Similarly to the QALYs model, we can include other terms in
Equation 5.12 to capture the impact of relevant covariates on piiu.
5.3.1 Sensitivity analysis (MNAR)
Finally, we expand the Hurdle Model under the “all cases” scenario to assess the robustness of
the results to some departures from MAR. Specifically, hurdle models offer a convenient setting
for performing a simple type of sensitivity analysis to the missingness assumptions.
The analysis involves two groups of cases: a) the individuals for whom utility values are miss-
ing throughout the follow up, i.e. uij = NA for all j = 1, . . . , J ; b) the individuals for whom all the
observed utilities are equal to 1, but with at least one time point j at which uij = NA.
For both these groups, it is impossible to compute the value of the indicator die according to
the information from the observed data and, under MAR, these cases are assigned by the model
to either e1i or e
<1
i . However, given that for these individuals no utility score < 1 is ever observed,
it is plausible to assume that at least some of them remain in full health for the entire duration of
the trial and are therefore belong to e1i . We can then use the structure of the Hurdle Model and
arbitrarily set the value of die to either 1 or 0 using different configurations, e.g. by varying the
number of structural values potentially observed in a given scenario. Since these configurations
are based on assumptions about the missing values that cannot be verified from the data at hand
(but are in fact arbitrarily set by the experimenter), they effectively represent a way to assess the
robustness of the results to some departures from MAR.
In the MenSS trial, there are n∗ = 13 (12%) individuals in the control and n∗ = 22 (26%)
in the intervention group who fall within group a or b. Thus, we perform sensitivity analysis by
defining a set of alternative MNAR scenarios for these individuals and assess the robustness of
the results across them. The four different scenarios considered are summarised in Table 5.1.
We choose these scenarios in order to assess the impact of different “extreme” combinations of
the number of potential structural ones in the intervention and control groups on the inferences
and cost-effectiveness conclusions compared with the “all cases” scenario under MAR. Although
these scenarios are associated with deterministic MNAR values, they can be incorporated in
the framework at no extra cost in terms of model complexity and are meant to provide a broad
assessment about the impact that missingness uncertainty may have on the final conclusions and
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Scenario Control (n∗ = 13) Intervention (n∗ = 22)
MNAR1 die = 1 die = 1
MNAR2 die = 0 die = 0
MNAR3 die = 1 die = 0
MNAR4 die = 0 die = 1
Table 5.1: Alternative MNAR scenarios considered in the MenSS study for the Hurdle Model. In each
scenario, individuals who are potentially associated with a unit QALYs in the control (n∗ = 13) and
intervention (n∗ = 22) group are assigned to either the structural or non-structural components by setting
the value of the indicator die equal to 1 or 0, respectively.
how these vary with respect to the results obtained under MAR. Specifically, if the results are
not robust to the departures explored, these “extreme” scenarios offer a starting point for further
analyses where more advanced methods can be used to explicitly allow for the variability in the
MNAR values, e.g. selection or pattern mixture models (Section 1.6). A novel modelling approach
which implements these methods in trial-based economic evaluations is presented and discussed
in Chapter 6.
5.4 Application to the MenSS trial
Following the original analysis in the MenSS trial, we fit all models under a “complete cases”
scenario and add the baseline utilities in the module for the QALYs. In the Hurdle Model, we
also include three fully-observed covariates, namely age, ethnicity and employment status (see
Section 3.1.1) in the linear predictor of Equation 5.9 to improve the estimation of the probability
of structural ones. We then extend the models to the “all cases” scenario by including the mod-
ule for ui0 into the framework and imputing all missing outcome data under MAR. In the Hurdle
Model, the baseline utilities are explicitly modelled using the hurdle approach and the estimation
of the probability of structural ones is again improved through the inclusion of age, ethnicity and
employment status in Equation 5.9 (for the QALYs) and Equation 5.12 (for the baseline utilities).
5.4.1 Software
We fitted all models to the MenSS data using JAGS, which is interfaced with R through the package
R2jags (Su and Yajima, 2015). We ran two chains with 20,000 iterations per chain, using a burn-in
of 10,000, for a total sample of 20,000 iterations for posterior inference. For each unknown quan-
tity in the model, we assessed convergence and autocorrelation of the simulations through visual
inspection of the density, trace and autocorrelation plots and other MCMC diagnostic measures.
These include the potential scale reduction factor (below 1.05 for all parameters) and the effective
sample size (at least 10,000 for all parameters).
Alternative prior distributions were considered to check that we were not incorporating any
unintended information into the models through the priors. We specified Uniform(0, 10000) and
Half-Normal(0, 1000) priors for the standard deviations or chose different values for the variance
of normally distributed regression parameters, e.g. Normal(0, 100000). Figure C.6, available in
Appendix C.3.3, shows the robustness of the posterior inferences of each model fitted to the
MenSS data to the three alternative priors considered. Overall, the results were robust to these
specifications.
The Hurdle Model as described in Section 5.2 can be implemented in JAGS using a simple “cod-
ing trick”. Appendix B.2 provides the full JAGS script for the Hurdle Model, while Appendix C.3.2
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shows the technical details of the coding trick for implementing the model and compares the
posterior results for the MenSS trial with respect to alternative configurations.
5.4.2 Model Assessment
We compare the fit of the different models using the DIC (Section 1.3.2). We consider a DIC
based on the observed data under an ignorability assumption for the missing data (i.e. integrated
over the missing data). The reason for the need to calculate the DIC for a specific model using
the observed data alone is that model fit should never be assessed with respect to the imputed
data (Daniels and Hogan, 2008). Indeed, the fit of the model to the imputed data depends on the
specific missingness assumptions made to derive those imputations, which can never be verified
from the available data, therefore making it difficult to use any measure of fit for the purpose of
model assessment. A sample algorithm for the computation of the DIC based on the observed
data is provided in Appendix A.2.1. In our analyses we calculated the observed data DIC only
for the modules that are in common between the models, i.e. excluding the contribution from the
structural indicators for the Hurdle Model.
Table 5.2 compares the values of the DIC and the effective number of parameters pD computed
from the observed data likelihood for each variable across the three models under the “all cases”
scenario. The total values for the DIC and pD for each model are also reported at the bottom of the
table, while values of the actual number of parameters for each variable and for the whole model
are reported in brackets. The number of parameters is similar in each specification, as indicated
Bivariate Normal Beta-Gamma Hurdle Model
variable DIC pD DIC pD DIC pD
u0 -92 3.7 (4) -322 4.3 (4) -2474 4 (4)
e | u0 -90 7.1 (6) -135 6.7 (6) -572 7.6 (6)
c | e 627 6.4 (6) 517 6 (6) 517 5.9 (6)
Total 445 17.2 (16) 60 17 (16) -2419 17.5 (16)
Table 5.2: DIC and pD based on the observed data likelihood for each variable in the Bivariate Normal,
Beta-Gamma and Hurdle Model fitted to the MenSS data. Total DIC and pD are reported at the bottom of
the table, while the actual number of parameters for each variable and for the whole models are reported
in brackets. The lowest DIC values are shown in italics.
by the almost identical values of pD; by contrast, the DIC values show considerable differences
between the models. The Bivariate Normal model is always associated with the highest DIC for
all variables. The Beta-Gamma and, especially the Hurdle model substantially improve the model
fit to the observed data. The baseline utilities are the variables associated with the largest DIC
decrease moving from either the Beta-Gamma or Bivariate Normal to the Hurdle Model. This is
expected as the Hurdle Model is better aligned with the empirical data distributions compared
with the other models. Similar conclusions are obtained when comparing the total DIC value for
the Bivariate Normal (536), Beta-Gamma (386) and Hurdle Model (−50) under a “complete cases”
scenario.
We also assess the fit of the models to the observed data using different types of posterior
predictive checks. Figure 5.3 shows the posterior predictive QALYs densities for the complete
cases from the Bivariate Normal, Beta-Gamma and Hurdle Model (light blue lines). These are
compared with the empirical distributions of the complete cases (dark blue lines) in both treatment
groups of the MenSS trial. When Normal distributions are used (Bivariate Normal model), the
replicated QALYs poorly fit the observed data in both the control and intervention groups. In
addition, the densities generated from the model fall outside the permitted range of the QALYs,
exceeding the upper threshold of 1. The Beta distributions (Beta-Gamma model) improve the
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Figure 5.3: Posterior predictive QALYs densities for Bivariate Normal, Beta-Gamma and Hurdle Model
(light blue lines) compared with the empirical distributions of the complete cases (dark blue lines) in the
control (panel a) and intervention (panel b) in the MenSS trial. For each model, 1000 replications of the
QALYs data are generated, of which only 15 are displayed in each graph for visualisation purposes.
fit to the observed data compared with the Normal distributions but, especially in the intervention
group, fail to capture the unit QALYs. Finally, extending the Beta distributions to a hurdle approach
for the structural ones (Hurdle Model) provides the best predictive performance among the models
assessed and most closely fits the empirical distributions in both treatment groups. The results
from other posterior predictive checks, which evaluate the predictive ability of the Hurdle Model
with respect to the QALYs variables are presented in Appendix C.3.5.
5.5 Results
5.5.1 Complete and All Cases Scenarios (MAR)
Figure 5.4 shows the posterior distributions of the mean QALYs and costs for both the control
and intervention group under a “complete cases” (red) and “all cases” (blue) scenarios for each
model under MAR. There are some discrepancies in the posterior distributions of the mean QALYs
(panels a-b) between the “complete cases” and “all cases” scenarios, with the magnitude varying
according to the treatment group and model considered. In general, the estimates under all cases
are lower in the control group and higher in the intervention group in comparison to those obtained
using the complete cases.
As for the mean costs (panels c-d), the estimates from a Gamma distribution are substantially
more skewed and are typically associated with higher estimates compared with those from a
Normal distribution. In addition, unlike the Bivariate Normal, both the Beta-Gamma and Hurdle
Model typically lead to mean cost estimates that are systematically lower under the “all cases”
scenario compared with the “complete cases” scenario.
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Figure 5.4: Posterior distributions for the marginal mean parameters of the QALYs (panels a-b) and cost
variables (panels c-d), expressed in £, in each group of the trial either under a “complete cases” (red)
or “all cases” (blue) scenario under MAR. The posterior results are presented for all model specifications
considered (Bivariate Normal, Beta-Gamma and Hurdle Model) and for each of these the posterior mean
estimates and associated 90% HPD interval bounds are reported.
5.5.2 Imputations under MAR
Figure 5.5 shows the observed QALYs in both treatment groups (indicated with black crosses)
as well as summaries of the posterior distributions for the imputed values, obtained from each
model. Imputations are distinguished based on whether the corresponding baseline utility value
is observed or missing (blue or red lines and dots, respectively) and are summarised in terms of
posterior mean and 90% HPD intervals.
There are clear differences in the imputed values and corresponding credible intervals be-
tween the three models in both treatment groups. Neither the Bivariate Normal nor the Beta-
Gamma models produce imputed values that capture the structural one component in the data.
In addition, as to be expected, the Bivariate Normal fails to respect the natural support for the
observed QALYs, with many of the imputations exceeding the unit threshold bound. These un-
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Figure 5.5: Imputed QALYs in the control and intervention groups based on the Bivariate Normal, Beta-
Gamma and Hurdle Model. Imputations are summarised in terms of posterior means and 90% HPD
intervals (coloured dots and lines) while an x symbol is used to denote the observed cases. Imputed
values are also distinguished according to whether the baseline utilities were either observed (blue) or
missing (red). The solid black line represents the upper bound for the QALYs (calculated over one year),
set at the value of 1.
realistic imputed values highlight the inadequacy of the Normal distribution for the data and may
lead to distorted inferences. Conversely, imputations under the Hurdle Model are more realistic,
as they can replicate values in the whole range of the observed data, including the structural ones.
Imputed unit QALYs with no discernible interval are only observed in the intervention group due
to the original data composition, i.e. individuals associated with a unit baseline utility and missing
QALYs are almost exclusively present in the intervention group.
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5.5.3 Sensitivity Analysis (MNAR)
For each of the alternative MNAR scenarios described in Section 5.3.1, as well as for the analysis
under MAR, Figure 5.6 shows posterior density strips (Jackson, 2008) for the structural one prob-
ability p¯ie and the marginal mean QALYs µe, in the control (red) and intervention (blue) groups.
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Figure 5.6: Density strip plots for the posterior distributions of the probability of structural ones (panel
a) and the marginal mean QALYs (panel b) under MAR and four alternative MNAR scenarios. For each
scenario, results are presented for the control (red) and the intervention (blue) groups.
Estimates under MAR indicate that the new intervention is associated with a probability of ob-
serving a structural one and a mean QALYs that are on average higher compared to the control.
Although the variations in the posterior mean QALYs across all scenarios do not exceed 0.05,
they have a substantial impact in terms of the relative effectiveness between the two treatments
because are associated with mean QALYs differentials of opposite sign. Specifically, while the re-
sults under both MAR and MNAR1 suggest that on average the new intervention is cost-effective
with respect to the control (E[∆e] > 0), the estimated quantities are highly unstable across the
other three MNAR scenarios. For example, under MNAR2 the probability of structural ones is sub-
stantially reduced in both groups and suggests on average an equivalent effectiveness between
the two groups (E[∆e] = 0). However, under MNAR3 and MNAR4 the differences between the
estimated probabilities and mean QALYs in the two groups are increased in magnitude and lead
to opposite mean differentials (E[∆e] < 0 under MNAR3 and E[∆e] > 0 under MNAR4).
These results indicate a high sensitivity of the sign of the effectiveness differential for the two
treatments in the MenSS trial with respect to the to the MNAR departures explored about the
number of structural ones which can be potentially observed in both groups.
5.6 Economic Evaluation
We complete the analysis on the MenSS trial by assessing the cost-effectiveness of the new
intervention with respect to the control, comparing the results of the different models under MAR
and the alternative MNAR scenarios explored for the Hurdle Model. We specifically rely on the
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examination of the EIB and IB distribution, together with the CEP and the CEAC to summarise
the economic analysis.
We first compare the economic results between the different models estimated under MAR
in terms of the impact on the Expected Incremental Benefit and Incremental Benefit distribution,
shown in Figure 5.7. Overall, for all willingness to pay k values, the three models show positive
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Figure 5.7: Expected Incremental Benefit (panel a) and Incremental Benefit distribution at k = 20000
(panel b) associated with the Bivariate Normal (red solid and dashed lines), Beta-Gamma (green solid
and dashed lines) and Hurdle (blue solid and dashed lines) models fitted to the data from the MenSS
study under the “all cases” scenario.
EIB values (solid lines, panel a). However, the Bivariate Normal model is associated with the
steepest slopes for the lines of the EIB and related lower/upper bounds (red solid and dashed
lines), followed by the Beta-Gamma (green lines) and Hurdle model (blue lines). This is reflected
in the plot of the IB (panel b), evaluated at k = £20, 000, where the distribution under the Bivariate
Normal model is shifted to the right compared with that of the Beta-Gamma and, even more, with
respect to that of the Hurdle model. The highest probability of cost-effectiveness (shaded areas)
is associated with the Bivariate Normal (0.95), followed by the Beta-Gamma (0.88) and the Hurdle
model (0.71).
The CEP (Figure 5.8, panel a) shows that, at a willingness to pay k = £20, 000, more than
70% of the samples for all three models (light red for the Bivariate Normal, light green for the
Beta-Gamma and light blue for the Hurdle Model) fall in the sustainability area and are associated
with negative ICERs, indicated by corresponding darker coloured dots. This suggests that the
new intervention can be considered as cost-effective compared with the control, by producing a
QALYs gain at virtually no extra costs or even saving money.
The CEAC (Figure 5.8, panel b) is evaluated up to a range for k of £40, 000 per QALY gained.
For each model, the results under MAR are reported using solid lines with different colours, i.e. red
for the Bivariate Normal, green for the Beta-Gamma and blue for the Hurdle Model. In addi-
tion, the results associated with the four MNAR scenarios are reported using different types of
dashed lines. Under MAR, for the Bivariate Normal and Beta-Gamma models the CEACs indi-
cate the cost-effectiveness of the new intervention with a probability above 0.8 for most values of k.
Conversely, under the Hurdle Model, the curve is shifted downward by 0.24 and 0.16 with respect to
the Bivariate Normal and Beta-Gamma models, respectively, and suggests a more uncertain con-
clusion. Perhaps unsurprisingly, none of these results is robust to the alternative MNAR scenarios
explored. The CEAC plot clearly shows a large sensitivity of the cost-effectiveness probability with
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Figure 5.8: CEPs (panel a) and CEACs (panel b) associated with the Hurdle (blue dots and line), Bivariate
Normal (red dots and line) and Beta-Gamma (green dots and line) models. In the CEPs, the ICERs based
on the results from the three model specifications under MAR are indicated with corresponding darker
coloured dots. For the CEACs, in addition to the results under MAR (solid lines), the probability values for
the four MNAR models described in Section 5.5.3 are represented with different types of dashed lines.
respect to the assumed number of structural ones in both treatment groups. Indeed, the curves
span a huge probability range from 0.2 under MNAR4 to 1 under MNAR3. This implies a consid-
erable change in the output of the decision process and severely undermines the validity of the
conclusions obtained under MAR.
5.7 Application to the PBS study
We show the flexibility of our framework by adapting the models in Section 5.1 to accommodate
the characteristics of the PBS data (Section 3.1.2). Specifically, we scale the QALYs to avoid neg-
ative values when using a Beta distribution, account for the multilevel structure in both outcomes
and replace the Gamma distribution for the costs with a LogNormal distribution, which improves
the fit to the observed data. In particular, the fit of the LogNormal distribution has a better fit com-
pared with a Gamma distribution, with respect to both the empirical density and cumulative density
functions evaluated on the observed costs in both treatment groups of the trial (see Figure C.12
in Appendix C.3.6).
We assess and compare the performance of three models. These are: 1) Bivariate Normal
for the two outcomes; 2) Beta marginal for the QALYs and LogNormal conditional for the costs;
and 3) Hurdle Model. All models account for the multilevel structure in the data and include three
fully-observed categorical covariates (living condition, level of disability and type of carer) to es-
timate the mean QALYs and costs. All models are fitted and assessed using the same software
configuration and diagnostic measures as in Section 5.4.1. The robustness of the posterior infer-
ences of each model fitted to the PBS data with respect to the three alternative prior specifications
described in Section 5.4.1 are shown in Figure C.7, which is available in Appendix C.3.3.
We first apply the models to the complete cases and then extend the analysis to all cases under
MAR. No sensitivity analysis as in Section 5.3.1 can be performed for the PBS study because for
each missing individual we observe a utility value that is lower than one at least at one time point,
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i.e. none of them can be a structural one. In the next section, we present the specification of
the Beta-LogNormal model to show an example of how the framework in Section 5.1 has been
modified to address the characteristics of the PBS data.
5.7.1 Beta-LogNormal
The second model consists of a Beta marginal for the QALYs and a LogNormal conditional for
the costs. Since the Beta distribution does not allow negative values, we scale the QALYs on
(0, 1) through the transformation e?i =
ei−min(ei)
max(ei)−min(ei) and fit the model to these transformed val-
ues. A similar scaling is applied to the baseline utilities u?i0 when these are modelled in the “all
cases” scenario. In both cases we use the theoretical lower (−0.594) and upper (1) bounds for the
utilities and QALYs to derive the variables on the transformed scale (the range of the two variables
are the same since QALYs are evaluated over one year in the PBS trial – see Section 1.2).
The Beta distribution is parameterised as in Section 5.2.2. The multilevel structure in the
QALYs and cost model is accounted for through site-specific regression coefficients for the base-
line utility and cost and intercept terms, respectively (i.e. varying-intercept/slope models), in ac-
cordance with the model specification assumed for the multilevel models in Chapter 4.
The QALYs are modelled as e?i | θe ∼ Beta (φieτie, (1− φie)τie) with location
logit(φie) = α0s + α1su?i0 [+ . . .], (5.13)
where αs = (α0s, α1s) include the structured coefficients for the intercept and u?i0 which are asso-
ciated with the s = 1, . . . , S sites.
The costs are modelled as ci | e?i ,θc ∼ LogNormal (φic, τc), where the mean and standard
deviation parameters (φic, τc) are defined on the log scale. The centered baseline costs (c?i0 =
ci0 − c¯0) are included in the cost model using the same multilevel specification used for ui0 in the
QALYs model. Modelling e?i on a transformed scale does not allow to directly identify the marginal
mean µe as in Equation 5.8 and therefore it is not possible to include the centered QALYs in the
cost regression.
This, however, does not affect the estimates of the model because mean centering is only
used to improve the efficiency of the MCMC sampling. Consequently, the cost location is
φic = β0s + β1s(e
?
i ) + β2s(ci0 − c¯0) [+ . . .], (5.14)
where βs = (β0s, β1s, β2s) are the site-specific baseline cost regression coefficients.
We retrieve the marginal means on the natural scale for both outcomes through Monte Carlo
integration. At each iteration of the posterior distribution for the model parameters in the MCMC
output, we generate a large number of samples for ei and ci and take the expectation over these
values to obtain Monte Carlo estimates of the marginal means µe and µc.
The model is completed by specifying Normal priors for the structured coefficients α i.i.d.∼
Normal(0,σα) and βs
i.i.d.∼ Normal(0,σβ) with shared standard deviations σα and σβ. Finally, we
choose independent Normal(0, 1000) priors for the other regression coefficients in Equation 5.13
and Equation 5.14 and a Uniform(0, 1000) for the standard deviations of the costs. The priors
on the standard deviations of the QALYs are specified using the same approach described in
Section 5.2.2.
5.7.2 Model Assessment
Similarly to the MenSS analysis, we compare each model fitted to the PBS trial using the DIC.
For multilevel models, the DIC can be computed in different ways according to whether the data
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likelihood is obtained by integrating out the random effects or conditional on them. Following cur-
rent recommendations (Ntzoufras, 2009), for all multilevel models we compute the DIC based on
the observed data likelihood under ignorability of the missing data but conditional on the random
effects. For those models for which the sampling distributions of the outcomes were not available
in closed form (Beta-LogNormal and Hurdle), Monte Carlo integration was used to calculate the
corresponding likelihood and DIC. A more detailed discussion of how this type of DIC for multilevel
models can be computed is provided in Appendix A.2.
Table 5.3 compares the DIC and pD values computed from the observed data likelihood for
each variable in the three models specified under the “all cases” scenario. Since ci0 are fully
available in the PBS study, these variables are not directly modelled but are only included as
covariates in all models. The total DIC and pD values are reported at the bottom of the table. The
Bivariate Normal Beta-LogNormal Hurdle Model
variable DIC pD DIC pD DIC pD
u0 210 4.1 -103 4.1 -402 4.0
e | u0 45 28 -124 26 -135 25
c | e 4431 18 4080 39.8 4082 41
Total 4686 50.1 3853 69.9 3545 70
Table 5.3: DIC and pD based on the observed data likelihood for each variable in the Bivariate Normal,
Beta-LogNormal and Hurdle Model fitted to the PBS data. Total DIC and pD are reported at the bottom of
the table, with the lowest DIC value shown in italics.
cluster-specific terms in both the QALYs and cost regressions do not allow to identify the actual
number of parameters in the models. DIC values are computed conditional on the cluster, where
pD incorporates the estimated dimensionality of the random effects and takes into account the
partial pooling of the coefficient estimates.
The Hurdle Model is associated with the lower DIC values for all variables compared with the
alternative specifications. The DIC computed on both the modules of ui0 and ei0 show relatively
large differences between the Bivariate Normal and either the Beta-LogNormal or the Hurdle
Model. Cost variables are generally associated with lower DIC values when assuming LogNormal
compared with Normal distributions. Similar conclusions are obtained when computing the total
DIC values for the Bivariate Normal (5017), Beta-LogNormal (4538) and the Hurdle Model (3930)
under the “complete cases” scenario.
Figure 5.9 compares the posterior predictive cost densities for the complete cases from the
three models (light blue lines) with the empirical cost distributions (dark blue lines) in both treat-
ment groups of the PBS trial. The replicated data under both the Beta-LogNormal and Hurdle
Model more closely fit the observed data distributions compared with those from the Bivariate
Normal, especially in the control group (panel a), even though no replicated samples seem to ad-
equately capture the spike of the costs in the intervention (panel b) group. Among all replications
compared, those from the Bivariate Normal have the worst fit to the observed data and lead to
some unrealistic negative cost values. Appendix C.3.5 provides the results from other posterior
predictive checks for the Hurdle Model, computed on the cost variables.
5.8 Results
5.8.1 Complete and All Cases (MAR)
Figure 5.10 shows the QALYs and cost mean parameters posterior densities by treatment group
from the Bivariate Normal, Beta-LogNormal and Hurdle Model. The posterior distributions of the
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Figure 5.9: Posterior predictive cost densities for Bivariate Normal, Beta-LogNormal and Hurdle Model
(light blue lines) compared with the empirical distributions of the complete cases (dark blue lines) in the
control (panel a) and intervention (panel b) in the PBS trial. For each model, 1000 replications of the cost
data are generated, of which only 15 are displayed in each graph for visualisation purposes.
mean parameters are almost identical between the “complete cases” and “all cases” scenarios for
both outcomes and treatment groups. Mean QALYs estimates show slight variations between the
models (panels a-b), especially in the intervention where estimates under the Beta-LogNormal
and Hurdle Model are lower compared to the Bivariate Normal. Mean cost distributions are char-
acterised by some differences between the models in both treatment groups (panels c-d), with
estimates from the Beta-LogNormal and Hurdle Model which are systematically lower compared
with the Bivariate Normal.
5.8.2 Imputations under MAR
Figure 5.11 shows the imputed QALYs in both treatment groups in the PBS study under MAR for
the Bivariate Normal, Beta-LogNormal and Hurdle Model. Some imputations under the Bivariate
Normal exceed the upper threshold of one for the QALYs in both treatment groups. Therefore,
implausible values ( i.e. QALYs values that could not be observed in the PBS study) occur among
the imputations. Conversely, both the Beta-LogNormal and Hurdle Model show imputed values
that fall within the correct range of the data and suggest a better ability of the models to fit the
observed data compared with the Bivariate Normal. No imputed value in both treatment groups
under the Hurdle Model is associated with a structural one. This is due to the fact that all individ-
uals in the PBS trial are associated with at least one observed utility value which is less than one
at some time point, i.e. they cannot be associated with a unit QALYs.
5.9 Economic Evaluation
Figure 5.12 compares the estimates for the Expected Incremental Benefit and Incremental Ben-
efit distribution obtained under the different models under MAR. The Bivariate Normal model is
associated with the steepest EIB slope with positive/negative value after/before the willingness to
pay value k = £20, 000 (red solid line, panel a). The Beta-Lognormal and Hurdle model show
very similar estimates for the EIB, which are negative for most of the values of k (green and blue
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Figure 5.10: Posterior distributions for the marginal mean parameters of the QALYs (panels a-b) and cost
variables (panels c-d), expressed in £, in each group of the PBS trial under either a “complete cases” (red)
or “all cases” (blue) scenarios. Results are presented for all model specifications considered (Bivariate
Normal, Beta-LogNormal and Hurdle Model), with mean estimates and 90% HPD intervals reported in
the graphs.
solid lines). Similar conclusions are obtained by looking at the EIB falling within the lower/upper
bound estimates (dashed lines) which, however, contain both positive and negative values for all
models. Most of the IB distribution under each model (panel b), evaluated at k = £20, 000, falls
below 0, especially for the Beta-Lognormal and Hurdle models which show a probability of cost-
effectiveness (green and blue shaded areas) that are substantially lower compared with that of
the Bivariate Normal (red shaded area).
Figure 5.13 shows the CEP and CEAC for the Bivariate Normal (red dots and line), Beta-
LogNormal (green dots and line) and Hurdle Model (blue dots and line) for the “all cases” scenario
under MAR.
For all three models, almost all samples in the CEPs (Figure 5.13, panel a) are located in
the North-Eastern quadrant and most of them fall in the sustainability area at a willingness to
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Figure 5.11: Imputed QALYs in both groups in the PBS trial based on the Bivariate Normal, Beta-
LogNormal and Hurdle Model. Imputations are summarised in terms of means and 90% HPD intervals
(coloured dots and lines) while an x symbol denotes the observed cases. Imputed values are distin-
guished according to whether the corresponding baseline utilities were either observed (blue) or missing
(red). The solid black line represents the upper bound for the QALYs (calculated over one year), set at the
value of 1.
pay k = £20, 000. Results from the Bivariate Normal model suggest a higher cost-effectiveness
of the new intervention and are associated with a lower ICER compared with those of the other
two models. This is reflected in the CEACs (Figure 5.13, panel b) which show a probability of
cost-effectiveness that is on average 20% higher for the Bivariate Normal with respect to the Beta-
LogNormal and Hurdle Model.
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Figure 5.13: CEPs (panel a) and CEACs (panel b) associated with the Hurdle (blue dots and line),
Bivariate Normal (red dots and line) and Beta-LogNormal (green dots and line) models.
5.10 Discussion
In this chapter we have presented a flexible Bayesian framework that can handle the typical com-
plexities affecting outcome data in CEA, while also being relatively easy to implement using freely
available Bayesian software. This is a key advantage that can encourage practitioners to move
away from likely biased methods and promote the use of our framework in routine analyses.
The analysis of both case studies shows notable variations in the results, compared with those
of the original analyses. In the MenSS trial, accounting for the structural ones and missingness
uncertainty has a considerable impact on the cost-effectiveness of the new intervention and future
research prioritisation. In the PBS trial, the results of the economic evaluation change substan-
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tially when skewness is accounted for. In both cases, the Hurdle Model represents the best model
among those assessed as it captures both skewness and structural values, while the other speci-
fications fail to deal with at least one of these features.
Our results are obtained with specific reference to the two case studies. Specifically, the
MenSS trial is a pilot RCT in which a large proportion of individuals have missing QALYs and
cost values, while in the PBS trial some individuals in both treatment groups have negative QALY
values. However, both the MenSS and PBS trials are very much representative of the “typi-
cal” dataset used in CEAs alongside RCTs. Thus, it is highly likely that the same features (and
potentially the same contradictions in the results, upon varying the complexity of the modelling
assumptions) apply to many real cases.
We have demonstrated one possible way of assessing the robustness of the results to some
“extreme” MNAR scenarios that can be incorporated in the framework at no extra cost in terms
of model complexity. This analysis is easy to implement and offers a plausible starting point to
assess the impact of missing data uncertainty on the results. In Chapter 6, we will show how
the framework can be extended to incorporate a sensitivity analysis to nonignorable missingness
using a PMM approach.
In conclusion, our framework can: a) jointly model costs and QALYs; b) account for skewness
and structural values; and c) assess the robustness of the results under a set of differing miss-
ingness assumptions. The original contribution of this work consists in the joint implementation of
methods that account for the complexities of the data within a unique and flexible framework that is
relatively easy to apply. In the next chapter we will take a step forward in the analysis and present
a longitudinal model that can use all observed utility and cost data in the analysis, explore alterna-
tive nonignorable missing data assumptions, while simultaneously handling the complexities that
affect the data.
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Key points of this chapter:
• We present a flexible Bayesian framework that jointly allows for the typical com-
plexities that affect QALYs and cost data in CEA (e.g. skewness and spikes).
The framework relies on the specification of a general modelling structure based
on parametric distributions and combined modules in which variables are linked
through logical relationships.
• We applied our framework to the MenSS and PBS trials. We compared the perfor-
mance and inferences from a set of increasingly complex models that accounted
for different types of complexities and data characteristics. Posterior results were
in general sensitive to model specification and demonstrated the bias associated
with routine analyses that ignore at least some of the complexities.
• In the MenSS trial, the model specification was extended to assess the robustness
of the results to some “extreme” MNAR departures that can be implemented in the
framework at no extra cost in terms of model complexity. As expected from the
large proportions of unobserved values, inferences were sensitive to missingness
assumptions and demonstrated that results under MAR are likely to be biased for
this study.
• Our approach allows to jointly account for different data complexities within a
unique and flexible framework, which can be implemented using freely available
Bayesian software (e.g. JAGS). These are key features that can encourage an-
alysts to abandon likely biased methods and improve the quality of the work in
economic evaluations.
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Chapter 6
A Bayesian Longitudinal Model for
Handling Nonignorable
Missingness in Health Economic
Evaluation
In the previous chapter we have shown how a flexible Bayesian parametric framework can be
constructed to jointly handle some of the complexities that affect trial-based CEA data and to
conduct a sensitivity analysis to some “extreme” MNAR scenarios within a cross-sectional setting.
In this chapter we extend the missing data analysis to formally account for the longitudinal nature
of the data using a proper nonignorabale approach to handle missingness.
We present a Bayesian parametric model for conducting inference on the bivariate health
economic response formed by the utility and cost data at each time point in a trial. The model
expands the framework in Section 5.1 to a longitudinal setting to more efficiently deal with miss-
ingness and accommodates a sensitivity analysis to assess the robustness of the inferences and
decision-making to a range of plausible nonignorable assumptions.
The proposed approach is motivated by and applied to the PBS data (Section 3.1.2), which
present some features that make the study more suited to the implementation of the proposed
framework compared with the MenSS trial. These include: a larger sample size and more mod-
erate missingness rates across the follow-ups, an equal number of utility and cost variables at
each time point (the baseline costs were not collected in the MenSS study), and the existence of
observed utilities or costs at each time which can be used to inform the imputation of the other
outcome at the same time (Section 3.1). Finally, while in the MenSS trial no external information
was available to inform the MNAR departures to explore in sensitivity analysis, in the PBS trial it
was possible to at least partially inform the direction and magnitude of the departures from MAR
based on a discussion with the people involved in the trial. A synthesised version of this chapter in
the form of a research article has been submitted for publication in Journal of the Royal Statistical
Society: Series A.
6.1 Longitudinal Modelling Framework
We first present the longitudinal modelling framework for handling nonignorable missingness in
trial-based individual-level CEA. Then, we demonstrate the benefits of adopting this approach
using the PBS trial as motivating example.
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Our nonignorable approach consists in specifying a full data model p(y, r) for the joint distri-
bution of the response y = (uijt, cijt) and missingness r = (ruijt, r
c
ijt) process based on the utility
and cost data collected on the i-th person at time j in treatment group t of the trial. The modelling
strategy uses the extrapolation factorisation (Section 1.6.1) to factor p(y, r) into the observed data
distribution p(yrobs, r) and the extrapolation distribution p(y
r
mis | yrobs, r).
The observed data distribution p(yrobs, r) is specified using a working model, which is fitted
to p(y, r) and from which missingness is integrated out to leave the extrapolation distribution
unidentified. A pattern mixture factorisation is used to separately specify a model for the marginal
distribution of the missingness patterns p(r | λ) and the distribution of the response conditional
on the patterns p(y | r,η), respectively indexed by the parameters λ and η.
Ideally, all pattern-specific response distributions should be modelled separately. However,
in the PBS study, missingness is non-monotone and the data in most patterns are sparse (see
Section 3.1.2), which makes practically infeasible to fit the response model within each pattern,
with the exception of the completers (r = 1). Alternative non-ignorable approaches, e.g. Selec-
tion Models (Section 1.6) could be considered but these are not well-suited for implementing the
extrapolation factorisation and make the identification of sensitivity parameters, and therefore the
incorporation of missingness assumptions, not transparent and often difficult to check (Daniels
and Hogan, 2008).
Thus, to overcome this problem, we collapse together all the non-completers patterns (r 6= 1)
and fit the model separately to this aggregated pattern and to the completers. This strategy as-
sumes that the reasons for missingness do not largely differ across the non-completers, which
may not be realistic in some cases. However, it allows to identify the distribution of the responses
for those who have some unobserved data without relying on the observations from the com-
pleters. The model is also well-suited to implement the extrapolation factorisation, which in turn
allows to retrieve differences across the non-completers’ patterns through the incorporation of
sensitivity parameters with distributions that vary by type of outcome and time point (see Sec-
tion 6.3.1).
Using the pattern mixture model approach (Section 1.6) we can express the full data model as
p(y, r | ω) = p(y | r,η)p(r | λ), (6.1)
where ω = (η,λ) are the parameters of the joint distribution. Next, we apply the extrapolation
factorisation to the right hand side of Equation 6.1 (Section 1.6.1) and obtain
p(y, r | ω) = p(yrobs | r,ηO)p(yrmis | yrobs, r,ηE)p(r | λ), (6.2)
where η = (ηO,ηE) are the parameters which index p(y | r) and which are associated with the
observed data and the extrapolation distributions. Finally, we re-arrange the terms in Equation 6.2
and distinguish the components of p(y | r) on the right-hand side with respect to the completers
(r = 1) and non-completers (r 6= 1), and the sets of parameters associated with these cases:
ηr=1O = ηC for the completers, η
r 6=1
O = ηNC for the observed data among the non-completers, and
ηr 6=1E = ηE for the missing data among the non-completers. The model can be represented as
p(y, r | ω) = p(r | λ) [p(yrobs | ηC)]I{r=1}
[p(yrobs | ηNC)]I{r 6=1}
}
observed data distribution (6.3)
[p(yrmis | yrobs,ηE)]I{r 6=1} , extrapolation distribution
where the upper index I is used to distinguish the different components of the model according
to the sets of cases to which they are related. The parameters ω = (η,λ) index the full data
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model, while η = (ηC,ηNC,ηE) are the parameters of the pattern-specific response model: ηC
and ηNC are the distinct subsets of η that index the response model for the observed data in the
completers and non-completers patterns, while ηE is the subset of η that indexes the extrapolation
distribution. Among the non-completers there are both yrmis and y
r
obs because the model is fitted
to the aggregated pattern r 6= 1 where intermittent missingness occurs (e.g. some individuals can
be observed at j = 1 but not at j = 0).
The joint distribution p(y, r | ω) has three components. The first is the model for the missing-
ness patterns and the response model fitted to r = 1. The second is a model fitted to the joint
set of the noncompleters, from which the missing values are integrated out to obtain a model for
the observed data in r 6= 1. This, together with the first component, forms the observed data
distribution. The last is the extrapolation distribution. Example 6.1 shows how each component of
the factorisation in Equation 6.3 can be identified within a basic analysis setting.
Table 6.1 displays the utility and cost data from the first few individuals in the PBS study and
indicates the components of yrmis and y
r
obs in r 6= 1 with red and blue cells, respectively. Across
the non-completers, the missing and observed responses vary between utilities and costs and by
time point. For example, at j = 1, yr 6=1mis includes the missing utilities for i = 5, 6, 7, 10 and y
r 6=1
obs
includes the observed utilities for i = 4, 8, 9. Similarly, at time j = 1, yr 6=1mis contains the missing
costs for i = 7, 10 and yr 6=1obs contains the observed costs for i = 4, 5, 6, 8, 9.
r i j = 0 j = 1 j = 2
pattern subject utilities costs utilities costs utilities costs
r = 1 1 0.173 £9214 0.329 £961 0.436 £1973
r = 1 2 0.850 £2492 0.692 £3437 0.336 £4550
r = 1 3 -0.166 £15283 0.242 £2535 0.815 £3007
r 6= 1 4 – £1085 0.436 £1595 0.365 £3728
r 6= 1 5 0.815 £3799 – £2176 0.848 £533
r 6= 1 6 0.436 £178 – £474 0.244 £879  yr 6=1mis
r 6= 1 7 0.436 £4051 – – 1 £107
r 6= 1 8 0.367 £1197 0.367 £2580 – –  yr 6=1obs
r 6= 1 9 0.708 £3788 0.815 £1597 – –
r 6= 1 10 0.273 £3412 – – – –
Table 6.1: Utility and cost data for the i-th subject at each time j derived from a subset of the first 10
subjects in the PBS study. The response components in yr 6=1mis and y
r 6=1
obs are indicated with red and blue
coloured cells, respectively. Missing responses are indicated with a − sign.
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Example 6.1
Let yij and rij denote a partially-observed univariate outcome and the corresponding missing
data indicator associated with the i−th individual at the j−th time point in the study. Consider
the simplified framework in which the total number of time points is two (j = 0, 1) and three
different missingness patterns r = (r0, r1) are observed: completers; r = (1, 1), missing
only at j = 0; r = (0, 1), and missing only at j = 1; r = (1, 0).
We specify the full data model p(y, r | ω) in terms of the marginal model of the pat-
terns p(r | λ) and the conditional model of the response given the patterns p(y | r,η),
where ω = (η,λ). The response model p(y | r,η) is specified using a multivariate Normal
distribution yr ∼ Normal (µr,Σr), where µr and Σr denote the mean and covariance matrix
parameters in each pattern. We focus our attention on the mean parameters µr and assume
that the covariance matrix has a simplified form Σr = Σ that can be estimated from the data.
Thus, the parameters of interest are given by µr =
(
µ
r=(1,1)
j , µ
r=(0,1)
j , µ
r=(1,0)
j
)
, for j = 0, 1.
Because the responses are missing in certain patterns, not all parameters can be identified
from the data. Equation 6.3 identifies µr through the extrapolation factorisation, which splits
the response distribution into three components.
1 The distribution of the completers p(yrobs | ηC), indexed by the parameters ηC =
(µ
r=(1,1)
0 , µ
r=(1,1)
1 ), includes all the responses y in r = (1, 1).
2 The distribution for the observed data among the non-completers p(yrobs | ηNC), indexed
by the parameters ηNC = (µ
r=(1,0)
0 , µ
r=(0,1)
1 ), only includes the observed responses
across r 6= 1, i.e. y0 in r = (1, 0) and y1 in r = (0, 1).
3 The extrapolation distribution p(yrmis | yrobs,ηE), indexed by the parameters ηE =
(µ
r=(0,1)
0 , µ
r=(1,0)
1 ), only includes the missing responses across r 6= 1, i.e. y0 in
r = (0, 1) and y1 in r = (1, 0).
The parameters ηC and ηNC are estimated from fitting the model to the completers and the
joint set of the non-completers patterns under ignorability, respectively. This ensures that
inferences are obtained only based on the fit of the model to the observed data (which can
be validated) without making any assumptions about the distribution of the missing values
(which cannot be checked). Therefore, it is possible to perform model selection and choose
the model which has the best fit to the observed cases among those assessed. The identifi-
cation of the model can be then completed using a combination of identifying restrictions and
sensitivity parameters to identify the parameters of the extrapolation distribution ηE. Differ-
ent types of identifying restrictions can be used in practice, but they all have the objective to
provide a convenient framework for the incorporation of sensitivity parameters into the model
on which informative priors are typically specified to define the MNAR departures to explore.
For example, in the given example, we can identify ηE using the complete case missing value
restrictions (Section 1.6.3) and some sensitivity parameters δ,
ηE = ηC + δ.
When δ = 0, the model is fully identified using only information from the observed data and
some constraints (which cannot be verified from the data) to identify the parameters that
index the missing data distribution (i.e. equal to those of the completers). However, these
constraints can then be relaxed through the specification of informative priors on δ to define
a range of nonignorable departures, for example, by eliciting some external source of evi-
dence (e.g. experts’ opinion). Compared to alternative nonignorable models, e.g. selection
models (Section 1.6), this approach do not rely on assumptions about the joint distribution
of observed and missing data, which are often difficult to check and which make the identifi-
cation of sensitivity parameters and the incorporation of external information into the model
more problematic.
Within the given setting, each component in the extrapolation factorisation can be identified
in relatively easy way. However, in real applications, analysts are typically faced with a more
complex framework (e.g. multivariate outcomes, higher number of time points and missing-
ness patterns) which makes the implementation of the model more challenging. Section 6.4
shows the application of the proposed approach to the PBS study.
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Since the mean utilities and costs are the target of the inference, in our analysis we do not
require the full identification of the extrapolation distribution. Instead, we only require the identi-
fication of the marginal means for the missing responses in each pattern. Thus, we identify the
extrapolation distribution using a combination of partial identifying restrictions and sensitivity pa-
rameters (Section 1.6.3). We compute the marginal means E[yrmis] by averaging only with respect
to the components of yrobs across r 6= 1, and then add some sensitivity parameters δ. We start
by setting δ = 0 as a benchmark assumption and then explore the sensitivity of the results to
alternative scenarios by using different prior distributions on δ, calibrated on the observed data.
For example, we can choose the values of the hyperparameters of these priors in terms of the
variability in the observed data (e.g. using the sample standard deviations) to define the extent of
the departures from the benchmark. Once the working model has been fitted to the observed data
and the extrapolation distribution has been identified, the overall marginal mean for the response
model can be computed by marginalising over r, i.e. E [y] =
∑
p(r)E [y | r].
6.2 Observed Data Distribution
The observed data distribution p(yrobs, r) is specified in terms of a model for the missingness
patterns r and a model for the observed responses yrobs in both the completers (r = 1) and
non-completers (r 6= 1) patterns. We specify these in the following subsections.
6.2.1 Model for the missingness patterns
The model for the missingness patterns is specified as a multinomial distribution
r ∼ Multinomial (λrt ) , (6.4)
which is defined on {1, . . . , Rt}, with the total number of patterns Rt and the probabilities λrt
conditional on the treatment assignment t. Since the proportions of the individuals in the com-
pleters is considerably higher in both treatment groups of the PBS trial compared with any other
pattern (Section 3.1.2), it seems reasonable to account for this characteristic of the data in the
construction of the prior for λrt . We specify a prior on λrt that gives more weight on the completers
compared with the other patterns. For all non-completers, we assume equal prior weights since
no information was available to justify the choice of pattern-specific weights, which are also ex-
pected to have limited impact on the posterior inferences of the model due to the sparsity of the
data among the non-completers.
Therefore, we choose a Dirichlet
(
1− x, xR? , . . . , xR?
)
prior, where x and R? are the expected
total dropout rate and the total number of potential patterns, respectively. In the PBS trial, the ex-
pected dropout rate is equal to 0.2 and is obtained from the original analysis plan of the study (Has-
siotis et al., 2018), while the number of potential patterns is given by 22J = 64. This prior choice is
consistent with the design of the study, where the experimenter expects at least (1−x)% of the in-
dividuals to provide complete data, i.e. to fall in r = 1. In practice, this prior is not likely to affect the
results as the amount of observed data is enough to learn the posterior of λrt . For comparison pur-
poses, we also consider another specification based on a noninformative Dirichlet(1, . . . , 1) prior
for λrt in Equation 6.4. Posterior results for the patterns’ probabilities λrt and the marginal mean
utilities and costs, which are shown in Figure C.13 and Figure C.14 in Appendix C.4.1, were robust
to the alternative prior choices.
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6.2.2 Model for the observed responses
The model for the observed responses yrobs is specified separately for each treatment group t and
extends the cross-sectional framework described in Section 5.1 to handle the utilities and costs
within a longitudinal setting. In particular, the model accounts for three different types of complex-
ities that affect the data.
First, the dependence both between each pair of outcome variables (uij , cij) and over time is
accounted for using a series of conditional distributions. Second, skewness is handled assum-
ing Beta and Log-Normal distributions for the utilities and costs, respectively. Since in the PBS
study negative values for uij occur, as for the analysis in Section 5.7, utilities are scaled on [0, 1]
through the transformation u?ij =
uij−min(uj)
max(uj)−min(uj) . The Beta distributions are then fitted to these
transformed variables, which are referred to simply as uij to ease the notation. Third, to account
for the structural values uij = 1 and cij = 0 a hurdle approach is specified by including in the
model the corresponding indicator variables duij := I(uij = 1) and dcij := I(cij = 0). These indica-
tors take value 1 if subject i is associated with a structural value at time j and 0 otherwise. The
probabilities of observing these values, as well as the mean of each variable, are then modelled
conditionally on the utilities and costs at the current and previous times via linear regressions
defined on the logit or log scale. Compared to the hurdle approach in Section 5.1, which only ac-
counted for the structural ones in the QALYs, the model includes the indicator variables to handle
the structural values in both the utility and cost outcomes. This is due to the fact that, within the
cross-sectional framework of Section 5.7, where the modelled variables were cit, no individual
was associated with a null total cost. However, within a longitudinal framework, where the costs
at each time point cijt are modelled, some individuals in both treatment groups (3 in the control
and 2 in the intervention) are associated with a zero at some time point and a hurdle approach is
then used to handle them.
The model can be summarised as follows (for simplicity we omit the treatment index t). At time
j = 0, we model the nonzero costs and the indicator dci0 := I(ci0 = 0) as:
ci0 | dci0 = 0 ∼ LogNormal (φc0, τ c0 )
dci0 ∼ Bernoulli(pic0)
(6.5)
where φc0 and τ c0 are the mean and standard deviation for ci0 given ci0 6= 0 on the log scale,
while pic0 is the probability of a zero cost value. We next model the utilities and the indicator
dui0 := I(ui0 = 1) conditionally on the costs at the same time:
ui0 | dui0 = 0, ci0 ∼ Beta (φui0τui0, (1− φui0)τui0)
logit(φui0) = α00 + α10 log ci0
dui0 | c0 ∼ Bernoulli(piui0)
logit(piui0) = γ00 + γ10 log ci0
(6.6)
where φui0 and τ
u
i0 are the mean and precision for ui0 given ui0 6= 1 and ci0, while piui0 is the
probability of having a utility value of one given ci0. We use logistic transformations to define a
linear dependence for p(ui0 | ci0, ui0 6= 1) and include the costs on the log scale to avoid numeric
instability in the estimation of the logistic regression parameters. This was due to the sparsity of
the data (especially among the non-completers) and the very different range of values between
the costs on the natural scale (in the order of thousands) and the probabilities.
At time j = 1, 2, we extend the approach illustrated in Equation 6.5 and Equation 6.6 for j = 0,
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assuming a first-order Markov dependence structure. For the costs we have:
cij | dcij = 0, cij−1, uij−1 ∼ LogNormal
(
φcij , τ
c
j
)
φcij = β0j + β1j log cij−1 + β2juij−1
dcij | cij−1, uij−1 ∼ Bernoulli(picij)
logit(picij) = ζ0j + ζ1j log cij−1 + ζ2juij−1.
(6.7)
Similarly to time j = 0, the mean and standard deviation on the log scale and the probability
parameters for the costs at time j are indicated with φcij , τ
c
j and pi
c
ij . The regression parame-
ters βj = (β0j , β1j , β2j) and ζj = (ζ0j , ζ1j , ζ2j) in Equation 6.7 capture the dependence between
costs at j and the costs and utilities at j − 1, for the non-zero and zero components, respectively.
The model for the utilities is:
uij | duij = 0, cij , uij−1 ∼ Beta
(
φuijτ
u
ij , (1− φuij)τuij
)
logit(φuij) = α0j + α1j log cij + α2juij−1
duij | cij , uij−1 ∼ Bernoulli(piuij)
logit(piuij) = γ0j + γ1j log cij + γ2juij−1.
(6.8)
We denote with φuij , τ
u
ij and pi
u
ij the mean, precision and probability parameters for the utilities at
time j. The regression parameters αj = (α0j , α1j , α2j) and γj = (γ0j , γ1j , γ2j) in Equation 6.8
capture the dependence between utilities at j and costs at j and utilities at j−1. Both Equation 6.7
and Equation 6.8 include costs as covariates on the log scale to avoid numeric instability in the
estimation of the parameters of the logistic regressions, as in Equation 6.6.
For all relevant parameters in the model vague prior distributions are specified. Specifically we
choose a Normal(0, 1000) for the regression coefficients and a Uniform(0, 10000) over a large pos-
itive range for the standard deviations (for the Beta distributions, priors on the standard deviations
are specified as in Section 5.2.2). Figure 6.1 shows a graphical representation of the structure of
the model considering only the baseline response pair (ui0, ci0) for simplicity.
First, the module for dci0 (brown box) is specified, upon which the two components c
0
i0 and
c>0i0 in the baseline costs are distinguished in the mixture module for ci0 (red box). Individuals
associated with a non-zero cost are then marginally modelled using a LogNormal distribution.
Next, the module for dui0 (green box) is specified conditional on the baseline costs, which allows
to separate the two components u1i0 and u
<1
i0 in the mixture module for ui0 (blue box). Individuals
who are associated with a non-one utility are modelled using a Beta distribution conditionally on
the baseline costs.
The modular structure of the framework is then repeated for j = 1, 2 and the time dependence
between the response is captured through a series of conditional specifications for the utility
and cost mixture and hurdle modules. The flexibility of this modelling strategy for the observed
data distribution allows to account for all the typical complexities of the data: correlation between
utilities and costs, skewness and spikes in the outcome variables.
The marginal cost and utility means at each time j are obtained through Monte Carlo inte-
gration. First, we fitted the model separately to the completers (r = 1) and the joint set of all
other patterns (r 6= 1) for t = 1, 2. Second, at each iteration of the MCMC output, we draw
l = 1, . . . , L replications yjl = (cjl, ujl) from their sampling distributions given the current value
of the relevant parameters, with L = 40, 000. Third, we approximated the posterior distribution
of the marginal means for yrj by taking the expectation over these sampled values at each iter-
ation, i.e. E[yrj ] =
1
L
∑L
l=1 yjl. Finally, we derived the overall marginal means in each treatment
group µjt = (µcjt, µ
u
jt) as weighted averages across the marginal means in each pattern, using
the posterior λrt as weights.
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c>0i0c
0
i0
ci0
φc0τ
c
0
u<1i0
φui0 τ
u
i0
α
u1i0
ui0
piui0
dui0
γpic0
dci0
Mixture module for c0 | dc0
Hurdle module for dc0
Mixture module for u0 | c0, du0
Hurdle module for du0 | c0
Figure 6.1: Four modules form the framework related to ci0 and ui0. The two boxes at the bottom indicate
the hurdle modules for dci0 and d
u
i0, which separates the structural (c
0
i0, u
1
i0) and non-structural (c
>0
i0 , u
<1
i0 )
values in ci0 and ui0, respectively indicated with the brown and green colours. The two boxes at the top
are the mixture modules for ci0 and ui0 in which the non-structural values are modelled using LogNormal
and Beta distributions, respectively indicated with the red and blue colours. The solid black arrows show
the dependence relationships between the parameters within the modules, while the coloured arrows
show the dependence between the parameters of different modules.
Once the marginal utility and cost means are derived from the model using Monte Carlo inte-
gration, these are used to compute the population QALYs and total cost mean parameters in each
treatment group
µet =
J∑
j=1
(
µujt + µ
u
j−1t
) δj
2
and µct =
J∑
j=1
µcjt, (6.9)
where δj = 0.5 for each j in the PBS study. The population means in Equation 6.9 are effectively
derived using the formulae typically applied to uij and cij for computing the QALYs and total cost
variables (Section 1.2) to the mean estimates µujt and µ
c
jt.
6.3 Extrapolation Distribution
Partial identifying restrictions are used to identify the posterior of the marginal means of the ex-
trapolation distribution. We only require the identification of the marginal means for the missing
responses in each pattern because the economic analysis is exclusively based on quantities de-
rived from the cost and utility marginal means.
6.3.1 Partial Identifying Restrictions and Sensitivity Parameters
Sensitivity parameters δ are embedded within the restrictions to assess the impact of alternative
missingness assumptions on the quantities of interest. We choose δj = (δcj , δuj ) to be time-
specific location shifts at the utility and cost means in each pattern. At each time j, the marginal
mean of the missing data in each pattern yrmis,j is identified by averaging across the observed
components at the same time point yrobs,j for r 6= 1 and adding the sensitivity parameters δj . More
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formally, the mean of the missing responses is identified as
E
[
yrmis,j | r 6= 1
]
= E
[
yrobs,j + δj | r 6= 1
]
, (6.10)
for j ∈ {0, 1, 2}. As a reasonable benchmark assumption we set δj = 0. Under this scenario, the
mean of the missing response in Equation 6.10 is obtained using only the mean parameters esti-
mated from the model, averaged across the non-completers. We then use alternative informative
priors on δj to explore plausible departures for missing utilities and costs and assess their impact
on cost-effectiveness conclusions.
In the PBS study, no external source of information was available to inform the direction or the
magnitude of these departures. We formulate the assumptions about the missing values based on
a discussion with the people involved in the original analysis of the trial (direction of departures)
and on what we deem to be some plausible scenarios (magnitude of departures). According
to these considerations, we assume that subjects with a missing value at time j have a lower
utility and a higher cost compared with those who are observed at the same time but were not a
completer. We then calibrate the priors on δj using the observed standard deviations for costs
and utilities at each time j to define the amplitude of the departures from δj = 0.
6.3.2 Priors on the Sensitivity Parameters
We consider three alternative sets of priors on δj = (δuj , δcj ), calibrated based on the variability
in the observed data at each time j. The three types of priors used are the following:
• δflat: Flat between 0 and twice the observed standard deviation:
δcj ∼ Uniform[0, 2 sd(cj)] and δuj ∼ Uniform[−2 sd(uj), 0]
• δskew0: Skewed towards values closer to 0, over the same range as δflat:
δcj = 2 sd(cj)
(
1−
√
U
)
and δuj = −2 sd(uj)
(
1−
√
U
)
• δskew1: Skewed towards values far from 0, over the same range as δflat:
δcj = 2 sd(cj)
(√
U
)
and δuj = −2 sd(uj)
(√
U
)
,
where U ∼ Uniform(0, 1) and sd(uj) and sd(cj) are the standard deviations computed on the
observed utilities and costs at time j for r 6= 1. Although alternative priors could be considered,
since no formal experts’ opinion or other information about missingness was collected in the PBS
trial, the proposed priors for δj were proposed based on a discussion with the people involved
in the trial. In particular, these priors were chosen as departures from δj = 0 for both outcomes
were believed unlikely to be larger than twice the observed standard deviations at each time j.
Figure 6.2 shows a graphical representation of the densities of the three types of priors using the
sensitivity parameters δ1 = (δu1 , δc1) as examples.
The three distributions for δ1 are defined over the same range of values (negative for utilities
and positive for costs) but assign different weights to the values within the range. The distribution
of δflat (panels a-b) assign the same weight to all values for both outcomes. By contrast, the
distributions of δskew0 (panels c-d) and δskew1 (panels e-f) give more weights to values closer
and far from zero and respectively express more and less conservative assumptions about the
departures from the benchmark δ1 = 0. Overall, the prior and posterior distributions of δj were
similar under each nonignorable scenario assessed for both treatment groups in the trial. The
comparison between the prior and posterior estimates of δj are shown in Figure C.15, Figure C.16
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and Figure C.17 (control) and Figure C.18, Figure C.19 and Figure C.20 (intervention), which are
provided in Appendix C.4.2.
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Figure 6.2: Densities of the prior distributions of the sensitivity parameters that identify the means for
the missing utility and cost variables at j = 1 under three alternative scenarios: δflat (panels a-b), δskew0
(panels c-d) and δskew1 (panels e-f)
6.4 Application to the PBS study
Among the non-completers (r 6= 1), we set to 0 the regression parameters (ζ11,ζ21) and (γ10,γ11,γ21)
for the model fitted to the control and intervention group, respectively. This simplification was re-
quired because, among the non-completers, there is only one observed cj = 0 at time j = 1
in the control group and one observed uj = 1 at time j = {0, 1} in the intervention group. We
therefore drop from the model the dependence between the probabilities of having a structural
value at these times and the variables at the previous or same times to ensure the convergence
of the algorithm and avoid identifiability problems. The full JAGS code of the model fitted to the
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PBS data is provided in Appendix B.3.1. The R code used to derive the mean estimates under
each nonignorable scenario is available in Appendix B.3.2.
The model was fitted using JAGS, which is interfaced with R through the package R2jags. We
ran two chains with 20,000 iterations per chain, using a burn-in of 5,000, for a total sample of
30,000 iterations for posterior inference (without any thinning). Convergence and autocorrela-
tion of the MCMC simulations were assessed using the same diagnostic measures and criteria
described in Section 5.4.1. These include a value for the potential scale reduction factor below
1.05 and an effective sample size of at least 20,000 for the model parameters. Convergence was
also assessed with respect to the use of different overdispersed values for the parameters, which
were generated from the priors. For the model fitted to the non-completers, some of the model
parameters were poorly identified (e.g. the logistic regression parameters for the hurdle models
estimated using very few numbers of structural values at some time point). For some of these
parameters, although an effective sample size lower then 20,000 were observed, however, the
potential scale reduction factor was always below 1.05 and it was therefore assumed that they did
not affect the overall convergence the model. The total computational time required for the model
based to produce representative samples from the posterior distributions of interest was about 50
minutes.
6.4.1 Model Assessment
We perform model checking to evaluate the adequacy of the fit of the model to the observed data.
Specifically, we use the DIC to assess the fit of the model with respect to an alternative parametric
specification, where the LogNormal distributions are replaced with Gamma distributions for the
cost variables. In our analysis, we consider a DIC on the observed data under MAR as its value
does not depend on the values of the sensitivity parameters. Because the sampling distribution of
the observed data was not available in closed form, Monte Carlo integration was used to compute
it. Results between the two alternative specifications are reported for each modelled variable
in Table 6.2. The total values for both DIC and pD are reported at the bottom of the table.
Gamma LogNormal
variable DIC pD DIC pD
c0 2147.91 2.05 2133.39 1.97
u0 | c0 -377.52 2.87 -377.62 2.82
c1 | c0, u0 1904.53 4.16 1827.45 4.13
u1 | u0, c1 -468.02 5.37 -468.19 5.32
c2 | c1, u1 1913.69 4.65 1856.23 4.36
u2 | u1, c2 -454.07 5.87 -453.47 5.99
Total 4667 25 4518 25
Table 6.2: DIC and pD based on the observed data likelihood for each variable in the model. Two models
are assessed either assuming LogNormal or Gamma distributions for the cost variables. Total DIC and
pD are also reported at the bottom of the table.
The DIC components for the costs are systematically lower when LogNormal distributions are
used compared with Gamma distributions (lower values shown in italics in Table 6.2), and result
in an overall better fit to the data for the first model.
Additionally, we assess the absolute fit of the model using posterior predictive checks based
on observed data replications. A total of 40, 000 samples for the responses and missingness
patterns were drawn from the posterior predictive distribution of the model p(y˜, r˜ | yrobs, r,ω).
Conditional on the replicated patterns r˜, the replicated observed data in each pattern are defined
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as y˜r˜obs = {y˜j : r˜j = 1}, that is the components of y˜ for which the corresponding missing data
indicators at time j in the replicated patterns r˜ are equal to one.
We compute the rank correlations between each pair of variables for each replicated dataset,
and compare them with the corresponding values from the real dataset. The results, shown in
Figure 6.3, suggest that the proposed parametric model captures most of the correlations well
both in the control (panel a) and intervention (panel b) group.
Finally, we assess the fit of the model to the empirical distributions of the observed utility and
cost data. Figure 6.4 compares the posterior predictive utility and cost densities at each time j
based on the samples generated from the model (light blue lines) with the empirical distributions of
the observed cases (dark blue lines) in both the control (panels a and c) and intervention (panels
b and d) group of the PBS trial. With the only exception of the utilities at j = 2 in the intervention
group, the replicated samples closely approximate the empirical distributions of both utilities and
costs at each time point.
6.5 Results
6.5.1 Scenarios
Table 6.3 summarises the different scenarios compared in the economic analysis of the PBS
study, derived either from the proposed approach or from alternative models. Within the modelling
model framework patterns missingness
δskew1 longitudinal r = 1 & r 6= 1 nonignorable
δskew0 longitudinal r = 1 & r 6= 1 nonignorable
δflat longitudinal r = 1 & r 6= 1 nonignorable
δ = 0 longitudinal r = 1 & r 6= 1 nonignorable
L-ALL longitudinal all ignorable
L-CC longitudinal r = 1 ignorable
CS-ALL cross-sectional all ignorable
CS-CC cross-sectional r = 1 ignorable
Table 6.3: List of the scenarios compared in the analysis of the PBS study. These are distinguished by
modelling framework (either longitudinal or cross-sectional), the patterns to which the models were fitted
(either r = 1, r = 1 & r 6= 1 or all patterns jointly), and the assumptions about missingness (either
ignorable or nonignorable). All longitudinal models and CS-ALL are specified using Beta-Lognormal dis-
tributions with a hurdle approach for both outcomes. CS-CC is specified using the “standard approach”
(independent Normal distributions for both outcomes).
framework of Section 6.1, the alternative missingness scenarios explored are indicated with δ = 0
(benchmark) and δflat, δskew0 and δskew1 (nonignorable departures). In addition, we consider four
scenarios. L-ALL and L-CC are two longitudinal models, specified as in Section 6.2.2, but fitted
jointly across all patterns under MAR and to the completers, respectively. CS-ALL and CS-CC are
two cross-sectional models (i.e. the modelled variables are the QALYs/total costs rather than the
utilities/costs): CS-ALL is specified using a Beta-LogNormal distribution with a hurdle approach
to handle both unit QALYs and zero costs and is fitted to all cases under MAR, while CS-CC is
specified using the “standard approach” (independent Normal distribution for both outcomes and
fitted to the completers).
The last four scenarios are included to assess the impact that alternative types of modelling
assumptions have on the results. Specifically, variations in the estimates may be due to either
the use of a different framework, alternative distributions for the responses, the incorporation of
the non-completers in the analysis or a combination thereof. It is important to distinguish how a
change in each of these assumptions affects the results of the analysis. For example, we can
obtain some information about the expected impact that the inclusion of the partially-observed
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Figure 6.3: Posterior predictive distributions for the pairwise correlation between utilities and costs vari-
ables in the control (panel a) and intervention (panel b) arm across 1000 observed replicated datasets
(light blue bars) compared with the observed value in the real dataset (vertical blue lines).
data may have on the inferences by comparing the observed responses between the completers
and non-completers in the PBS study.
Figure 6.5 shows the mean utility and cost profiles, calculated as a simple average of the
observed data at each time point in the PBS study, for the individuals in the completers (solid
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Figure 6.4: Posterior predictive utility and cost densities at each time j = 0, 1, 2 for the longitudinal
model (light blue lines) compared with the empirical distributions of the complete cases (dark blue lines)
in the control (panels a and c) and intervention (panel b and d) group in the PBS trial. For each variable,
1000 replications of the data are generated, of which only 15 are displayed in each graph for visualisation
purposes
lines) and non-completers (dashed lines), either in the control (red) or intervention group (blue).
In the control group (panels a and c), the completers are associated with consistently higher mean
profiles with respect to the non-completers for both outcomes; the largest differences occur at the
last follow-up for both the utilities (0.036) and the costs (£486). In the intervention group (panels
b and d), the mean profiles of the two patterns intersect once throughout the study period; the
largest differences are at baseline for both the utilities (0.037) and the costs (£703).
6.5.2 Utility/cost means
Figure 6.6 compares the posterior means and 95% HPD intervals for µujt (panel a) and µ
c
jt (panel
b) across six alternative scenarios: L-CC, L-ALL, δj = 0, δflat, δskew0 and δskew1. Since baseline
costs are fully observed, only the estimates under L-CC and L-ALL are shown for µc0. Results
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Figure 6.5: Observed mean utility and cost profiles in the PBS trial for the individuals in the com-
pleters (solid lines) and non-completers (dashed lines) patterns, either in the control (red) or intervention
group (blue).
associated with the control and intervention group are indicated in red and blue, respectively. The
distributions of both µuj and µ
c
j show values that are higher in the intervention than in the control at
each time j. Compared with L-CC, the estimates from L-ALL or δ = 0 show variations that are due
to the additional incorporation of the non-completers in the analysis (Figure 6.5), either by fitting
the model jointly across the patterns (L-ALL) or using the extrapolation factorisation (δ = 0).
With respect to the benchmark δ = 0, the impact of the alternative priors for the sensitivity pa-
rameters (see Section 6.3.2) on the inferences is reflected in the variations of the mean estimates
across the nonignroable scenarios. In the control group, compared with δ = 0, mean utilities show
an average decrease of 0.023 (δflat), 0.016 (δskew0) and 0.031 (δskew1), while mean costs show an
average increase of £83 (δflat), £56 (δskew0) and £112 (δskew1). In the intervention group, mean
utilities are on average 0.011 (δflat), 0.009 (δskew0) and 0.013 (δskew1) lower compared with δ = 0,
while mean costs are on average £56 (δflat), £37 (δskew0) and £74 (δskew1) higher.
6.5.3 QALYs/total cost means
We additionally compare the estimates of the population QALYs and total cost means µet and
µct, derived for each scenario assessed in Section 6.5.2, with those from CS-ALL and CS-CC.
Figure 6.7 shows the posterior means and 95% HPD intervals associated with the mean QALYs
(panel a) and total cost parameters (panel b) under all scenarios for both the control (denoted
with a red colour) and intervention (denoted with a blue colour) groups. Changes in the estimates
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Figure 6.6: Posterior means and 95% HPD intervals for the marginal utility and cost means in the control
(red dots and lines) and intervention (blue dots and lines) group at each time j in the PBS study across
alternative assumptions. Six scenarios are compared: L-CC,L-ALL, δ = 0, δflat, δskew0, and δskew1. Since
the baseline costs are fully observed in both groups, only the results under L-CC and L-ALL are displayed
for µc0.
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Figure 6.7: Posterior means and 95% HPD intervals for the marginal QALYs and total cost means in
the control (red dots and lines) and intervention (blue dots and lines) group in the PBS study across
alternative assumptions. Eight scenarios are compared: CS-CC, CS-ALL, L-CC, L-ALL, δ = 0, δflat,
δskew0 and δskew1.
are due to different types of modelling assumptions between the scenarios. For example, within
a cross-sectional framework, explicitly accounting for the complexities of the data (CS-ALL) leads
to almost no impact on the mean QALYs, with an increase of 0.001 for t = 1 and a decrease of
0.016 for t = 2, and small changes in the mean costs, with an increase of £210 for t = 1 and
£151 for t = 2, compared with the standard approach (CS-CC). Under the same distributional
specification, the change of the modelling framework from cross-sectional (CS-ALL) to longitudinal
(L-CC) is associated with limited variations in the mean QALYs and costs in both treatment groups
when the models are fitted to the same cases (completers only). However, when the additional
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information from the observed data of the non-completers is incorporated into the longitudinal
model, more substantial changes are observed in the estimates, especially for the QALYs in the
control group. More specifically, the mean estimates derived from the longitudinal model fitted
only to the completers (L-CC) are higher with respect to those from the model that additionally
incorporates the evidence from the non-completers (L-ALL), both for the QALYs (increases of 0.09
for t = 1 and 0.01 for t = 2) and costs (increases of £257 for t = 1 and £13 for t = 2). These
variations are larger in the control, which has higher proportions of missing data compared with
the intervention, and where the average observed utilities and costs from the non-completers are
systematically lower with respect to the completers (Figure 6.5).
Finally, compared with the benchmark δ = 0, changes of similar amplitude and with the same
sign to those observed for µjt affect the QALYs and total cost estimates across the nonignorable
scenarios δflat, δskew0 and δskew1. In the control, compared with δ = 0, mean QALYs show decre-
ments of 0.044 (δflat), 0.029 (δskew0) and 0.058 (δskew1), while mean costs show increments of £167
(δflat), £112 (δskew0) and £224 (δskew1), respectively.
In the intervention, the corresponding decreases in mean QALYs are 0.018 (δflat), 0.012 (δskew0)
and 0.024 (δskew1), while the increases in mean total costs are £110 (δflat), £73 (δskew0) and £147
(δskew1). Table C.15, which is provided in Appendix C.4.3, reports the mean and 95% estimates
associated with the mean QALYs and costs and other incremental quantities (e.g. net benefit) for
each model considered.
6.6 Economic Evaluation
We complete the analysis by assessing the cost-effectiveness of the new intervention with respect
to the control, comparing the results across the scenarios in Table 6.5. We specifically rely on the
examination of the EIB and IB distribution, as well as the CEP and CEAC to summarise the
economic analysis.
Figure 6.8 compares the estimates for the Expected Incremental Benefit and Incremental Ben-
efit distribution obtained under the longitudinal models fitted to only the completers (L-CC), to all
cases under MAR (L-ALL) and under the non-ignorable scenario δflat. The results for the other
nonignorable scenarios are provided in Appendix C.4.4. For almost all the values of the willing-
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Figure 6.8: Expected Incremental Benefit (panel a) and Incremental Benefit distribution at k = 20000
(panel b) associated with L-CC (blue solid and dashed lines), L-ALL (green solid and dashed lines) and
δflat (red solid and dashed lines) models fitted to the data from the PBS study.
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ness to pay k, the estimates of the EIB and its lower/upper bounds (panel a) are similar between
the L-CC and L-ALL scenarios, with a slightly steeper lines for L-ALL (green colour) compared
with L-CC (blue colour), while those under δflat are associated with an upward shift of the lines
and the steepest slope (red colour) among the model assessed. This indicates that, under the
non-ignorable scenario, the cost-effectiveness assessment is more favourable to the intervention
compared with the models fitted under an ignorability assumption. Similar conclusions are ob-
tained by looking at the estimated distribution of the IB (panel b), evaluated at k = £20, 000,
where the probability of cost-effectiveness is higher under δflat (0.56) with respect to both L-ALL
(0.29) and L-CC (0.27).
The CEP plot (Figure 6.9, panel a) shows the results only under the same scenarios (light
blue for L-CC, light green for L-ALL and light red for δflat) for clarity and visualisation purposes.
The results for the other nonignorable scenarios are provided in Appendix C.4.4. For all three
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Figure 6.9: CEPs (panel a) and CEACs (panel b) associated with alternative missingness scenarios. In
the CEPs, the ICERs based on the results from L-CC, L-ALL and δflat are indicated with corresponding
darker coloured dots. For the CEACs, in addition to the results from L-CC and L-ALL (solid lines), the
probability values for the alternative scenarios are represented with different coloured dashed lines.
scenarios almost all samples fall in the North-East quadrant and are associated with positive
ICERs. The ICER under δflat falls in the sustainability area and indicates a more positive cost-
effective assessment for the new intervention compared with L-CC and L-ALL.
The CEAC plot (Figure 6.9, panel b) shows the results under L-CC and L-ALL using blue and
green solid lines, respectively. In addition, the results derived under nonignorability are reported
using different coloured dashed lines. The CEACs under L-CC, L-ALL and δ = 0 show a similar
trend and indicate a probability of cost-effectiveness that is systematically lower compared with
the other nonignorable scenarios δflat, δskew0 and δskew1 for most values of k. The CEAC plot
shows that results are sensitive to the assumptions about the missing values, which can lead to a
considerable change in the output of the decision process and the cost-effectiveness conclusions.
We finally evaluate the results derived from the models that ignore the information from the
non-completers (L-CC, CS-ALL, CS-CC) and compare them with those from the models that in-
corporate this additional evidence (L-ALL and the nonignorable scenarios). Figure 6.10 shows the
CEPs (panel a) associated with L-CC, CS-ALL and CS-CC, respectively indicated with blue, green
and red coloured dots. In the CEACs (panel b), in addition to the probability values associated
with these scenarios (L-CC – solid blue line, CS-ALL – green dashed line, CS-CC – red dashed
line), the results from L-ALL and δflat are indicated with solid green and red lines, respectively.
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In the CEP plot (Figure 6.10, panel a), the posterior samples for all three scenarios fall almost
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Figure 6.10: CEPs (panel a) and CEACs (panel b) associated with alternative scenarios. In the CEPs, the
ICERs based on the results from the L-CC, CS-ALL, CS-CC and L-ALL are indicated with corresponding
darker coloured dots. For the CEACs, in addition to the results under CS-ALL and CS-CC (dashed lines),
the probability values for L-CC, L-ALL and δflat are represented with solid lines.
entirely in the North-East quadrant and, at k = £25,000, indicate a mild cost-effectiveness of the
new intervention compared with the control. However, ICERs under CS-ALL and L-CC lie at the
boundary of the sustainability area and are both higher compared with the ICER under CS-CC.
In the CEAC plot (Figure 6.10, panel b), the acceptability curves under CS-ALL and L-CC
show minimal discrepancies. This is due to the fact that, even though the two models are respec-
tively specified within a cross-sectional and longitudinal setting, they are both fitted only to the
completers and account for the same number of complexities in the data. Finally, the CEAC for
CS-CC is higher compared with L-CC, CS-ALL and L-ALL for most willingness to pay values, but
remains systematically lower with respect to δflat, δskew0 and δskew1 (in Figure 6.10 we only show
the results for δflat for clarity).
6.7 Discussion
In this chapter, we have proposed a new approach for conducting parametric Bayesian inference
under nonignorable missingness for a longitudinal bivariate outcome in economic evaluations.
The model uses the extrapolation factorisation, within a pattern mixture approach, to specify a
model for the distribution of the observed responses at each time point in the study and identify
the mean of the missing responses using a combination of partial identifying restrictions and
sensitivity parameters.
We motivate and apply our modelling framework to the data from the PBS study. Both in-
ferences and cost-effectiveness conclusions are sensitive to the three alternative nonignorable
scenarios explored and suggest a more cost-effective intervention compared with the results ob-
tained under ignorability. This may be due to the fact that the proportions of partially-observed
utility and cost data for the individuals in the control group are systematically higher with respect to
those in the intervention group (see Table 3.4). This may occur, for example, when the intervention
group is more effective in preventing people to drop out from the study, therefore ensuring higher
completeness rates in the outcomes than the comparator. Therefore, if the individuals who have
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missing values are associated with lower QALYs and higher costs compared to those observed
in both groups, it is possible that models based on an ignorable mechanism assumption will tend
overestimate the cost-effectiveness of the control with respect to the intervention.
The results from the analysis of the PBS study within a longitudinal framework show some
differences compared with those derived from cross-sectional models. These differences become
considerable when, as in the original analysis of the trial, the model does not account for all the
complexities of the data. This indicates that the statistical methods used by practitioners in routine
analyses are likely to be biased and can mislead the cost-effectiveness assessment.
Our approach provides some important advantages when dealing with missing data compared
with the standard approach used in trial-based CEAs. First, efficiency is improved since the
information from all observed data in each missingness pattern is retained when fitting the model,
rather than using only the data from the completers. Second, the model accounts for the time
dependence between the responses at different follow-ups, which may provide useful information
when imputing the missing values. Third, the complexities affecting the outcome data, such as
correlation, skewness and presence of structural values in both utilities and costs, are accounted
for through a flexible parametric specification for the observed data distribution. Finally, sensitivity
analysis is conducted to assess the robustness of the results to a range of plausible nonignorable
missingness assumptions for both utility and cost data. These are specified using informative
priors on the sensitivity parameters, calibrated from the observed data.
The model improves and expands the statistical approach used in routine CEAs and can help
practitioners to avoid biased results, which may in turn lead to misleading cost-effectiveness con-
clusions. The availability of methodological and practical tools, such as those presented in this
chapter, has the potential to improve the work of modellers and regulators alike, thus advancing
the fields of economic evaluation of health care interventions.
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Key points of this chapter:
• Our longitudinal model improves current CEA practice by accounting for all ob-
served data in the study, the dependence between outcomes and over time, and
the typical complexities that affect the data. In addition, the model assesses the
robustness of the results to plausible nonignorable missingness assumptions.
• We demonstrated the benefits of using our approach with the PBS study as a
motivating example. We used the extrapolation distribution and a pattern mixture
approach to separately fit a flexible parametric model to the observed data, and
identify the distribution of the missing data using partial identifying restrictions and
sensitivity parameters.
• Marginal mean utility and cost estimates were derived using Monte Carlo integra-
tion and then averaging across the pattern-specific estimates. The target popula-
tion mean QALYs and total cost parameters were then derived by combining the
utility and cost means estimated from the model at each time point.
• The fit of the model to the observed data was checked via relative (DIC) and
absolute (PCCs) predictive accuracy measures, both suggesting that the model
well-captures the characteristics of the observed data. Alternative nonignorable
assumptions were incorporated into the model using informative priors on the sen-
sitivity parameters, calibrated on the observed data.
• We compared the results from our model with those from a standard cross-
sectional model. Both inferences and cost-effectiveness conclusions were sen-
sitive to the missingness scenarios assessed and indicated a bias associated with
the methods used in routine analyses.
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Chapter 7
Conclusions and Extensions
In this chapter, we draw together the findings, strengths and limitations of the thesis with respect
to the three objectives that constitute the research questions of this work and suggest avenues of
future research.
7.1 Summary
The statistical methods implemented in the analyses of the two case studies in this thesis have the
objective of providing practical tools to improve the current practice in routine analyses. The meth-
ods illustrated follow the general NICE recommendations for conducting within-trial CEAs (NICE,
2013). These include the use of statistical methods that explicitly account for the typical complex-
ities of the data, such as correlation, clustering, skewness, structural values and missingness. In
addition, results of the economic evaluations are assessed with respect to both sampling vari-
ability and parameter uncertainty (including missing data uncertainty). The first is addressed by
exploring and comparing the fit of alternative model specifications to the observed QALYs and
costs and how they affect the posterior estimates and cost-effectiveness results. The choice of
the parametric distributions for each outcome variable is based on those typically used in the pub-
lished literature, such as Normal or Beta for QALYs and Normal, Gamma or LogNormal for costs,
while model assessment is performed using the DIC or posterior predictive checks as reference
approaches to evaluate model fit within the Bayesian framework.
The second is addressed through prior distributions to allow the full propagation of parameter
uncertainty in the model, which in turn is directly reflected into variations in the posterior quantities
of interest (e.g. mean incremental QALYs and costs) and accounts for the possible dependence
between the parameters of the model. The sensitivity of the results to alternative weakly infor-
mative prior specifications was assessed to ensure that no unintended informative content in the
priors was introduced into the model. Finally, the potential impact of missing data uncertainty
on the results is assessed either under MAR and some simple departures from it within a cross-
sectional framework or using a proper non-ignorable model via informative priors on the sensitivity
parameters to conduct sensitivity analysis to a range of plausible MNAR departures.
In the following sections we discuss how the different objectives of the thesis have been ad-
dressed and provide advice to practitioners for addressing more general situations which were
not relevant to the specific studies analysed but that may occur in practice.
113
7.1.1 Objective 1: Literature Review
The main added value provided by the literature review in Chapter 2 is represented by the Quality
Evaluation Scheme, a structural tool to qualitatively assess the information reported about miss-
ing data in CEAs. The appealing characteristic of the quality evaluation scheme is the possibility
to assign scores and to rank the studies based on a list of criteria that summarise the current
literature recommendations about the collection and reporting of missing data information. Au-
thors can evaluate the quality evaluation scheme score to assess the quality of their own analysis
with respect to the amount and type of information provided on missingness. This would lead to
a more comparable formalisation of the missing data uncertainty as well as a better indication of
possible issues in assessing the cost-effectiveness of new treatments.
The application of the quality evaluation scheme to the reviewed studies demonstrates the
need to improve the quality of CEAs in terms of missing data handling. Specifically, the review
highlights a large proportion of articles which are characterised by a lack of transparent assump-
tions about missingness and a dramatic shortage of sensitivity analyses for most of the studies.
The performance and scoring system of the quality evaluation scheme is affected by a subjec-
tive construction of the weights assigned to the different types of information provided about the
missing values. When applying the quality evaluation scheme to the reviewed articles, we pro-
vide a weight allocation criterion that is considered reasonable and proven to be robust to other
allocation schemes. However, alternative configurations could be investigated.
7.1.2 Objective 2: Limitations of the Standard Approach and Full Bayesian
Framework in CEA
The “standard” statistical approach in CEA is characterised by a series of limitations that under-
mine the credibility of the results derived from these analyses. These limitations are mostly related
to the failure of accounting for at least some complexities that typically affect trial-based outcome
data and the often unclear assumptions about the missing values. The analysis in Chapter 4 has
shown the potential implications in terms of missingness assumptions that small changes in the
implementation of standard methods may have on the final assessment.
The flexible Bayesian framework presented in Chapter 5 overcomes these limitations through
jointly tackling the complexities that affect the data, which is achieved through a flexible modular
structure that can handle any suitable distributional assumption and covariates in each module of
the framework. The Bayesian setting allows for the full characterisation and quantification of the
uncertainty for each variable in the model at a relatively small computational cost compared with
a frequentist approach. This naturally favours the incorporation of a sensitivity analysis to assess
the impact on the inferences and decision-making of alternative missingness assumptions. In
addition, the possibility of implementing the framework using freely available software makes it
relatively easy to use for practitioners.
We showed the benefits of using our framework with the MenSS and PBS trials and demon-
strated its flexibility by comparing the performance of a set of models that account for an increas-
ingly large number of complexities of the data. The results from both studies have substantially
different implications in terms of inferences and cost-effectiveness conclusions compared with
those of the original analyses, which instead ignored at least some of the complexities.
For the MenSS trial, we also assessed the robustness of the conclusions to some “extreme”
missingness assumptions. This type of sensitivity analysis can be incorporated in the frame-
work at no extra cost in terms of model complexity. The analyses from both studies highlight the
importance of adopting a comprehensive modelling approach to economic evaluations and the
strategic advantages of building these complex models within a Bayesian framework. An R pack-
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age, called missingHE, dedicated to encourage the implementation among practitioners of the
proposed Bayesian framework in routine analyses is currently under development. More details
on the structure and the types of models handled by the package are available in Appendix D.
A potential drawback of the framework is that, as the sample size and level of complexity in-
crease, these models may not run quickly in standard Bayesian software (e.g. JAGS). In addition,
when many partially-observed variables are incorporated into the model, the current capability
of these software limits the scope for easily implementing complex models and more specialised
MCMC sampling algorithms may be required. In these circumstances, a combination of numeri-
cal integration and multiple imputation techniques could be used to avoid some of the speed and
computational issues associated with full Bayesian models by separating the imputation and anal-
ysis tasks. However, the trade-off is the need to ensure that the imputation and analysis models
are compatible, which is not trivial.
7.1.3 Objective 3: Longitudinal Missingness Model in CEA
In Chapter 6 we presented a Bayesian parametric model for conducting inference on a partially-
observed bivariate health economic longitudinal outcome. Our approach is an alternative, more
efficient and likely less biased approach compared to current practice, which includes a longi-
tudinal model that uses the information from all observed data as well as accounts for the time
dependence between the responses.
Key advantages of using this modelling strategy are: 1) specification of a flexible parametric
model for the observed responses that accounts for the complexities of the data; 2) use of a prin-
cipled approach to missingness that partially identifies the distribution of the missing data using
partial identifying restrictions and sensitivity parameters; 3) possibility to apply the model to any
type of missingness patterns and to handle sparse data; 4) exploration of alternative non-ignorable
scenarios through different priors for the sensitivity parameters, calibrated on the observed data.
The analysis of the PBS data shows the benefits of using our approach compared with stan-
dard cross-sectional models as well as a considerable impact of alternative nonignorable assump-
tions on the final decision-making conclusions. A major advantage of using a Bayesian modelling
framework is to allow for the formal incorporation of external evidence into the analysis through
the use of informative prior distributions. This is particularly useful for parameters that are left
unidentified by the observed data and that we do not want to be identified by other undesired (and
often non-transparent) modelling assumptions. Although the priors for the sensitivity parameters
in Section 6.3.2 were not derived from the formal elicitation of experts’ opinion, which was not
available in the PBS study, they offer a convenient framework to assess the robustness of the
conclusions to differing nonignorable departures. This represents a considerable step forward
for the handling missingness in economic evaluations compared with the current practice, which
typically relies on methods that assume the ignorability of the missingness mechanism and rarely
conducts sensitivity analysis to nonignorable departures.
However, further improvements are certainly possible. When experts’ knowledge is available,
practical tools for eliciting expert opinion (e.g. questionnaires) may be used to extract experts’
beliefs and incorporate them into the priors for the sensitivity parameters; for example, questions
may be devised to the experts to quantify plausible differences in the mean utility scores between
individuals who did and did not complete the health questionnaires. In addition, the modelling
framework can be extended to handle partially-observed covariates and use alternative strategies
to incorporate the missingness assumptions into the model. These are discussed in Section 7.2.
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7.1.4 General advice for trial-based CEAs
The statistical methods and approaches illustrated in this thesis for the analysis two case studies
described in Section 3 provide useful tools to improve the current practice in trial-based CEAs.
However, in practice, these methods may need to be tailored to address the specific characteris-
tics of data which may vary according to a number of factors (e.g data collection methods, time
horizon, missing data information, etc.). We therefore provide some advice to practitioners to
extend the methods applied in this thesis to more general situations.
First, the interpretation and range of the QALYs values associated with the individuals in the
trial depends on the time horizon of the economic evaluation. For both the case studies in the
thesis, the time horizon was one year, which ensures that the range of the observed QALYs
coincide with that of the utility scores collected at each time point (see Section 1.2). However,
this does not hold for longer time horizon in which the QALYs can assume values outside this
range, e.g. larger than 1. In these cases, the use of parametric distributions restricted to the
range (0, 1), such as the Beta distribution, is problematic and alternative approaches need to be
considered. A possible approach is to re-scale the data using some transformations to make
them fall in the desired range before fitting the model (O’Hagan and Stevens, 2001; Basu and
Manca, 2012). However, caution should be used when back-transforming the data to ensure
that the estimates are derived correctly on the original scale. For example, when modelling the
costs on the logarithmic scale, the results have to be back-transformed appropriately, which is
not straightforward when there is heteroskedasticity in the data (Barber and Thompson, 2004).
Alternatively, other distributional specifications that allow for all the observed values on the original
scale of the data can be used (e.g. using the Normal distributions if the degree of skewness is
not high or the sample size is large). When structural values occur in either or both outcome
variables (e.g. unit utilities and zero costs), hurdle models provide useful methods which allow to
improve the fit of the model to the observed data by explicitly handling these values while using
appropriate parametric distributions for the other values.
Second, when the randomisation procedures are correctly implemented, the individuals as-
signed to different groups in RCTs are generally considered to be similar in both observed and
unobserved factors, therefore avoiding the need to adjust for potential confounders in the analysis.
However, when imbalances between treatment groups occur in some baseline variables that are
highly correlated with the outcomes (e.g. the baseline utilities/costs), then these factors should be
included in the analysis both to improve efficiency and to adjust the QALYs and total costs mean
estimates for the baseline imbalance in these variables (Manca et al., 2005; Hunter et al., 2015).
Third, the specific characteristics of the studies should be taken into account when modelling
the data and interpreting the cost-effectiveness results. For example, when the data are collected
from different centres, such as in the PBS trial, the multilevel structure of the data must be explic-
itly recognised in the model to obtain unbiased estimates, e.g. through the inclusion of random
effects (Gomes et al., 2012b; Diaz-Ordaz et al., 2014b). In addtion, for pilot trials, e.g. the MenSS
trial, the cost-effectiveness results must be interpreted with caution because these studies are
typically characterised by a small sample size and the objective of the analysis is only to provide
a preliminary economic evaluation, which is then used to inform the decision about the feasibility
of assessing the cost-effectiveness of the interventions in a full-scale trial.
Fourth, when information about missing data is collected in the trial, for example in the form
of some auxiliary variables which are thought to be predictive of missingness, it should be incor-
porated in the analysis to make the MAR assumption more plausible. In addition, the plausibility
of MAR depends on the characteristics of the data in the spefic context analysed. For example,
when missingness follows a monotone pattern, it turns out that MAR has an intuitive represen-
tation in terms of the hazard of dropout and valid inferences under MAR can be obtained using
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different approaches which respect the MAR condition (Molenberghs and Kenward, 2007; Daniels
and Hogan, 2008). However, when missingness is non-monotone, no transparent MAR condition
can be defined and the recommended approach is to use all the information in the observed data
to improve the estimates of the distribution of the missing data given the observed. In a frequen-
tist framework (e.g. using MI) this can be achieved by including some auxiliary variables and the
outcome in the imputation model, provided that this is correctly specified. In a full Bayesian frame-
work the estimation and imputation steps are performed jointly so that only the potential auxiliary
variables need to be included in the imputation model to improve the estimation of the quantities
of interest. Although auxiliary variables can be used to make MAR more plausible, however, it is
never possible to verify this assumption from the data at hand. Thus, alternative MNAR depar-
tures should be explored in sensitivity analysis to assess the robustness of the inferences to a
range of plausible missingness scenarios.
Nonignorable models provide useful tools to handle MNAR and alternative types of modelling
approaches can be used (Daniels and Hogan, 2008; Molenberghs et al., 2015). Among these, pat-
tern mixture models are well-suited for the identification of sensitivity parameters δ, which provide
a framework for assessing sensitivity of the inferences to MNAR departures and for incorporating
these into the model. The choice of the sensitivity parameters, the direction and the magnitude
of the departures is typically informed from sources external to the data, for example by eliciting
experts’ opinion. In particuar, the sensitivity parameters should be defined such that: 1) there is
not information in the data about δ and, 2) upon specification of δ, the effects of interest are iden-
tified in the model. In the analysis of the PBS study in Chapter 6, since no formal experts’ opinion
was available to inform the MNAR departures, specified their prior distributions on the sensitivity
parameters based on a discussion with the people who were familiar with the data to indicate
the plausible ranges/directions to explore. However, if experts’ opinion is available, this should be
formaly incorporated into the model using practical elicitation tools, e.g. questionnaires (Mason
et al., 2017), to provide more accurate and plausible departures in sensitivity analysis.
Finally, when dealing with partially-observed data, any measure of predictive accuracy of a
model, such as the DIC, can be defined in different ways and are therefore not straightforward
to interpret. The recommended approach is to compute these measures and perform model
selection based only on the fit to the observed data (a sample algorithm that can be used to
compute the DIC based on the observed data is provided in Appendix A.2.1). Nevertheless, this
can only provide a partial assessment of the model fit since the fit to the unobserved data can
never be checked.
7.1.5 Other potential sources of bias
It is important to note that, in trial-based analyses, the inferences and the final cost-effectiveness
conclusions could be affected by different sources of bias, such as treatment non-adherence,
recruitment methods and measurement error. In the analysis of the MenSS and PBS studies we
did not addressed these potential sources of bias as they fall outside the scope of this thesis, but
we acknowledge their existence and their potential impact on the results. Some of these sources
of bias, together with their implications and possible methods that can be used to address them,
are now briefly described.
Treatment non-adherence
Treatment non-adherence in RCTs refers to situations where some participants do not receive
their allocated treatment as intended. When non-adherence occurs, randomisation no longer
guarantees that the relationship between treatment receipt and the power to detect the treatment
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effects may be reduced. Previous systematic reviews investigating the reporting and statistical
handling of non-adherence in RCTs have found that adherence to treatment is often under-
reported and when reported, sufficient detail on how adherence was defined is often not in-
cluded (Dodd et al., 2012; Zhang et al., 2014; Agbla and Diaz-Ordaz, 2018). In the presence
of non-adherence, estimates under both an intention to treat analysis (inidviduals allocated to the
treatments assigned) and an as treated analysis (indiividuals allocated to the treatments received)
may be derived to assess the potnetial impact of non-adherence on the results. The latter esti-
mate can be typically obtained using instrumental variable methods, which have been recently
extended and applied to trial-based CEAs (Diaz-Ordaz et al., 2018).
Recruitment methods
Individual participant recruitment is a key issue in RCTs, as there are a number of ways in which
biased participant recruitment can lead to baseline imbalances in important prognostic factors.
Typically, recruitment bias is avoided by concealing the random allocation from the potential par-
ticipant and researcher until after they have been recruited. However, in cluster RCTs sometimes
this is not possible because groups (or clusters) of participants are randomised rather than in-
dividuals, yet data are collected on individual participants. Selective recruitment of individual
participants can occur in these trials if the people recruiting participants know the participants’ al-
location, even when allocation of clusters has been adequately concealed (Eldridge et al., 2009).
Potential strategies to handle this problem are usually implemented at the design stage of the
trial, e.g. no recruiting of individual participants, recruiting of participants before randomisation,
recruiting outside the cluster setting or masking of the recruiters.
Measurement error
In trial analyses, when estimating the treatment effect on a continuous response variable observed
at baseline and some follow-up points, baseline observations may be prone to measurement
error, which is typically a result of within-patient biological variability and technical variability. It
is generally known that measurement error at baseline will attenuate the regression slope that
summarises the association between the responses observed at baseline and at follow-up points,
which can estimated for example using ordinary least squares methods (Chan et al., 2004). In
RCTs, if there is no measurement error, the observed baseline differences between treatment
groups are entirely due to sampling variation. However, when the baseline data are additionally
subject to measurement error, any observed baseline differences arise from the combined effects
of sampling variation and measurement error, and there is no easy way of differentiating between
these two components. Controversies exist in the literature about whether attenuation of the slope
due to measurement error in the baseline data is problematic in RCTs, and whether it should
be ignored or adjusted for using alternative estimators of the treatment effect (Chambless and
Roeback, 1993; Yanez et al., 1998).
7.2 Extensions
There is scope for extending the work of this thesis in a number of directions, especially with
respect to the modelling approach described in Chapter 5 and Chapter 6.
One possibility is to incorporate into the modelling frameworks some baseline covariates that
are predictive of missingness, either at the cross-sectional or longitudinal level. There are a
number of reasons making the incorporation of covariates in the analysis a potentially difficult
task. First, as the number of variables increases, the level of complexity of the model is increased
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as well, which may considerably slow down convergence of the MCMC algorithms. Second, when
some of these variables are partially-observed, it may be necessary to explicitly model the missing
data mechanism to allow for informative missingness in the covariates. The obvious consequence
is that substantial complexity is added to the existing full data model through additional sub-
models, one for each nonignorable covariate, for which plausible missingness scenarios should
be elicited and explored in sensitivity analysis. Implementing models with this level of complexity
may not be feasible in standard software such as JAGS or OpenBUGS, in which case alternative
software and/or approximations to the full data model, e.g. tailored MCMC samplers, would need
to be sought or developed.
Another possible area of extension is to further increase the flexibility of the proposed ap-
proach by relaxing the parametric assumptions of the model and specify semi-parametric or non-
parametric distributions for the observed data, which allow a weakening of the model assumptions
and likely further improve the fit of the model to the data. Different strategies are available to imple-
ment these distributions depending on the type of responses and model specification. Examples
are the use of shrinkage priors to share information and improve estimation stability for sparsely
observed patterns (Gaskins et al., 2016) or the specification of a Dirichlet process mixture model
as a prior on the joint distribution of the working model (Linero and Daniels, 2015).
These approaches have been mostly applied to univariate longitudinal responses, where miss-
ingness is typically monotone and the objective of the analysis is the estimation of some treat-
ment effects at some follow-up. It would be interesting to adapt these strategies to improve the
performance of the model while simultaneously accounting for the complexities that typically char-
acterise utility and cost data in trial-based CEAs.
Finally, with respect to the nonignorable strategy used in Chapter 6, another possible area
of future work is to develop alternative types of identifying restrictions for conducting sensitivity
analysis. Many different restrictions have been proposed in the literature, mostly for handling
monotone missingness. Conversely, restrictions for nonmonotone missingness, which often oc-
curs in trial-based CEA data, is a topic that has been treated sparingly in the literature (Linero and
Daniels, 2018) and further research is needed. For example, the identifying restrictions could be
specified such that the sensitivity parameters are introduced at the conditional mean (rather than
marginal mean) for each missing response in the model. Once a benchmark scenario is chosen,
then plausible departures from it could be explored through suitably-defined informative priors on
the sensitivity parameters.
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Executive Summary
Three main research objectives were studied in this thesis. These are: 1) to review the missing
data methods used in trial-based economic evaluations and assess the quality of routine analyses
with respect to the reporting and handling of missingness; 2) to identify potential limitations in the
standard approach used by practitioners and propose a full Bayesian framework that can improve
the current practice and avoid biased results; 3) to develop a Bayesian principled approach to
handle missingness that can combine a model for the observed data with explicit assumptions
about the missing values.
In Chapter 1, the theoretical underpinnings for these objectives were summarised with respect
to the three main research areas involved, namely the health economics framework, the Bayesian
statistical approach and the methods used in missing data analyses. The first objective was
addressed in Chapter 2, which showed the results from a literature review on the missing data
methods in trial-based economic evaluations. Guidelines were also provided for assessing the
quality of missing data analyses in the form of a structural framework, which was applied to the
articles studied in the review. An extended version of this chapter is published as a research arti-
cle in PharmacoEconomics-Open (https://link.springer.com/article/10.1007/s41669-017-
0015-6).
Chapter 3 presented the two case studies analysed in the thesis and described the standard
approach used by practitioners in routine analyses. The second objective was addressed in the
following two chapters. Chapter 4 illustrated a pitfall related to alternative implementations of
the standard approach in terms of missing data assumptions. Both case studies were used to
demonstrate the potential bias associated with this approach. The content of this chapter has
been submitted in the form of a research article for publication in Health Economics and is cur-
rently available on arXiv (https://arxiv.org/abs/1805.07149).
Chapter 5 presented a general Bayesian modelling framework for economic evaluations that
improves the standard approach by jointly tackling the typical complexities affecting the data,
while also accounting for missing data uncertainty. Both case studies are used to demonstrate
the benefits and flexibility of the proposed framework with respect to the standard approach. The
content of this chapter has been submitted in the form of a research article for publication in
Statistics in Medicine and is currently available on arXiv (https://arxiv.org/abs/1801.09541).
Chapter 6 addressed the third objective through the proposition of a parametric Bayesian longi-
tudinal model that extends the typical modelling framework in economic evaluations to incorporate
a principled sensitivity analysis to missingness, while simultaneously accounting for the complex-
ities of the data. This approach was motivated and applied using the data from one of the two
case studies analysed in the thesis. The content of this chapter has been submitted in the form
of a research article for publication in Journal of the Royal Statistical Society: Series A and is
currently available on arXiv (https://arxiv.org/abs/1805.07147).
Finally, Chapter 7 summarised the main conclusions from the thesis and proposed directions
for future research. Some of the methods presented in this thesis have been wrapped into an R
package called MissingHE, which is still under development and for which a preliminary version
120
is available on GitHub (https://github.com/AnGabrio). The package is specifically dedicated to
encourage and facilitate the implementation among practitioners of the Bayesian methods illus-
trated in this thesis.
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Appendix A
Supplementary Information
A.1 Monte Carlo integration
Monte Carlo integration is a simulation method that can be used to derive inferences from a model
when the posterior distribution, while possibly known in closed form, is not analytically tractable.
In Monte Carlo integration, the integral in the posterior is replaced by the average obtained from
simulated values. Let t(θ) denote a generic summary measure of interest for the parameter θ.
Then, the posterior summary
∫
t(θ)p(θ | y)dθ is the expected value E[t(θ) | y] of t(θ) under
the distribution p(θ | y). Assume we have S independently sampled values {θ1, . . . , θS} for the
parameter θ from p(θ | y), then for S large
∫
t(θ)p(θ | y)dθ ≈ t¯S = 1
S
S∑
s=1
t(θs), (A.1)
according to the Strong Law of Large Numbers. The unbiased estimator t¯S is called the Monte
Carlo estimator of E[t(θ) | y]. For a discrete θ, the integral in Equation A.1 is replaced by a
sum. The consequence of MC integration is that probabilities, summations and integrals can be
approximated by the MC method and the empirical distribution of sampled values converges to
the true posterior as S →∞.
According to the Central Limit Theorem, the precision with which the true summary measure
is estimated may be quantified by the interval
[
t¯S ± 1.96 st√S
]
. The quantity st is the standard
deviation of the sampled t(θs)−values and st√
S
is called the Monte Carlo standard error. The first
is an approximation of the posterior standard deviation while the second is an estimate of the
uncertainty of the estimated posterior mean.
A.2 Deviance Information Criterion
As any information criterion, DIC can be used to compare models based on their predictive accu-
racy and is based on a measure of overall fit of a model, the deviance, and a penalty for model
complexity, the effective number of parameters.
The devianceD(θ) is a general measure that can be used to assess model fit and is defined as
D(θ) = −2 logL(θ | y), (A.2)
where logL(θ | y) is the log-predictive density or log-likelihood, which summarises the informa-
tion in the data y about the parameters θ, with larger values of the deviance indicating poorer
fit. In Bayesian statistics, the quantity in Equation A.2 can be summarised in different ways. For
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example, the posterior mean of the deviance D(θ) = Eθ|y[D(θ)] has been suggested as a sensi-
ble Bayesian measure of fit (Dempster, 1973). Alternatively, the deviance can be evaluated at the
posterior mean of the parameters, i.e. D(θ¯) = D(Eθ|y[θ]). In general, we use the notation Eθ|y[θ]
to denote the expectation of θ with respect to the posterior distribution p(θ | y).
Using these two summary measures of the deviance, Spiegelhalter et al. (2002) proposed the
penalty term
pD = D(θ)−D(θ¯), (A.3)
which is used as an estimate of the “effective number of parameters” in the model. An alternative
and slightly different definition of pD has also been proposed (Gelman et al., 2004):
pD = Vθ|y[D(θ)], (A.4)
where Vθ|y[D(θ)] denotes the variance of the posterior deviance. Compared with the quantity
in Equation A.3, the definition of the effective number of parameters in Equation A.4 has the
advantage of always being positive and is generally more stable.
Based on D(θ) and pD, Spiegelhalter et al. (2002) proposed the DIC as a Bayesian model
selection criterion, defined as
DIC = D(θ¯) + 2pD = D(θ) + pD, (A.5)
with the model taking the smallest value of DIC being preferred. An attractive aspect of using
Equation A.5 is that it can readily be calculated from an MCMC run by monitoring θ and D(θ). Let
{θ1, . . . ,θS} be the posterior samples for the parameters θ from a converged Markov chain. We
can then easily calculate the approximations D(θ¯) ≈ 1S
∑S
s=1D(θ
s) and D(θ) ≈ D( 1S
∑S
s=1 θ
s).
DIC can alternatively be written as a function of the log-likelihood
DIC = 2 logL{Eθ|y [θ | y]} − 4Eθ|y [logL(θ | y)] . (A.6)
DIC can often be calculated automatically by software such as OpenBUGS, where Equation A.6 is
derived by taking D(θ) as the posterior mean of −2 logL(θ | y) and evaluating D(θ¯) as −2 times
the log-likelihood at the posterior mean of the stochastic nodes.
The DIC implementation and automatic calculation in many MCMC programmes, such as
OpenBUGS or JAGS, has greatly encouraged its use among applied statisticians. However, there
are some potential difficulties and pitfalls when using DIC to compare models (Spiegelhalter et al.,
2002). First, pD and therefore DIC are not invariant to reparameterisation of the model. Second,
a negative pD may occur with a non-logconcave likelihood and when the prior is in conflict with
the data. Third, the best model as determined by the DIC can change depending on the choice
of “likelihood”; for example, for multilevel models the likelihood can take one of two forms: the
likelihood obtained by integrating out the random effects or the likelihood without the random
effects integrated out. Another limitation, common to all likelihood based criteria, is that for some
models, the likelihood is not available in closed form (e.g. the Hurdle models in Chapter 5), for
which the likelihood can be typically evaluated using Monte Carlo integration.
Finally, the DIC is not uniquely defined in the presence of missing data and its use and in-
terpretation are not straightforward (Celeux et al., 2006; Mason et al., 2012a). In this situation,
a common practice is to compare models using a DIC computed on the observed values alone,
using Monte Carlo integration when the sampling distribution of the observed data is not available
in closed form (Daniels and Hogan, 2008). The appropriate extension of the observed data DIC
for multilevel models with missing data is based on the observed data likelihood L(θ | yobs) under
ignorability of the missing data but conditional on the random effects (Ntzoufras, 2009). This is
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the DIC typically implemented for multilevel models in the BUGS software and, in the context of the
missing data, is computed as
DIC = D(θ,u | yobs) + 2pD
= 2D(θ,u | yobs)−D(θ,u | yobs)
= 2 logL{Eθ,u|yobs [θ,u | yobs]} − 4Eθ|yobs [logL(θ,u | yobs)] .
where the random effects u are considered as extra parameters to be estimated, i.e.D(θ,u | yobs) =
−2Eθ|yobs [logL(yobs | θ,u)] and pD denotes the number of effective parameters, which is defined
as D(θ,u | yobs)−D(θ,u | yobs). When the response distribution does not have a known closed
form, Monte Carlo integration is typically used to calculate the corresponding likelihood and the
DIC.
A.2.1 Algorithm for the computation of the DIC based on the observed data
likelihood
Let p(y | θ) be the joint model of interest, formed by the usual bivariate economic outcome
y = (e, c) and indexed by the parameters θ = (θe,θc). For example, consider the modelling
framework described in Chapter 5, which is based on the factorisation of the joint into a marginal
distribution of the QALYs p(e | θe) and a conditional distribution of the costs p(c | e,θc), indexed by
the parameters θe and θc, respectively. The algorithm implemented in our applications to calculate
the observed DIC proceeds as follows.
1 Carry out a standard MCMC run on the joint model p(y | θ) = p(e | θe)p(c | e,θc) and
save the posterior samples for the parameters θ = (θe,θc), which are denoted as θ(k), for
k = 1, . . . ,K.
2 Evaluate the posterior means of θ across the posterior samples, denoted by θ =
(
θe,θc
)
.
3 At each iteration of the posterior distribution, generate a sample e(kl)mis, for l = 1 . . . , L, from
the appropriate likelihood evaluated at θ(k)e , e.g. e
(kl)
mis ∼ Beta
(
µ
(k)
e τ
(k)
e , (1− µ(k)e )τ (k)e
)
.
4 Then evaluate
h(k) = E
emis|eobs,θ(k)e
[
p(c | eobs, emis,θ(k)c )
]
≈ 1
L
L∑
l=1
p(c | eobs, e(kl)mis,θ(k)c )
5 Calculate the posterior expectation of the observed data log likelihood as
1
K
K∑
k=1
[
logL(θ(k)e | eobs) + log h(k)
]
and multiply this by −2 to get the posterior mean of the deviance, denoted as D(θ).
6 Generate a new sample e(l)mis, for l = 1, . . . , L, using θe. Evaluate the plug-in observed data
log likelihood using the posterior mean of the parameters as
logL(θe | eobs) + log
(
Eemis|eobs,θe
[
p(c | eobs, emis,θc)
])
,
where
Eemis|eobs,θe
[
p(c | eobs, emis,θc)
] ≈ 1
L
L∑
l=1
p(c | eobs, e(l)mis,θc)
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and multiply this plug-in log likelihood by −2 to get the plug-in deviance, denoted as D(θ)
7 Finally, calculate DIC = 2D(θ)−D(θ)
A.3 Condition of Validity for Complete Case Analysis
When the focus of the analysis is in some aspect of the conditional distribution of the response
y given some covariate x (e.g. regression parameter estimates), then CCA will lead unbiased
estimates as long as the distribution of y | x in the completers is the same as in the target
population. However, this condition does not match exactly the definition of the Rubin’s classes
since it typically holds when the missingness mechanism is MCAR, but also under certain MAR
and MNAR mechanisms (White and Carlin, 2010).
For example, suppose the interest is to perform a linear regression model on some data formed
by the outcome y and covariates x variable, for which some values in either y or x could be
unobserved. Let r denote whether a subject is a complete case (r = 1) or not (r = 0). Under
a CCA, all missing values are ignored with the analysis being performed on the complete cases
alone. Compared with a full data analysis (where all data are observed), the regression parameter
estimates will be less precise due to the loss of efficiency caused by the fewer cases on which
the model is fitted. However, the condition of validity of CCA (in terms of the bias associated with
the regression estimates) changes according to the type of the missing data mechanism and the
variable affected by missingness. Specifically, under a MCAR mechanism in either y or x, the
parameter estimates are unbiased because the complete cases are still a random sample from
the population. When missingness is conditionally independent of y given x (i.e. r |= y | x), then
the parameter estimates under CCA are still unbiased because the conditional distribution y | x
in the complete cases is the same as in the target population:
p(y | x, r = 1) = p(y,x, r = 1)
p(x, r = 1)
=
p(r = 1 | y,x)p(x,y)
p(r = 1 | x)p(x)
=
p(r = 1 | x)p(x,y)
p(r = 1 | x)p(x)
= p(y | x)
where, under the assumption that r |= y | x, then p(r = 1 | y,x) = p(r = 1 | x). When,
instead, missingness depends on y, even after conditioning on x, then the regression estimates
are biased. Figure A.1 visually displays the regression line estimated from the linear model of
y | x using CCA on a simulated dataset under three alternative scenarios: using all cases with
no missing values (panel a), when all cases with a response value higher than the mean of y are
removed from the analysis (panel b), and when all cases with a covariate value higher than the
mean of x are removed from the analysis (panel c). The regression line estimated on all cases
(panel a) is the benchmark and most efficient scenario since all data are used for the estimation
of the regression parameters. When missingness is dependent only on the outcome y (panel b),
the estimated regression parameters are biased, while when missingness is dependent on the
covariate x but not on y (panel c), the estimated regression parameters are unbiased.
In general the condition of validity for CCA is that misssingness should be (conditionally) inde-
pendent of the outcome, which may occur under different types of missing data mechanisms. If
missingness only affects y, then CCA’s validity assumption coincides with the MAR assumption.
However, when missingness affects x, CCA’s validity condition does not fit neatly into the Rubin’s
categories. For example, suppose we divide the covariates x into x1 and x2, where x2 is always
observed while x1 can be missing. Then, if missingness depends only on x2, then the data are
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Figure A.1: Estimated regression line from the conditional linear model y | x using CCA under three
scenarios: with fully observed data (panel a), when missingness depends on y (panel b) and when
missingness depends on x (panel c).
MAR but if missingness depends on x1 or jointly on x, then the data are MNAR. In both cases,
since missingness is conditionally independent of the response y, the regression estimates under
CCA are unbiased.
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Appendix B
Model Code
B.1 Mean Baseline Adjustment
The complete JAGS code for implementing the CC/AC version of the mean baseline adjustment
for the model fitted to the MenSS study in Chapter 4 is presented below.
model{
# N1 = 75 number of subjects in the control (t=1)
# N2 = 84 number of subjects in the intervention (t=2)
# et = QALYs variables in the two groups
# ct = Total cost variables in the two groups
# u0_t = Baseline utility variables in the two groups
# u0_cc[t] = Mean baseline utilities based on the CC in both groups
# u0_ac[t] = Mean baseline utilities based on the AC in both groups
for(i in 1 : N1){ #control
e1[i] ∼ dnorm(mu.e[i, 1], tau.e[1])
mu.e[i, 1] <- beta0[1] + beta1[1] * u0_1[i]
cost1[i] ∼ dnorm(mu.c[1], tau.c[1])
}
for(i in 1 : N2){ #intervention
eff2[i] ∼ dnorm(mu.e[i, 2], tau.e[2])
mu.e[i,2] <- beta0[2] + beta1[2] * u0_2[i]
cost2[i] ∼ dnorm(mu.c[2], tau.c[2])
}
# mean baseline utilities provided as data
mu.e.cc[1] <- beta0[1] + beta1[1] * u0_cc[1]
mu.e.cc[2] <- beta0[2] + beta1[2] * u0_cc[2]
mu.e.ac[1] <- beta0[1] + beta1[1] * u0_ac[1]
mu.e.ac[2] <- beta0[2] + beta1[2] * u0_ac[2]
# from precision to variance and standard deviation
for(t in 1 : 2){
tau.e[t] <- 1 / ss.e[t]
ss.e[t] <- sd.e[t] * sd.e[t]
sd.e[t] <- exp(ls.e[t])
tau.c[t] <- 1 / ss.c[t]
ss.c[t] <- sd.c[t] * sd.c[t]
sd.c[t] <- exp(ls.c[t])
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# priors
beta0[t] ∼ dnorm(0, 0.00001)
beta1[t] ∼ dnorm(0, 0.00001)
ls.e[t] ∼ dunif(-5, 10)
ls.c[t] ∼ dunif(-5, 10)
mu.c[t] ∼ dnorm(0, 0.00001)
}
# incremental quantities
delta_e.cc <- mu.e.cc[2] - mu.e.cc[1] # based on u0_cc
delta_e.ac <- mu.e.ac[2] - mu.e.ac[1] # based on u0_ac
delta_c <- mu.c[2] - mu.c[1] #cost increment
}
B.2 Hurdle Model
The complete JAGS code for implementing the Hurdle Model in Chapter 5 for the analysis of the
MenSS data is given below.
model {
# N1 = 75 number of subjects in the control (t=1)
# N2 = 84 number of subjects in the intervention (t=2)
# et = QALYs variables in the two groups
# ct = Total cost variables in the two groups
# u0_t = Baseline utility variables in the two groups
# d.et = Structural one indicators for et in the two groups
# d.u0_1 = Structural one indicators for u0_t in the two groups
# aget, ethnicityt, employmentt = Covariate variables in the two groups
for(i in 1 : N1) { # control
# 1. module for the structural ones in the QALYs
d.e1[i] ∼ dbern(pi.e[i, 1])
logit(pi.e[i, 1]) <- gamma0[1] + gamma1[1] * (u0_1[i] - mean(u0_1[])) +
gamma2[1] * (age1[i] - mean(age1[])) + gamma3[ethnicity1[i], 1] +
gamma4[employment1[i], 1]
#2. module for the structural ones in the baseline utilities
d.u0_1[i] ∼ dbern(pi.u[i, 1])
logit(pi.u[i, 1]) <- eta0[1] + eta1[1] * (age1[i] - mean(age1[])) +
eta2[ethnicity1[i], 1] + eta3[employment1[i], 1]
#3. marginal module for the QALYs
e1[i] ∼ dbeta(phi.e[i, 1] * tau.e[i, 1], (1 - phi.e[i, 1]) * tau.e[i, 1])
tau.e[i, 1] <- phi.e[i, 1] * (1 - phi.e[i, 1]) /
pow(sigma.e[d.e1[i] + 1], 2) - 1
logit(phi.e[i, 1]) <- alpha0[d.e1[i]+1, 1] +
alpha1[d.e1[i]+1, 1] * (u0_1[i] - mean(u0_1[]))
#4. marginal module for the baseline utilities
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u1[i] ∼ dbeta(mu.u[d.u0_1[i] + 1, 1] * tau.u[d.u0_1[i] + 1, 1],
(1 - mu.u[d.u0_1[i] + 1, 1]) * tau.u[d.u0_1[i] + 1, 1])
#5. conditional module for the costs
c1[i] ∼ dgamma(phi.c[i, 1] * tau.c[i, 1], tau.c[i, 1])
tau.c[i, 1] <- phi.c[i, 1] / pow(sigma.c[1], 2)
log( phi.c[i, 1]) <- beta0[1] + beta1[1] * (e1[i] - mu.e[1])
}
for(i in 1 : N2) { #intervention
#1. module for the structural ones in the QALYs
d.e2[i] ∼ dbern(pi.e[i, 2])
logit(pi.e[i, 2]) <- gamma0[2] + gamma1[2] * (u0_2[i] - mean(u0_2[])) +
gamma2[2] * (age2[i] - mean(age2[])) + gamma3[ethnicity2[i], 2] +
gamma4[employment2[i], 2]
#2. module for the structural ones in the baseline utilities
d.u0_2[i] ∼ dbern(pi.u[i, 2])
logit(pi.u[i, 2]) <- eta0[2] + eta1[2] * (age2[i] - mean(age2[])) +
eta2[ethnicity2[i], 2] + eta3[employment2[i], 2]
#3. marginal module for the QALYs
e2[i] ∼ dbeta(phi.e[i, 2] * tau.e[i, 2], (1 - phi.e[i, 2]) * tau.e[i, 2])
tau.e[i,2] <- phi.e[i, 2] * (1 - phi.e[i, 2]) /
pow(sigma.e[d.e2[i] + 1], 2) - 1
logit(phi.e[i, 2]) <- alpha0[d.e2[i] + 1, 2] +
alpha1[d.e2[i] + 1, 2] * (u0_2[i] - mean(u0_2[]))
#4. marginal module for the baseline utilities
u0_2[i] ∼ dbeta(mu.u[d.u0_2[i] + 1, 2] * tau.u[d.u0_2[i] + 1, 2],
(1 - mu.u[d.u0_2[i] + 1, 2]) * tau.u[d.u0_2[i] + 1, 2])
#5. conditional module for the costs
c2[i] ∼ dgamma(phi.c[i, 2] * tau.c[i, 2], tau.c[i, 2])
tau.c[i, 1] <- phi.c[i, 1] / pow(sigma.c[2], 2)
log( phi.c[i, 2]) <- beta0[2] + beta1[2] * (e2[i] - mu.e[2])
}
# priors for module 1 and 2
for(t in 1 : 2) {
gamma0[t] ∼ dlogis(0, 1)
gamma1[t] ∼ dnorm(0, 0.00001)
gamma2[t] ∼ dnorm(0, 0.00001)
eta0[t] ∼ dlogis(0, 1)
eta2[t] ∼ dnorm(0, 0.00001)
# priors on coefficients for categorical covariates
#(set reference category as 0)
gamma3[1, t] <- 0
gamma4[1, t] <- 0
eta2[1, t] <- 0
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eta3[1, t] <- 0
}
# priors for all other categories
# mu and tau values provided as data variables
#with zero means and small precisions (0.00001)
# ethnicity has different numbers of categories between arms
gamma3[2:14, 1] ∼ dmnorm(mu1.gamma3[], tau1.gamma3[, ])
gamma3[2:12, 2] ∼ dmnorm(mu2.gamma3[], tau2.gamma3[, ])
gamma4[2:6, 1] ∼ dmnorm(mu1.gamma4[], tau1.gamma4[, ])
gamma4[2:6, 2] ∼ dmnorm(mu2.gamma4[], tau2.gamma4[, ])
eta2[2:14, 1] ∼ dmnorm(mu1.eta2[], tau1.eta2[, ])
eta2[2:12, 2] ∼ dmnorm(mu2.eta2[], tau2.eta2[, ])
eta3[2:6, 1] ∼ dmnorm(mu1.eta3[], tau1.eta3[, ])
eta3[2:6, 2] ∼ dmnorm(mu2.eta3[], tau2.eta3[, ])
for(t in 1 : 2) {
# priors for model 3
# priors for the ones group in the QALYs
alpha0[2, t] <- logit(0.999999)
alpha1[2, t] <- 0
sigma.e[2, t] <- 0.00001
# priors for the non-ones group in the QALYs
alpha0[1, t] ∼ dnorm(0, 0.000001)
alpha1[1, t] ∼ dnorm(0, 0.000001)
sigma.e[1, t] ∼ dunif(0, sd.limit.e[t])
sd.limit.e[t] <- pow(mu.e[1, t] * (1 - mu.e[1, t]), 0.5)
# priors for model 4
# priors for the ones group in the baseline utilities
tau.u[2, t] <- mu.u[2, t] * (1 - mu.u[2, t]) /
pow(sigma.u[2, t], 2) - 1
logit(mu.u[2, t]) <- delta0[2, t]
delta0[2, t] <- logit(0.999999)
sigma.u[2, t] <- 0.00001
# priors for the non-ones group in the baseline utilities
tau.u[1, t] <- mu.u[1,t] * (1 - mu.u[1, t]) /
pow(sigma.u[1, t], 2) - 1
logit(mu.u[1, t]) <- delta0[1,t]
delta0[1, t] ∼ dnorm(0, 0.00001)
sigma.u[1, t] ∼ dunif(0, sd.limit.u[t])
sd.limit.u[t] <- pow(mu.u[1, t] * (1 - mu.u[1, t]), 0.5)
# priors for module 5
beta0[t] ∼ dnorm(0, 0.00001)
sigma.c[t] ∼ dunif(0, 1000)
beta1[t] ∼ dnorm(0, 0.00001)
# obtain marginal probabilities for weighting
p[t] <- ilogit(gamma0[t])
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# obtain the weighted marginal mean QALYs
mu.e[t] <- p[t] + (1-p[t]) * ilogit(alpha0[t])
}
# compute incremental QALYs and costs
delta_e <- mu.e[2] - mu.e[1]
delta_c <- mu.c[2] - mu.c[1]
}
B.3 Longitudinal Model
B.3.1 Model Code
The JAGS code for fitting the longitudinal model in Chapter 6 to the completers and non-completers
patterns in the PBS study is given below.
model{
# r = pattern indicator
# uj, cj = utilities and costs at time j = 0,1,2
# dj.u, dj.c = indicators for the structural values at time j
# trt = treatment indicator (1 = control, 2 = intervention)
# N = 244 total number of individuals
# N.r1 = 204 number of individuals in the completers pattern
# N.r2 = N - N.r1 = 40 number of individuals in the non-completers pattern
# R.star = number of theoretical patterns
# prior.psi = vector containing the hyperprior values for psi
# model for patterns r
for(i in 1:N){
r[i] ∼ dcat(psi[1:R.star,trt[i]])
}
# priors on model for r
for(t in 1:2){
psi[1:R.star,t] ∼ ddirch(prior.psi[])
}
# model for the responses in the completers (r1) stratified by treatment
for(i in 1:N.r1){
c0[i] ∼ dlnorm(nu0.c.r1[d0.c[i]+1,trt[i]],tau0.c.r1[d0.c[i]+1,trt[i]])
d0.c[i] ∼ dbern(pi0.c.r1[trt[i]])
u0[i] ∼ dbeta(a0.r1[i,trt[i]],b0.r1[i,trt[i]])
a0.r1[i,trt[i]] <- nu0.u.r1[i,trt[i]]*(nu0.u.r1[i,trt[i]]*
(1-nu0.u.r1[i,trt[i]])/pow(sigma0.u.r1[d0.u[i]+1,trt[i]],2)-1)
b0.r1[i,trt[i]] <- (1-nu0.u.r1[i,trt[i]])*(nu0.u.r1[i,trt[i]]*
(1-nu0.u.r1[i,trt[i]])/pow(sigma0.u.r1[d0.u[i]+1,trt[i]],2)-1)
logit(nu0.u.r1[i,trt[i]]) <- alpha00.r1[d0.u[i]+1,trt[i]]+
alpha10.r1[d0.u[i]+1,trt[i]]*log(c0[i])
d0.u[i] ∼ dbern(pi0.u.r1[i,trt[i]])
logit(pi0.u.r1[i,trt[i]]) <- gamma00.r1[trt[i]]+
gamma10.r1[trt[i]]*log(c0[i])
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c1[i] ∼ dlnorm(nu1.c.r1[i,trt[i]],tau1.c.r1[d1.c[i]+1,trt[i]])
nu1.c.r1[i,trt[i]] <- beta01.r1[d1.c[i]+1,trt[i]]+
beta11.r1[d1.c[i]+1,trt[i]]*log(c0[i])+beta21.r1[d1.c[i]+1,trt[i]]*u0[i]
d1.c[i] ∼ dbern(pi1.c.r1[i,trt[i]])
logit(pi1.c.r1[i,trt[i]]) <- zeta01.r1[trt[i]]+
zeta11.r1[trt[i]]*log(c0[i])+zeta21.r1[trt[i]]*u0[i]
u1[i] ∼ dbeta(a1.r1[i,trt[i]],b1.r1[i,trt[i]])
a1.r1[i,trt[i]] <- nu1.u.r1[i,trt[i]]*(nu1.u.r1[i,trt[i]]*
(1-nu1.u.r1[i,trt[i]])/pow(sigma1.u.r1[d1.u[i]+1,trt[i]],2)-1)
b1.r1[i,trt[i]] <- (1-nu1.u.r1[i,trt[i]])*(nu1.u.r1[i,trt[i]]*
(1-nu1.u.r1[i,trt[i]])/pow(sigma1.u.r1[d1.u[i]+1,trt[i]],2)-1)
logit(nu1.u.r1[i,trt[i]]) <- alpha01.r1[d1.u[i]+1,trt[i]]+
alpha11.r1[d1.u[i]+1,trt[i]]*log(c1[i])+alpha21.r1[d1.u[i]+1,trt[i]]*u0[i]
d1.u[i] ∼ dbern(pi1.u.r1[i,trt[i]])
logit(pi1.u.r1[i,trt[i]]) <- gamma01.r1[trt[i]]+
gamma11.r1[trt[i]]*log(c0[i])+gamma21.r1[trt[i]]*u0[i]
c2[i] ∼ dlnorm(nu2.c.r1[i,trt[i]],tau2.c.r1[d2.c[i]+1,trt[i]])
nu2.c.r1[i,trt[i]]<- beta02.r1[d2.c[i]+1,trt[i]]+
beta12.r1[d2.c[i]+1,trt[i]]*log(c1[i])+beta22.r1[d2.c[i]+1,trt[i]]*u1[i]
d2.c[i] ∼ dbern(pi2.c.r1[i,trt[i]])
logit(pi2.c.r1[i,trt[i]]) <- zeta02.r1[trt[i]]+
zeta12.r1[trt[i]]*log(c1[i])+zeta22.r1[trt[i]]*u1[i]
u2[i] ∼ dbeta(a2.r1[i,trt[i]],b2.r1[i,trt[i]])
a2.r1[i,trt[i]] <- nu2.u.r1[i,trt[i]]*(nu2.u.r1[i,trt[i]]*
(1-nu2.u.r1[i,trt[i]])/pow(sigma2.u.r1[d2.u[i]+1,trt[i]],2)-1)
b2.r1[i,trt[i]] <- (1-nu2.u.r1[i,trt[i]])*(nu2.u.r1[i,trt[i]]*
(1-nu2.u.r1[i,trt[i]])/ pow(sigma2.u.r1[d2.u[i]+1,trt[i]],2)-1)
logit(nu2.u.r1[i,trt[i]]) <- alpha02.r1[d2.u[i]+1,trt[i]]+
alpha12.r1[d2.u[i]+1,trt[i]]*log(c2[i])+alpha22.r1[d2.u[i]+1,trt[i]]*u0[i]
d2.u[i] ∼ dbern(pi2.u.r1[i,trt[i]])
logit(pi2.u.r1[i,trt[i]]) <- gamma02.r1[trt[i]]+
gamma12.r1[trt[i]]*log(c1[i])+gamma22.r1[trt[i]]*u1[i]
}
# obtain standard deviations from precisions for cj
for(d in 1:2){
for(t in 1:2){
tau0.c.r1[d,t] <- 1/pow(sigma0.c.r1[d,t],2)
tau1.c.r1[d,t] <- 1/pow(sigma1.c.r1[d,t],2)
tau2.c.r1[d,t] <- 1/pow(sigma2.c.r1[d,t],2)
}
}
# priors on model for uj and cj
# priors on cj>0 and uj<1
for(t in 1:2){
alpha00.r1[1,t] ∼ dnorm(0,0.0001)
alpha01.r1[1,t] ∼ dnorm(0,0.0001)
alpha02.r1[1,t] ∼ dnorm(0,0.0001)
alpha10.r1[1,t] ∼ dnorm(0,0.0001)
alpha11.r1[1,t] ∼ dnorm(0,0.0001)
alpha12.r1[1,t] ∼ dnorm(0,0.0001)
alpha21.r1[1,t] ∼ dnorm(0,0.0001)
alpha22.r1[1,t] ∼ dnorm(0,0.0001)
sigma0.u.limit.r1[t] <- sqrt(ilogit(alpha00.r1[1,t])*
(1-ilogit(alpha00.r1[1,t])))
sigma0.u.r1[1,t] ∼ dunif(0,sigma0.u.limit.r1[t])
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sigma1.u.limit.r1[t] <- sqrt(ilogit(alpha01.r1[1,t])*
(1-ilogit(alpha01.r1[1,t])))
sigma1.u.r1[1,t] ∼ dunif(0,sigma1.u.limit.r1[t])
sigma2.u.limit.r1[t] <- sqrt(ilogit(alpha02.r1[1,t])*
(1-ilogit(alpha02.r1[1,t])))
sigma2.u.r1[1,t] ∼ dunif(0,sigma2.u.limit.r1[t])
nu0.c.r1[1,t] ∼ dnorm(0,0.0001)
beta01.r1[1,t] ∼ dnorm(0,0.0001)
beta02.r1[1,t] ∼ dnorm(0,0.0001)
beta11.r1[1,t] ∼ dnorm(0,0.0001)
beta12.r1[1,t] ∼ dnorm(0,0.0001)
beta21.r1[1,t] ∼ dnorm(0,0.0001)
beta22.r1[1,t] ∼ dnorm(0,0.0001)
sigma0.c.r1[1,t] ∼ dunif(0,10000)
sigma1.c.r1[1,t] ∼ dunif(0,10000)
sigma2.c.r1[1,t] ∼ dunif(0,10000)
# priors on cj=0 and uj=1
alpha00.r1[2,t] <- logit(0.999999)
alpha01.r1[2,t] <- logit(0.999999)
alpha02.r1[2,t] <- logit(0.999999)
alpha10.r1[2,t] <- 0
alpha11.r1[2,t] <- 0
alpha12.r1[2,t] <- 0
alpha21.r1[2,t] <- 0
alpha22.r1[2,t] <- 0
sigma0.u.r1[2,t] <- 0.000001
sigma1.u.r1[2,t] <- 0.000001
sigma2.u.r1[2,t] <- 0.000001
nu0.c.r1[2,t] <- log(pow(0.000001,2)/
(sqrt(pow(0.000001,2)+pow(0.000001,2))))
beta01.r1[2,t] <- log(pow(0.000001,2)/
(sqrt(pow(0.000001,2)+pow(0.000001,2))))
beta02.r1[2,t] <- log(pow(0.000001,2)/
(sqrt(pow(0.000001,2)+pow(0.000001,2))))
beta11.r1[2,t] <- 0
beta12.r1[2,t] <- 0
beta21.r1[2,t] <- 0
beta22.r1[2,t] <- 0
sigma0.c.r1[2,t] <- sqrt(log(pow(0.000001,2)/pow(0.000001,2)+1))
sigma1.c.r1[2,t] <- sqrt(log(pow(0.000001,2)/pow(0.000001,2)+1))
sigma2.c.r1[2,t] <- sqrt(log(pow(0.000001,2)/pow(0.000001,2)+1))
# priors on model for d.uj and d.cj
gamma00.r1[t] ∼ dnorm(0,0.0001)
gamma01.r1[t] ∼ dnorm(0,0.0001)
gamma02.r1[t] ∼ dnorm(0,0.0001)
gamma10.r1[t] ∼ dnorm(0,0.0001)
gamma11.r1[t] ∼ dnorm(0,0.0001)
gamma12.r1[t] ∼ dnorm(0,0.0001)
gamma21.r1[t] ∼ dnorm(0,0.0001)
gamma22.r1[t] ∼ dnorm(0,0.0001)
pi0.c.r1[t] ∼ dunif(0,1)
zeta01.r1[t] ∼ dnorm(0,0.0001)
zeta02.r1[t] ∼ dnorm(0,0.0001)
zeta11.r1[t] ∼ dnorm(0,0.0001)
zeta12.r1[t] ∼ dnorm(0,0.0001)
zeta21.r1[t] ∼ dnorm(0,0.0001)
zeta22.r1[t] ∼ dnorm(0,0.0001)
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}# model for the responses in the non-completers (r2) stratified by treatment
for(i in N.r1+1:N){
c0.r2[i] ∼ dlnorm(nu0.c.r2[d0.c[i]+1,trt[i]],tau0.c.r2[d0.c[i]+1,trt[i]])
d0.c[i] ∼ dbern(pi0.c.r2[trt[i]])
u0[i] ∼ dbeta(a0.r2[i,trt[i]],b0.r2[i,trt[i]])
a0.r2[i,trt[i]] <- nu0.u.r2[i,trt[i]]*(nu0.u.r2[i,trt[i]]*
(1-nu0.u.r2[i,trt[i]])/pow(sigma0.u.r2[d0.u[i]+1,trt[i]],2)-1)
b0.r2[i,trt[i]] <- (1-nu0.u.r2[i,trt[i]])*(nu0.u.r2[i,trt[i]]*
(1-nu0.u.r2[i,trt[i]])/pow(sigma0.u.r2[d0.u[i]+1,trt[i]],2)-1)
logit(nu0.u.r2[i,trt[i]]) <- alpha00.r2[d0.u[i]+1,trt[i]]+
alpha10.r2[d0.u[i]+1,trt[i]]*log(c0[i])
d0.u[i] ∼ dbern(pi0.u.r2[i,trt[i]])
logit(pi0.u.r2[i,trt[i]]) <- gamma00.r2[trt[i]]+
gamma10.r2[trt[i]]*log(c0[i])
c1[i] ∼ dlnorm(nu1.c.r2[i,trt[i]],tau1.c.r2[d1.c[i]+1,trt[i]])
nu1.c.r2[i,trt[i]] <- beta01.r2[d1.c[i]+1,trt[i]]+
beta11.r2[d1.c[i]+1,trt[i]]*log(c0[i])+beta21.r2[d1.c[i]+1,trt[i]]*u0[i]
d1.c[i] ∼ dbern(pi1.c.r2[i,trt[i]])
logit(pi1.c.r2[i,trt[i]]) <- zeta01.r2[trt[i]]+
zeta11.r2[trt[i]]*log(c0[i])+zeta21.r2[trt[i]]*u0[i]
u1[i] ∼ dbeta(a1.r2[i,trt[i]],b1.r2[i,trt[i]])
a1.r2[i,trt[i]] <- nu1.u.r2[i,trt[i]]*(nu1.u.r2[i,trt[i]]*
(1-nu1.u.r2[i,trt[i]])/pow(sigma1.u.r2[d1.u[i]+1,trt[i]],2)-1)
b1.r2[i,trt[i]] <- (1-nu1.u.r2[i,trt[i]])*(nu1.u.r2[i,trt[i]]*
(1-nu1.u.r2[i,trt[i]])/pow(sigma1.u.r2[d1.u[i]+1,trt[i]],2)-1)
logit(nu1.u.r2[i,trt[i]]) <- alpha01.r2[d1.u[i]+1,trt[i]]+
alpha11.r2[d1.u[i]+1,trt[i]]*log(c1[i])+alpha21.r2[d1.u[i]+1,trt[i]]*u0[i]
d1.u[i] ∼ dbern(pi1.u.r2[i,trt[i]])
logit(pi1.u.r2[i,trt[i]]) <- gamma01.r2[trt[i]]+
gamma11.r2[trt[i]]*log(c0[i])+gamma21.r2[trt[i]]*u0[i]
c2[i] ∼ dlnorm(nu2.c.r2[i,trt[i]],tau2.c.r2[d2.c[i]+1,trt[i]])
nu2.c.r2[i,trt[i]] <- beta02.r2[d2.c[i]+1,trt[i]]+
beta12.r2[d2.c[i]+1,trt[i]]*log(c1[i])+beta22.r2[d2.c[i]+1,trt[i]]*u1[i]
d2.c[i] ∼ dbern(pi2.c.r2[i,trt[i]])
logit(pi2.c.r2[i,trt[i]]) <- zeta02.r2[trt[i]]+
zeta12.r2[trt[i]]*log(c1[i])+zeta22.r2[trt[i]]*u1[i]
u2[i] ∼ dbeta(a2.r2[i,trt[i]],b2.r2[i,trt[i]])
a2.r2[i,trt[i]] <- nu2.u.r2[i,trt[i]]*(nu2.u.r2[i,trt[i]]*
(1-nu2.u.r2[i,trt[i]])/pow(sigma2.u.r2[d2.u[i]+1,trt[i]],2)-1)
b2.r2[i,trt[i]] <- (1-nu2.u.r2[i,trt[i]])*(nu2.u.r2[i,trt[i]]*
(1-nu2.u.r2[i,trt[i]])/pow(sigma2.u.r2[d2.u[i]+1,trt[i]],2)-1)
logit(nu2.u.r2[i,trt[i]]) <- alpha02.r2[d2.u[i]+1,trt[i]]+
alpha12.r2[d2.u[i]+1,trt[i]]*log(c2[i])+alpha22.r2[d2.u[i]+1,trt[i]]*u0[i]
d2.u[i] ∼ dbern(pi2.u.r2[i,trt[i]])
logit(pi2.u.r2[i,trt[i]]) <- gamma02.r2[trt[i]]+
gamma12.r2[trt[i]]*log(c1[i])+gamma22.r2[trt[i]]*u1[i]
}
# obtain standard deviations from precisions for cj
for(d in 1:2){
for(t in 1:2){
tau0.c.r2[d,t] <- 1/pow(sigma0.c.r2[d,t],2)
tau1.c.r2[d,t] <- 1/pow(sigma1.c.r2[d,t],2)
tau2.c.r2[d,t] <- 1/pow(sigma2.c.r2[d,t],2)
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}}
# priors on model for uj and cj
# priors on cj>0 and uj<1
for(t in 1:2){
alpha00.r2[1,t] ∼ dnorm(0,0.0001)
alpha01.r2[1,t] ∼ dnorm(0,0.0001)
alpha02.r2[1,t] ∼ dnorm(0,0.0001)
alpha10.r2[1,t] ∼ dnorm(0,0.0001)
alpha11.r2[1,t] ∼ dnorm(0,0.0001)
alpha12.r2[1,t] ∼ dnorm(0,0.0001)
alpha21.r2[1,t] ∼ dnorm(0,0.0001)
alpha22.r2[1,t] ∼ dnorm(0,0.0001)
sigma0.u.limit.r2[t] <- sqrt(ilogit(alpha00.r2[1,t])*
(1-ilogit(alpha00.r2[1,t])))
sigma0.u.r2[1,t] ∼ dunif(0,sigma0.u.limit.r2[t])
sigma1.u.limit.r2[t] <- sqrt(ilogit(alpha01.r2[1,t])*
(1-ilogit(alpha01.r2[1,t])))
sigma1.u.r2[1,t] ∼ dunif(0,sigma1.u.limit.r2[t])
sigma2.u.limit.r2[t] <- sqrt(ilogit(alpha02.r2[1,t])*
(1-ilogit(alpha02.r2[1,t])))
sigma2.u.r2[1,t] ∼ dunif(0,sigma2.u.limit.r2[t])
nu0.c.r2[1,t] ∼ dnorm(0,0.0001)
beta01.r2[1,t] ∼ dnorm(0,0.0001)
beta02.r2[1,t] ∼ dnorm(0,0.0001)
beta11.r2[1,t] ∼ dnorm(0,0.0001)
beta12.r2[1,t] ∼ dnorm(0,0.0001)
beta21.r2[1,t] ∼ dnorm(0,0.0001)
beta22.r2[1,t] ∼ dnorm(0,0.0001)
sigma0.c.r2[1,t] ∼ dunif(0,10000)
sigma1.c.r2[1,t] ∼ dunif(0,10000)
sigma2.c.r2[1,t] ∼ dunif(0,10000)
# priors on for cj=0 and uj=1
alpha00.r2[2,t] <- logit(0.999999)
alpha01.r2[2,t] <- logit(0.999999)
alpha02.r2[2,t] <- logit(0.999999)
alpha10.r2[2,t] <- 0
alpha11.r2[2,t] <- 0
alpha12.r2[2,t] <- 0
alpha21.r2[2,t] <- 0
alpha22.r2[2,t] <- 0
sigma0.u.r2[2,t] <- 0.000001
sigma1.u.r2[2,t] <- 0.000001
sigma2.u.r2[2,t] <- 0.000001
nu0.c.r2[2,t] <- log(pow(0.000001,2)/
(sqrt(pow(0.000001,2)+pow(0.000001,2))))
beta01.r2[2,t] <- log(pow(0.000001,2)/
(sqrt(pow(0.000001,2)+pow(0.000001,2))))
beta02.r2[2,t] <- log(pow(0.000001,2)/
(sqrt(pow(0.000001,2)+pow(0.000001,2))))
beta11.r2[2,t] <- 0
beta12.r2[2,t] <- 0
beta21.r2[2,t] <- 0
beta22.r2[2,t] <- 0
sigma0.c.r2[2,t] <- sqrt(log(pow(0.000001,2)/pow(0.000001,2)+1))
sigma1.c.r2[2,t] <- sqrt(log(pow(0.000001,2)/pow(0.000001,2)+1))
sigma2.c.r2[2,t] <- sqrt(log(pow(0.000001,2)/pow(0.000001,2)+1))
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# priors on model for d.uj and d.cj
gamma00.r2[t] ∼ dnorm(0,0.0001)
gamma01.r2[t] ∼ dnorm(0,0.0001)
gamma02.r2[t] ∼ dnorm(0,0.0001)
gamma12.r2[t] ∼ dnorm(0,0.0001)
gamma22.r2[t] ∼ dnorm(0,0.0001)
pi0.c.r2[t] ∼ dunif(0,1)
zeta01.r2[t] ∼ dnorm(0,0.0001)
zeta02.r2[t] ∼ dnorm(0,0.0001)
zeta12.r2[t] ∼ dnorm(0,0.0001)
zeta22.r2[t] ∼ dnorm(0,0.0001)
}
gamma10.r2[1] ∼ dnorm(0,0.0001)
gamma11.r2[1] ∼ dnorm(0,0.0001)
gamma21.r2[1] ∼ dnorm(0,0.0001)
gamma10.r2[2] <- 0
gamma11.r2[2] <- 0
gamma21.r2[2] <- 0
zeta11.r2[1] <- 0
zeta21.r2[1] <- 0
zeta11.r2[2] ∼ dnorm(0,0.0001)
zeta21.r2[2] ∼ dnorm(0,0.0001)
}
B.3.2 Monte Carlo Integration and Marginal Means Computation
R code for the MCI used to approximate the posterior distribution of the marginal utility and cost
means for the model in Chapter 6 under the nonignorable scenarios δ = 0, δflat, δskew0 and δskew1.
# N.sim = 20,000 number of the iterations
# N.rep = 40,000 replicated samples at each iteration
# r1 = completers pattern
# r2 = non-completers pattern
# r.con = number of observed patterns in the control
# r.int = number of observed patterns in the intervention
# all relevant parameters saved from JAGS into R objects
# e.g. nu0.c.r1[1:N.sim, 1:2] = c0 mean for r1
# psi.obs.con[1:N.sim,1:r.con] = patterns' probabilities (control)
# psi.obs.int[1:N.sim, 1:r.int] = patterns' probabilities (intervention)
# compute Monte Carlo estimates for mean uj and cj at each time j=0,1,2
mu.c0.r1 <- mu.c1.r1 <- mu.c2.r1 <- matrix(NA,N.sim,2)
mu.u0.r1 <- mu.u1.r1 <- mu.u2.r1 <- matrix(NA,N.sim,2)
mu.c0.r2 <- mu.c1.r2 <- mu.c2.r2 <- matrix(NA,N.sim,2)
mu.u0.r2 <- mu.u1.r2 <- mu.u2.r2 <- matrix(NA,N.sim,2)
# control
for(k in 1:N.sim){
mu.c0.r1[k,1] <- mean(rlnorm(N.rep,nu0.c.r1[k,1],sigma0.c.r1[k,1]))
mu.c1.r1[k,1] <- mean(rlnorm(N.rep,nu1.c.r1[k,1],sigma1.c.r1[k,1]))
mu.c2.r1[k,1] <- mean(rlnorm(N.rep,nu2.c.r1[k,1],sigma2.c.r1[k,1]))
mu.u0.r1[k,1] <- mean(rbeta(N.rep,a0.r1[k,1],b0.r1[k,1]))
136
mu.u1.r1[k,1] <- mean(rbeta(N.rep,a1.r1[k,1],b1.r1[k,1]))
mu.u2.r1[k,1] <- mean(rbeta(N.rep,a2.r1[k,1],b2.r1[k,1]))
mu.c0.r2[k,1] <- mean(rlnorm(N.rep,nu0.c.r2[k,1],sigma0.c.r2[k,1]))
mu.c1.r2[k,1] <- mean(rlnorm(N.rep,nu1.c.r2[k,1],sigma1.c.r2[k,1]))
mu.c2.r2[k,1] <- mean(rlnorm(N.rep,nu2.c.r2[k,1],sigma2.c.r2[k,1]))
mu.u0.r2[k,1] <- mean(rbeta(N.rep,a0.r2[k,1],b0.r2[k,1]))
mu.u1.r2[k,1] <- mean(rbeta(N.rep,a1.r2[k,1],b1.r2[k,1]))
mu.u2.r2[k,1] <- mean(rbeta(N.rep,a2.r2[k,1],b2.r2[k,1]))
# intervention
mu.c0.r1[k,2] <- mean(rlnorm(N.rep,nu0.c.r1[k,2],sigma0.c.r1[k,2]))
mu.c1.r1[k,2] <- mean(rlnorm(N.rep,nu1.c.r1[k,2],sigma1.c.r1[k,2]))
mu.c2.r1[k,2] <- mean(rlnorm(N.rep,nu2.c.r1[k,2],sigma2.c.r1[k,2]))
mu.u0.r1[k,2] <- mean(rbeta(N.rep,a0.r1[k,2],b0.r1[k,2]))
mu.u1.r1[k,2] <- mean(rbeta(N.rep,a1.r1[k,2],b1.r1[k,2]))
mu.u2.r1[k,2] <- mean(rbeta(N.rep,a2.r1[k,2],b2.r1[k,2]))
mu.c0.r2[k,2] <- mean(rlnorm(N.rep,nu0.c.r2[k,2],sigma0.c.r2[k,2]))
mu.c1.r2[k,2] <- mean(rlnorm(N.rep,nu1.c.r2[k,2],sigma1.c.r2[k,2]))
mu.c2.r2[k,2] <- mean(rlnorm(N.rep,nu2.c.r2[k,2],sigma2.c.r2[k,2]))
mu.u0.r2[k,2] <- mean(rbeta(N.rep,a0.r2[k,2],b0.r2[k,2]))
mu.u1.r2[k,2] <- mean(rbeta(N.rep,a1.r2[k,2],b1.r2[k,2]))
mu.u2.r2[k,2] <- mean(rbeta(N.rep,a2.r2[k,2],b2.r2[k,2]))
}
# priors on the sensitivity parameters
# flat prior
delta.c0.flat <- runif(N.sim,0,2*sd(c0))
delta.u0.flat <- runif(N.sim,-2*sd(u0),0)
delta.c1.flat <- runif(N.sim,0,2*sd(c1))
delta.u1.flat <- runif(N.sim,-2*sd(u1),0)
delta.c2.flat <- runif(N.sim,0,2*sd(c2))
delta.u2.flat <- runif(N.sim,-2*sd(u2),0)
# skew0 prior
delta.c0.skew0<- 2*sd(c0)*(1-sqrt(runif(N.sim,0,1))
delta.u0.skew0<- -2*sd(u0)*(1-sqrt(runif(N.sim,0,1))
delta.c1.skew0<- 2*sd(c1)*(1-sqrt(runif(N.sim,0,1))
delta.u1.skew0<- -2*sd(u1)*(1-sqrt(runif(N.sim,0,1))
delta.c2.skew0<- 2*sd(c2)*(1-sqrt(runif(N.sim,0,1))
delta.u2.skew0<- -2*sd(u2)*(1-sqrt(runif(N.sim,0,1))
#skew1 prior
delta.c0.skew1 <- 2*sd(c0)*sqrt(runif(N.sim,0,1)
delta.u0.skew1 <- -2*sd(u0)*sqrt(runif(N.sim,0,1)
delta.c1.skew1 <- 2*sd(c1)*sqrt(runif(N.sim,0,1)
delta.u1.skew1 <- -2*sd(u1)*sqrt(runif(N.sim,0,1)
delta.c2.skew1 <- 2*sd(c2)*sqrt(runif(N.sim,0,1)
delta.u2.skew1 <- -2*sd(u2)*sqrt(runif(N.sim,0,1)
# stratify the marginal means by pattern and arm under delta=0
# control
mu.c0.r.con <- mu.c1.r.con <- mu.c2.r.con <- matrix(NA,N.sim,9)
mu.c0.r.con[,1] <- mu.c0.r1[,1]
mu.c0.r.con[,2:9] <- mu.c0.r2[,1]
mu.c1.r.con[,1] <- mu.c1.r1[,1]
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mu.c1.r.con[,2:9] <- mu.c1.r2[,1]
mu.c2.r.con[,1] <- mu.c2.r1[,1]
mu.c2.r.con[,2:9] <- mu.c2.r2[,1]
mu.u0.r.con <- mu.u1.r.con <- mu.u2.r.con <- matrix(NA,N.sim,9)
mu.u0.r.con[,1] <- mu.u0.r1[,1]
mu.u0.r.con[,2:9] <- mu.u0.r2[,1]
mu.u1.r.con[,1] <- mu.u1.r1[,1]
mu.u1.r.con[,2:9] <- mu.u1.r2[,1]
mu.u2.r.con[,1] <- mu.u2.r1[,1]
mu.u2.r.con[,2:9] <- mu.u2.r2[,1]
# intervention
mu.c0.r.int <- mu.c1.r.int <- mu.c2.r.int <- matrix(NA,N.sim,6)
mu.c0.r.int[,1] <- mu.c0.r1[,2]
mu.c0.r.int[,2:6] <- mu.c0.r2[,2]
mu.c1.r.int[,1] <- mu.c1.r1[,2]
mu.c1.r.int[,2:6] <- mu.c1.r2[,2]
mu.c2.r.int[,1] <- mu.c2.r1[,2]
mu.c2.r.int[,2:6] <- mu.c2.r2[,2]
mu.u0.r.int <- mu.u1.r.int <- mu.u2.r.int <- matrix(NA,N.sim,6)
mu.u0.r.int[,1] <- mu.u0.r1[,2]
mu.u0.r.int[,2:6] <- mu.u0.r2[,2]
mu.u1.r.int[,1] <- mu.u1.r1[,2]
mu.u1.r.int[,2:6] <- mu.u1.r2[,2]
mu.u2.r.int[,1] <- mu.u2.r1[,2]
mu.u2.r.int[,2:6] <- mu.u2.r2[,2]
# marginal means for missing data in each pattern and arm under each prior
mu.c1.r.con.flat <- mu.c1.r.con.skew0 <- mu.c1.r.con.skew1 <- mu.c1.r.con
mu.c2.r.con.flat <- mu.c2.r.con.skew0 <- mu.c2.r.con.skew1 <- mu.c2.r.con
mu.u0.r.con.flat <- mu.u0.r.con.skew0 <- mu.u0.r.con.skew1 <- mu.u0.r.con
mu.u1.r.con.flat <- mu.u1.r.con.skew0 <- mu.u1.r.con.skew1 <- mu.u1.r.con
mu.u2.r.con.flat <- mu.u2.r.con.skew0 <- mu.u2.r.con.skew1 <- mu.u2.r.con
mu.c1.r.int.flat <- mu.c1.r.int.skew0 <- mu.c1.r.int.skew1 <- mu.c1.r.int
mu.c2.r.int.flat <- mu.c2.r.int.skew0 <- mu.c2.r.int.skew1 <- mu.c2.r.int
mu.u0.r.int.flat <- mu.u0.r.int.skew0 <- mu.u0.r.int.skew1 <- mu.u0.r.int
mu.u1.r.int.flat <- mu.u1.r.int.skew0 <- mu.u1.r.int.skew1 <- mu.u1.r.int
mu.u2.r.int.flat <- mu.u2.r.int.skew0 <- mu.u2.r.int.skew1 <- mu.u2.r.int
# control
# c, j=1 (missing for r.con=8,9)
mu.c1.r.con.flat[,c(8,9)] <- mu.c1.r2[,1]+delta.c1.flat
mu.c1.r.con.skew0[,c(8,9)] <- mu.c1.r2[,1]+delta.c1.skew0
mu.c1.r.con.skew1[,c(8,9)] <- mu.c1.r2[,1]+delta.c1.skew1
# c, j=2 (missing for r.con=6,9)
mu.c2.r.con.flat[,c(6,9)] <- mu.c2.r2[,1]+delta.c2.flat
mu.c2.r.con.skew0[,c(6,9)] <- mu.c2.r2[,1]+delta.c2.skew0
mu.c2.r.con.skew1[,c(6,9)] <- mu.c2.r2[,1]+delta.c2.skew1
# u, j=0 (missing for r.con=2,5)
mu.u0.r.con.flat[,c(2,5)] <- mu.u0.r2[,1]+delta.u0.flat
mu.u0.r.con.skew0[,c(2,5)] <- mu.u0.r2[,1]+delta.u0.skew0
mu.u0.r.con.skew1[,c(2,5)] <- mu.u0.r2[,1]+delta.u0.skew1
# u, j=1 (missing for r.con=3,5,7,8,9)
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mu.u1.r.con.flat[,c(3,5,7,8,9)] <- mu.u1.r2[,1]+delta.u1.flat
mu.u1.r.con.skew0[,c(3,5,7,8,9)] <- mu.u1.r2[,1]+delta.u1.skew0
mu.u1.r.con.skew1[,c(3,5,7,8,9)] <- mu.u1.r2[,1]+delta.u1.skew1
# u, j=2 (missing for r.con=4,6,7,9)
mu.u2.r.con.flat[,c(4,6,7,9)] <- mu.u2.r2[,1]+delta.u2.flat
mu.u2.r.con.skew0[,c(4,6,7,9)] <- mu.u2.r2[,1]+delta.u2.skew0
mu.u2.r.con.skew1[,c(4,6,7,9)] <- mu.u2.r2[,1]+delta.u2.skew1
# intervention
# c, j=1 (missing for r.int=5,6)
mu.c1.r.int.flat[,c(5,6)] <- mu.c1.r2[,2]+delta.c1.flat
mu.c1.r.int.skew0[,c(5,6)] <- mu.c1.r2[,2]+delta.c1.skew0
mu.c1.r.int.skew1[,c(5,6)] <- mu.c1.r2[,2]+delta.c1.skew1
# c, j=2 (missing for r.int=6)
mu.c2.r.int.flat[,6] <- mu.c2.r2[,2]+delta.c2.flat
mu.c2.r.int.skew0[,6] <- mu.c2.r2[,2]+delta.c2.skew0
mu.c2.r.int.skew1[,6] <- mu.c2.r2[,2]+delta.c2.skew1
# u, j=0 (missing for r.int=2)
mu.u0.r.int.flat[,2] <- mu.u0.r2[,2]+delta.u0.flat
mu.u0.r.int.skew0[,2] <- mu.u0.r2[,2]+delta.u0.skew0
mu.u0.r.int.skew1[,2] <- mu.u0.r2[,2]+delta.u0.skew1
# u, j=1 (missing for r.int=3,5,6)
mu.u1.r.int.flat[,c(3,5,6)] <- mu.u1.r2[,2]+delta.u1.flat
mu.u1.r.int.skew0[,c(3,5,6)] <- mu.u1.r2[,2]+delta.u1.skew0
mu.u1.r.int.skew1[,c(3,5,6)] <- mu.u1.r2[,2]+delta.u1.skew1
# u, j=2 (missing for r.int=4,6,7,9)
mu.u2.r.int.flat[,c(4,6)] <- mu.u2.r2[,2]+delta.u2.flat
mu.u2.r.int.skew0[,c(4,6)] <- mu.u2.r2[,2]+delta.u2.skew0
mu.u2.r.int.skew1[,c(4,6)] <- mu.u2.r2[,2]+delta.u2.skew1
# marginal means across observed patterns in each group under each prior
mu.c0.bench <- mu.c1.bench <- mu.c2.bench <- matrix(NA,N.sim,2)
mu.u0.bench <- mu.u1.bench <- mu.u2.bench <- matrix(NA,N.sim,2)
mu.c0.flat <- mu.c1.flat <- mu.c2.flat <- matrix(NA,N.sim,2)
mu.u0.flat <- mu.u1.flat <- mu.u2.flat <- matrix(NA,N.sim,2)
mu.c0.skew0 <- mu.c1.skew0 <- mu.c2.skew0 <- matrix(NA,N.sim,2)
mu.u0.skew0 <- mu.u1.skew0 <- mu.u2.skew0 <- matrix(NA,N.sim,2)
mu.c0.skew1 <- mu.c1.skew1 <- mu.c2.skew1 <- matrix(NA,N.sim,2)
mu.u0.skew1 <- mu.u1.skew1 <- mu.u2.skew1 <- matrix(NA,N.sim,2)
# control
mu.c0.bench[,1] <- rowSums(mu.c0.r.con*psi.obs.con)
mu.c1.bench[,1] <- rowSums(mu.c1.r.con*psi.obs.con)
mu.c2.bench[,1] <- rowSums(mu.c2.r.con*psi.obs.con)
mu.u0.bench[,1] <- rowSums(mu.u0.r.con*psi.obs.con)
mu.u1.bench[,1] <- rowSums(mu.u1.r.con*psi.obs.con)
mu.u2.bench[,1] <- rowSums(mu.u2.r.con*psi.obs.con)
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mu.c1.flat[,1] <- rowSums(mu.c1.r.con.flat*psi.obs.con)
mu.c2.flat[,1] <- rowSums(mu.c2.r.con.flat*psi.obs.con)
mu.u0.flat[,1] <- rowSums(mu.u0.r.con.flat*psi.obs.con)
mu.u1.flat[,1] <- rowSums(mu.u1.r.con.flat*psi.obs.con)
mu.u2.flat[,1] <- rowSums(mu.u2.r.con.flat*psi.obs.con)
mu.c1.skew0[,1] <- rowSums(mu.c1.r.con.skew0*psi.obs.con)
mu.c2.skew0[,1] <- rowSums(mu.c2.r.con.skew0*psi.obs.con)
mu.u0.skew0[,1] <- rowSums(mu.u0.r.con.skew0*psi.obs.con)
mu.u1.skew0[,1] <- rowSums(mu.u1.r.con.skew0*psi.obs.con)
mu.u2.skew0[,1] <- rowSums(mu.u2.r.con.skew0*psi.obs.con)
mu.c1.skew1[,1] <- rowSums(mu.c1.r.con.skew1*psi.obs.con)
mu.c2.skew1[,1] <- rowSums(mu.c2.r.con.skew1*psi.obs.con)
mu.u0.skew1[,1] <- rowSums(mu.u0.r.con.skew1*psi.obs.con)
mu.u1.skew1[,1] <- rowSums(mu.u1.r.con.skew1*psi.obs.con)
mu.u2.skew1[,1] <- rowSums(mu.u2.r.con.skew1*psi.obs.con)
# intervention
mu.c0.bench[,2] <- rowSums(mu.c0.r.int*psi.obs.int)
mu.c1.bench[,2] <- rowSums(mu.c1.r.int*psi.obs.int)
mu.c2.bench[,2] <- rowSums(mu.c2.r.int*psi.obs.int)
mu.u0.bench[,2] <- rowSums(mu.u0.r.int*psi.obs.int)
mu.u1.bench[,2] <- rowSums(mu.u1.r.int*psi.obs.int)
mu.u2.bench[,2] <- rowSums(mu.u2.r.int*psi.obs.int)
mu.c1.flat[,2] <- rowSums(mu.c1.r.int.flat*psi.obs.int)
mu.c2.flat[,2] <- rowSums(mu.c2.r.int.flat*psi.obs.int)
mu.u0.flat[,2] <- rowSums(mu.u0.r.int.flat*psi.obs.int)
mu.u1.flat[,2] <- rowSums(mu.u1.r.int.flat*psi.obs.int)
mu.u2.flat[,2] <- rowSums(mu.u2.r.int.flat*psi.obs.int)
mu.c1.skew0[,2] <- rowSums(mu.c1.r.int.skew0*psi.obs.int)
mu.c2.skew0[,2] <- rowSums(mu.c2.r.int.skew0*psi.obs.int)
mu.u0.skew0[,2] <- rowSums(mu.u0.r.int.skew0*psi.obs.int)
mu.u1.skew0[,2] <- rowSums(mu.u1.r.int.skew0*psi.obs.int)
mu.u2.skew0[,2] <- rowSums(mu.u2.r.int.skew0*psi.obs.int)
mu.c1.skew1[,2] <- rowSums(mu.c1.r.int.skew1*psi.obs.int)
mu.c2.skew1[,2] <- rowSums(mu.c2.r.int.skew1*psi.obs.int)
mu.u0.skew1[,2] <- rowSums(mu.u0.r.int.skew1*psi.obs.int)
mu.u1.skew1[,2] <- rowSums(mu.u1.r.int.skew1*psi.obs.int)
mu.u2.skew1[,2] <- rowSums(mu.u2.r.int.skew1*psi.obs.int)
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Appendix C
Supplementary Analyses
In this Appendix we present information and results from supplementary analyses based on the
models presented in Chapter 5 and Chapter 6.
C.1 Supplementary Analyses: Chapter 2
C.1.1 Alternative versions of the quality evaluation scheme
As a way of supporting the recommended scheme which weights the description (D), Method (M)
and Limitations (L) components using an allocation of 3:2:1 (denoted as version I), we have also
considered two alternative strategies. The first, assigns equal weight to each component with
an allocation of 1:1:1 (denoted as version II), while the second assigns the weights assuming a
greater discrepancy between the importance associated with each component using an allocation
of 6:3:1 (denoted as version III).
The three schemes are compared in Table C.1, which shows the score assigned to each of the
three components in the analysis (Description, Method and Limitations) by each weight allocation
version.
Version I (3:2:1) Version II (1:1:1) Version III (6:3:1)
Content Score Score ScoreD M L D M L D M L
Full 6 4 2 2 2 2 12 6 3
Partial 3 2 1 1 1 1 6 3 1
Limitations 0 0 0 0 0 0 0 0 0
Table C.1: Comparison of three weighting schemes, based on the information provided on missingness
in each component of the analysis: Description (D), Method (M) and Limitations (L)
Table C.2 shows the different scoring system and the classification into ordered categories
based on the total scores associated with the three alternative versions of the scheme.
Version I (3:2:1) Version II (1:1:1) Version III (6:3:1)
Category Total score Total score Total score
A 12 6 20
B 9-11 5 15-19
C 6-8 4 10-14
D 3-5 2-3 5-9
E 0-2 0-1 0-4
Table C.2: Scoring system associated with each group category in three weight allocation versions of the
Quality Evaluation Scheme.
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Table C.3 (costs) and Table C.4 (effects) show the number of articles falling within each cate-
gory defined by the three different schemes. The diagram representation visually compares the
original scheme (version I) against the two alternative schemes (version II and III) used. The cate-
gories indicated on the right-hand side of the graph, allow comparison between the three scoring
schemes and grouping methods. Since no major differences can to be detected, we believe that
our original weighting scheme can be considered as robust to (reasonable) changes. Other ex-
treme weight combinations could be tested (such as reversing the initial weight assignment from
a ratio 3:2:1 to a ratio 1:2:3) but the meaningfulness of such schemes is difficult to justify
Table C.3 shows limited differences in the classification of the articles for missing costs in
2009-2015 across the categories of the scheme between the versions compared. Specifically,
compared with version I, there is a decrease in the number of articles for category B (-1 in version
II and -2 in version III), C (-5 in version II and -4 in version III) and D (-1 only in version III), and an
increase for category D (+6 in version II and +7 in version III).
Version I (3:2:1) Version II (1:1:1) Version III (6:3:1)
Category # Articles # Articles # Articles
A 5 5 5
B 6 5 4
C 14 9 10
D 17 23 24
E 39 39 38
Table C.3: Missing cost articles distribution (total number of articles = 81) across the categories of the
Quality Evaluation Scheme for the three weight allocation versions compared.
Table C.4 shows limited differences in the classification of the articles for missing effects in
2009-2015 across the categories of the scheme between the versions compared. Specifically,
compared with version I, there is a decrease in the number of articles for category B (-3 in version
II and -1 in version III) and C (-10 in version II and -2 in version III), with an increase for category
D (+13 only in version II) or category E (+3 only in version III).
Version I (3:2:1) Version II (1:1:1) Version III (6:3:1)
Category # Articles # Articles # Articles
A 5 5 5
B 5 2 4
C 18 8 16
D 16 29 16
E 37 37 40
Table C.4: Missing effect articles distribution (total number of articles = 81) across the categories of the
Quality Evaluation Scheme for the three weight allocation versions compared.
As can be seen from Figure C.1, based on the information provided in the previous tables, the
overall distribution of the articles across the different graded categories indicated by letters is not
greatly affected. Indeed, no substantial difference is detected for the classification of the articles
between version I and III of the scheme. With respect to version II, the largest change is related to
an increase in the number of articles falling within category D in version II compared with version I,
due to the more limited structure and fewer scores for the former. Such a difference is mostly due
to the larger weight assigned to the Description component in the original version, which allows
it to more flexibly capture the difference across the articles’ quality performance compared to the
equal weight version.
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Description Method Limitations Weighting Schemes
I II III
A (12) A (6) A (20)
B (11) B (5) B (19)
B (10) B (5) B (18)
B (10) B (5) B (17)
B (9) C (4) B (16)
C (8) C (4) B (15)
B (8) B (4) C (14)
B (7) C (3) C (13)
C (6) C (2) C (12)
B (9) C (4) C (14)
C (8) C (4) C (13)
C (7) D (3) C (12)
C (7) D (3) C (11)
C (6) D (2) C (10)
D (5) D (2) D (9)
D (5) D (2) D (8)
D (4) D (2) D (7)
D (3) D (2) D (6)
C (6) D (2) D (8)
D (5) D (2) D (7)
D (4) D (2) D (6)
C (4) D (2) D (5)
D (3) D (2) E (4)
E (2) E (1) E (3)
E (2) E (1) E (2)
E (1) E (1) E (1)
E (0) E (1) E (0)
Figure C.1: Diagram representation for the quality score grades (E-A) based on final scores (0 - 12)
in three alternative weight allocation schemes for the Description, Method and Limitations components.
The weight allocations are 3:2:1 (version I), 1:1:1 (version II) and 6:3:1 (version III). Branches colour
represents the different way information can be provided: Red=Null information (N), Light Blue=Partial
information (P), Blue=Full information (F).
C.1.2 Robustness Method Analysis
Table C.5 and Table C.6 show the number of the articles in the literature review in the period
(2003-2009) associated with each combination of base-case and robustness methods for missing
costs and effects, respectively.
Table C.7 and Table C.8 show the number of the articles in the literature review in the period
(2009-2015) associated with each combination of base-case and robustness methods for missing
costs and effects, respectively.
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Costs Robustness method
None Others Lin Ext LVCF Mean Cond CCA MI More than one
Base-
case
method
Unclear 20 0 0 0 0 0 0 0 0
Others 9 0 0 0 0 0 1 1 1 20
Lin Ext 2 0 0 0 0 0 0 0 0 11
LVCF 1 0 0 0 0 0 0 0 1 2
Mean 8 0 0 0 0 0 1 0 0 9
Cond 4 0 0 0 0 0 1 2 1 8
CCA 19 2 0 1 0 0 0 4 1 27
MI 6 0 0 0 0 0 1 0 1 8
69 2 0 1 0 0 4 7 5
Table C.5: Comparison of methods used in the base-case analysis (rows) and those used as alternatives
in a robustness analysis (columns) for the articles between 2003-2009 for missing costs. The total number
of articles using each base-case and robustness method is reported in the last column at the right of
the table and in the last row at the bottom of the table. Legend: unspecified methods (Unclear), other
methods (Others), Linear Extrapolation (Lin Ext), Last Value Carried Forward (LVCF), Mean Imputation
(Mean), Conditional Imputation (Cond), Complete Case Analysis (CCA), Multiple Imputation (MI).
Effects Robustness method
None Others Lin Ext LVCF Mean Cond CCA MI More than one
Base-
case
method
Unclear 21 0 0 0 0 0 0 0 0 21
Others 7 0 0 0 0 0 0 1 0 8
Lin Ext 3 0 0 0 0 0 0 1 0 4
LVCF 5 1 0 0 0 0 1 0 2 9
Mean 6 1 0 0 0 0 0 0 0 7
Cond 1 0 0 0 0 0 0 0 1 2
CCA 16 0 0 1 2 1 0 3 1 24
MI 8 0 0 0 0 0 3 1 1 13
67 2 0 1 2 1 4 6 5
Table C.6: Comparison of methods used in the base-case analysis (rows) and those used as alternatives
in a robustness analysis (columns) for the articles between 2003-2009 for missing effects. The total
number of articles using each base-case and robustness method is reported in the last column at the right
of the table and in the last row at the bottom of the table. Legend: unspecified methods (Unclear), other
methods (Others), Linear Extrapolation (Lin Ext), Last Value Carried Forward (LVCF), Mean Imputation
(Mean), Conditional Imputation (Cond), Complete Case Analysis (CCA), Multiple Imputation (MI).
Costs Robustness method
None Others Lin Ext LVCF Mean Cond CCA MI More than one
Base-
case
method
Unclear 22 0 0 0 0 0 0 0 0 22
Others 7 0 0 0 0 0 0 0 2 9
Lin Ext 1 0 0 0 0 0 0 0 0 1
LVCF 4 0 0 0 0 0 0 0 0 4
Mean 1 0 0 0 0 0 1 0 0 2
Cond 2 0 0 0 0 0 0 0 0 2
CCA 10 2 0 1 0 0 0 1 0 14
MI 16 0 0 1 0 0 9 0 1 27
63 2 0 2 0 0 10 1 3
Table C.7: Comparison of methods used in the base-case analysis (rows) and those used as alternatives
in a robustness analysis (columns) for the articles between 2009-2015 for missing costs. The total number
of articles using each base-case and robustness method is reported in the last column at the right of
the table and in the last row at the bottom of the table. Legend: unspecified methods (Unclear), other
methods (Others), Linear Extrapolation (Lin Ext), Last Value Carried Forward (LVCF), Mean Imputation
(Mean), Conditional Imputation (Cond), Complete Case Analysis (CCA), Multiple Imputation (MI).
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Effects Robustness method
None Others Lin Ext LVCF Mean Cond CCA MI More than one
Base-
case
method
Unclear 8 0 0 0 0 0 0 0 0 8
Others 10 0 0 0 0 0 0 0 1 11
Lin Ext 1 0 0 0 0 0 0 0 0 1
LVCF 5 0 0 0 1 0 0 0 0 6
Mean 6 1 0 0 0 0 0 0 0 7
Cond 3 0 0 0 0 0 0 0 0 3
CCA 8 5 0 2 0 0 0 1 1 17
MI 16 1 0 1 0 0 7 1 2 28
57 7 0 3 1 0 7 2 4
Table C.8: Comparison of methods used in the base-case analysis (rows) and those used as alternatives
in a robustness analysis (columns) for the articles between 2009-2015 for missing effects. The total
number of articles using each base-case and robustness method is reported in the last column at the right
of the table and in the last row at the bottom of the table. Legend: unspecified methods (Unclear), other
methods (Others), Linear Extrapolation (Lin Ext), Last Value Carried Forward (LVCF), Mean Imputation
(Mean), Conditional Imputation (Cond), Complete Case Analysis (CCA), Multiple Imputation (MI).
Table C.9 shows the number of the articles in the literature review in the period (2009-2015)
associated with each combination of quality score derived from the Quality Evaluation Scheme
(see Section 2.1) and strength of missing data assumptions (classified in terms of the type of
missingness method used – see Section 2.3). Results are separately reported for missing costs
and effects.
Costs Strength of the assumptions
UNK SI CCA MI SA
Quality
score
A 0 1 0 4 0 5
B 0 3 0 3 0 6
C 0 2 2 10 0 14
D 7 6 2 2 0 17
E 14 8 8 9 0 39
21 19 12 24 0
Effects Strength of the assumptions
UNK SI CCA MI SA
Quality
score
A 1 0 0 3 1 5
B 0 2 0 3 0 5
C 0 3 7 8 0 18
D 2 8 1 5 0 16
E 5 15 8 9 0 37
8 28 16 28 1
Table C.9: Comparison of the quality scores (rows) and strength of missing data assumptions (columns)
associated with the studies between 2009-2015 for the missing costs and effects.The total number of
articles for each category of the quality scores and strength of assumptions is reported in the last column
at the right of the table and in the last row at the bottom of the table. The strength of assumptions for each
study are broadly summarised according to the type of missing data method used: UNK (Unknown), SI
(Single Imputation), CCA (Complete Case Analysis), MI (Multiple Imputation), SA (Sensitivity Analysis).
C.1.3 Statistical methods used in the reviewed studies
Table C.10 shows the numbers and proportions of articles in the literature review associated with
different types of statistical methods used to perform the cost-effectiveness analysis.
Method n of studies % of studies
Independent regressions with bootstrapping 30 38%
Independent regressions without bootstrapping 23 29%
Markov models 3 3%
Generalised estimating equations 2 2%
Seemingly unrelated regressions 2 2%
Generalised linear models 2 2%
MCMC methods 2 2%
Two-stage bootstrap methods 2 2%
Unclear 15 20%
Total 81 100%
Table C.10: Number (and frequency) of the studies by type of statistical methods used in the primary
CEAs across the articles included in the literature review in Chapter 2 between 2009-2015.
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C.2 Supplementary Analyses: Chapter 4
C.2.1 MenSS study
Figure C.2 compares the point and 95% CI estimates for the mean QALYs and costs parame-
ters in the two treatment groups of the MenSS trial, which are obtained under three modelling
approaches fitted to the completers using either the CC (red) or AC (blue) mean baseline util-
ity adjustment. The three approaches are: ordinary least square regressions independently for
QALYs and costs (Standard), Seemingly Unrelated Regressions (SUR) and Full Bayesian Model
(Bayesian). In particular, SURs have been implememted using multi-equation estimation methods
in the function systemfit, available from the R package systemfit (Henningsen and Hamann,
2018)
QALYs
Bayesian
SUR
Standard
0.85 0.9 0.95
CC
AC
(a) control
QALYs
Bayesian
SUR
Standard
0.85 0.9 0.95
CC
AC
(b) Intervention
Figure C.2: Mean QALYs and costs estimates in the control (panel a) and intervention (panel b) group of
the MenSS trial derived from three models fitted to the completers using either the CC (red) or AC (blue)
mean baseline utility adjustment. The models are: Standard Approach (Standard), which uses only the AC
mean baseline adjustment, Seemingly Unrelated Regression (SUR) and Full Bayesian Model (Bayesian).
Table C.11 compares the point and 95% CI estimates for the mean QALYs and costs and other
incremental parameters (e.g. net benefit), for the two treatment groups of the MenSS trial, which
are obtained under three modelling approaches: ordinary least square regressions independently
for QALYs and costs (Standard), Seemingly Unrelated Regressions using maximum likelihood
(SUR) and Full Bayesian Model (Bayesian).
C.2.2 PBS study
Table C.12 compares the point and 95% CI estimates for the mean QALYs and costs and other
incremental parameters (e.g. net benefit), for the two treatment groups of the PBS trial, which are
obtained under three modelling approaches: ordinary least square regressions independently for
QALYs and costs (Standard), Multivariate Linear Mixed effects Models using maximum likelihood
(MLME) and Full Bayesian Model (Bayesian). In particular, MLMEs have been implememted
using mixed-effects maximum likelihood estimation methods in the function lmer, available from
the R package lme4 (Bates et al., 2019).
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Parameter
Standard SUR CC SUR AC Bayesian CC Bayesian AC
Mean 95% interval Mean 95% interval Mean 95% interval Mean 95% interval Mean 95% interval
Control (t = 1)
mean QALY (µe1) 0.874 (0.843;0.905) 0.904 (0.873;0.935) 0.876 (0.845;0.908) 0.904 (0.873;0.935) 0.874 (0.841;0.907)
mean cost (µc1) 208 (106;310) 208 (106;310) 208 (106;310) 207 (104;307) 207 (104;307)
Intervention (t = 2)
mean QALY (µe2) 0.915 (0.873;0.957) 0.902 (0.859;0.944) 0.916 (0.873;0.958) 0.902 (0.859;0.943) 0.915 (0.873;0.959)
mean cost (µc2) 189 (112;266) 189 (131;285) 189 (131;285) 189 (111;266) 189 (111;266)
Incremental
QALY differential (∆e) 0.04 (-0.02;0.09) -0.002 (-0.05;0.05) 0.04 (-0.02;0.1) -0.002 (-0.054;0.05) 0.041 (-0.013;0.094)
Cost differential (∆c) -18 (-145;97) -18 (-160;107) -18 (-160;107) -18 (-146;110) -18 (-146;110)
IB (at k = 20000) -20 (-1385;1016) 801 (-484;2064) -23 (-1063;1042) 835 (-241;1928)
ICER 9625 -482 8822 -449
Table C.11: Means and 95% credible/confidence interval estimates of the mean QALYs and cost param-
eters for the control (t = 1) and intervention (t = 2) group in the MenSS trial obtained from different
models. The models are: the original model used by Bailey et al. (2016) (Standard), Seemingly Unrelated
Regression (SUR) and Full Bayesian model (Bayesian). The results of the last two models are distin-
guished according to whether they were fitted using the CC or AC mean baseline utilities. Mean QALYs
and cost differentials, the incremental benefits at k = 20000 and the ICERs are also reported. Cost values
are expressed in £.
Parameter
Standard MLME CC MLME AC Bayesian CC Bayesian AC
Mean 95% interval Mean 95% interval Mean 95% interval Mean 95% interval Mean 95% interval
Control (t = 1)
mean QALY (µe1) 0.529 (0.493;0.565) 0.493 (0.449;0.536) 0.523 (0.479;0.566) 0.493 (0.441;0.546) 0.521 (0.469;0.577)
mean cost (µc1) 2974 (2104;3843) 2984 (2050;4068) 2984 (2054;4070) 3054 (2122;3997) 3055 (2124;4000)
Intervention (t = 2)
mean QALY (µe2) 0.611 (0.575;0.647) 0.593 (0.531;0.676) 0.592 (0.531;0.676) 0.585 (0.531;0.637) 0.583 (0.529;0.635)
mean cost (µc2) 4568 (3915;5221) 5346 (4540;6287) 5349 (4543;6291) 5449 (4673;6217) 5456 (4693;6221)
Incremental
QALY differential (∆e) 0.08 (0.012;0.14) 0.08 (-0.02;0.18) 0.05 (-0.05;0.15) 0.09 (0.03;0.15) 0.06 (0.01;0.12)
Cost differential (∆c) 1608 (212;2434) 2362 (1125;3590) 2365 (1223;3562) 2395 (1172;3592) 2401 (1155;3567)
IB (at k = 20000) -353 (-3240;1493) -996 (-3841;893) -552 (-2220;1108) -1166 (-2876;452)
ICER 23971 32610 25985 38871
Table C.12: Means and 95% credible/confidence interval estimates of the mean QALYs and cost param-
eters for the control (t = 1) and intervention (t = 2) group in the PBS trial obtained from different models.
The models are: the original model used by Hassiotis et al. (2018) (Standard), Multivariate Linear Mixed
effects Model (MLME) and Full Bayesian model (Bayesian). The results of the last two models are distin-
guished according to whether they were fitted using the CC or AC mean baseline utilities. Mean QALYs
and cost differentials, the incremental benefits at k = 20000 and the ICERs are also reported. Cost values
are expressed in £.
Figure C.3 compares the point and 95% CI estimates for the mean QALYs and costs param-
eters in the two treatment groups of the PBS trial, which are obtained under three modelling
approaches fitted to the completers using either the CC (red) or AC (blue) mean baseline util-
ity adjustment. The three approaches are: ordinary least square regressions independently for
QALYs and costs (Standard), Multivariate Linear Mixed effects Model using maximum likelihood
(MLME) and Full Bayesian Model (Bayesian).
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Figure C.3: Mean QALYs and cost estimates in the control (panels a and c) and intervention (panels b
and d) group of the PBS trial derived from three models fitted to the completers using either the CC (red)
or AC (blue) mean baseline utility adjustment. The models are: Standard Approach (Standard), which
uses only the AC mean baseline adjustment, Multivariate Linear Mixed effects Model (MLME) and Full
Bayesian Model (Bayesian).
C.3 Supplementary Analyses: Chapter 5
C.3.1 Sensitivity to the choice of the scaling parameter for the costs
Figure C.4 shows the sensitivity of the inferences across the alternative specifications for the
scaling factor , which is added to the data of the MenSS trial to avoid zero values when using a
Gamma distributions for modelling the costs. Results in terms of mean posterior estimates and
90% HPD intervals were almost unchanged in all the cases. Thus, we can assert that model
performance was unaffected by the choice of the value for .
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Figure C.4: Sensitivity analysis for the choice of the scaling parameter  when fitting the Beta-Gamma
model to the QALYs and cost data under the “all cases” scenario for the MenSS trial. The different 
values are subtracted and added to the set of observed QALYs and cost data to avoid the boundary
values that fall outside the support of the Beta and Gamma distributions (1 for the QALYs and 0 for the
costs), respectively. For each value of  tested, posterior means and 90% HPD intervals for the mean
QALYs and cost parameters are respectively represented with dots and lines: red for the control (panels
a and c) and blue for the intervention (panels b and d).
C.3.2 Implementation “trick” for the Hurdle Model
The Hurdle Model described in Chapter 5 can be represented using a different sampling distribu-
tion for the QALYs, depending on the observed value of the indicator die
ei | die ∼
p(ei | die = 0) = p(ei | θ<1), if ei < 1p(ei | die = 1) = p(ei | θ1), if ei = 1, (C.1)
where the model for ei = 1 is degenerate at a point mass at 1, while that for ei < 1 is defined in
terms of a Beta distribution. We can conveniently re-write Equation C.1 more succinctly and with
specific reference to our case as
ei ∼ Beta
(
φdieie τ
die
ie ,
(
1− φdieie
)
τdieie
)
. (C.2)
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If we set φ1ie = 1 and select τ
1
ie in order to induce a variance as close to 0 as possible, the two
specifications are identical. Unfortunately, it is not possible to directly fit the model in Equation C.2
into BUGS/JAGS, because the Beta distribution is specified in the open interval (0, 1) and thus setting
φ1ie = 1 implies that τ
1
ie = 0, which is not allowed.
However, the required behaviour is very closely mimicked if we define our model with logit(φ1ie) =
α10 [+ . . .] and set α10 = logit(0.999999) and σe ≈ 0, which implies µe ≈ 1 with virtually no uncer-
tainty. In other words, we can specify extremely informative priors on the parameters θ1 so that
the implied distribution for the structural ones components of the mixture is concentrated around 1
with essentially no uncertainty. More importantly, with such a prior no amount of data can modify
the posterior. The critical aspect of this strategy, however, is that inferences may be potentially
sensitive to the way such priors are specified, that is whether a small variation in the hyperprior
values can affect the posterior estimates.
In fact, the estimation of the other parameters is not really affected by this choice, provided
that the encoded prior really induces the variance towards zero. It is also plausible that different
values for σ1e have an impact on measures of model fit, such as the DIC. This is essentially due
to the fact that the population is really comprised of two groups, one of which shows QALYs that
are identically one. Thus, the closer the approximation to zero for the variance the better the fit
to the observed data and therefore the smaller the resulting DIC. With this in mind, we have used
different values for σ1e to assess the impact on the mean QALYs estimates. Fixing the value of
the mean for the ones group to µ1e = 0.999999 corresponds to an upper bound for the standard
deviation of 0.0001 (see Section 5.2.2). We have explored a range of possibilities by progressively
decreasing this value and assessed their impact on posterior results.
Figure C.5 shows the sensitivity of the inferences across the alternative specifications for σ1e .
Results in terms of mean posterior estimates and 90% HPD intervals were almost unchanged
in all the cases. Thus, we can assert that model performance was unaffected by the choice of
the value for σ1e . We also observe that the DIC becomes smaller when the standard deviation
parameter decreases and the best-fitting model is the one associated with the smallest values,
although the results are hardly different from both an estimation and convergence perspective for
all the parameters.
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Figure C.5: Sensitivity analysis for the choice of the standard deviation for the distribution of the structural
ones in the QALYs. For each value of σ1e tested, posterior means and 90% HPD intervals for the mean
QALYs parameters are respectively represented with dots and lines (red for the control and blue for the
intervention group).
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C.3.3 Prior sensitivity
Figure C.6 and Figure C.7 compare the point and 95% CI estimates for the expected effectiveness
and cost differentials derived from the models fitted to the MenSS and PBS data in Chapter 5 with
those obtained under three alternative prior specifications. The original prior specifications (Orig-
inal) assume Normal priors for the regression parameters α,β ∼ Normal(0, 1000) and uniform
priors for the standard deviations σ ∼ Uniform(0, 1000) of the costs and the QALYs (for the latter,
whenever a Beta distribution is assumed, truncated uniform priors as described in Section 5.2.2
are used). The three alternative versions considered vary the priors on the standard deviations,
using either Uniform(0, 10000) (Uniform) or truncated Normal(0, 1000)T[0, ] (Half-Normal) specifi-
cations, and on the regression parameters, using Normal(0, 100000) (Normal) priors.
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Figure C.6: Mean and 95% credible interval estimates of the expected effectiveness (panel a) and cost
(panel b) differentials for the Bivariate Normal, Beta-Gamma and Hurdle Model (respectively indicated
by red, green and blue colours in the graphs) in the MenSS trial under different priors. The prior spec-
ification described in Section 5.2 (Original), denoted with dashed lines in the graphs, assumes Normal
priors for the regression parameters α,β ∼ Normal(0, 1000) and uniform priors for the standard devi-
ations σ ∼ Uniform(0, 1000) of the costs and the QALYs (for the latter, the Beta-Gamma and Hurdle
Model assume a truncated uniform prior as described in Section 5.2.2). Three alternative versions are
considered which vary the priors on the standard deviations, using either Uniform(0, 10000) (Uniform)
or truncated Normal(0, 1000)T[0, ] (Half-Normal) specifications, and on the regression parameters, using
Normal(0, 100000) (Normal) priors.
C.3.4 Posterior estimates
Table C.13 compares the point and 95% CI estimates for the mean QALYs and costs and other
incremental parameters (e.g. net benefit), in the two treatment groups of the MenSS trial between
three alternative specifications of the modelling framework described in Section 5.1: Normal for
both QALYs and costs (Bivariate Normal), Beta for the QALYs and Gamma for the costs (Beta-
Gamma) and Hurdle for the QALYs and Gamma for the costs (Hurdle Model).
Table C.14 compares the point and 95% CI estimates for the mean QALYs and costs and other
incremental parameters (e.g. net benefit), in the two treatment groups of the PBS trial between
three alternative specifications of the modelling framework described in Section 5.1: Normal for
both QALYs and costs (Bivariate Normal), Beta for the QALYs and LogNormal for the costs (Beta-
Gamma) and Hurdle for the QALYs and LogNormal for the costs (Hurdle Model).
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Figure C.7: Mean and 95% credible interval estimates of the expected effectiveness (panel a) and cost
(panel b) differentials for the Bivariate Normal, Beta-LogNormal and Hurdle Model (respectively indicated
by red, green and blue colours in the graphs) in the PBS trial under different priors. The prior speci-
fication described in Section 5.2 (Original), denoted with dashed lines in the graphs, assumes Normal
priors for the regression parameters α,β ∼ Normal(0, 1000) and uniform priors for the standard devia-
tions σ ∼ Uniform(0, 1000) of the costs and the QALYs (for the latter, the Beta-LogNormal and Hurdle
Model assume a truncated uniform prior as described in Section 5.2.2). Three alternative versions are
considered which vary the priors on the standard deviations, using either Uniform(0, 10000) (Uniform)
or truncated Normal(0, 1000)T[0, ] (Half-Normal) specifications, and on the regression parameters, using
Normal(0, 100000) (Normal) priors.
Parameter
Bivariate Normal Beta-Gamma Hurdle Model
Mean 95% interval Mean 95% interval Mean 95% interval
Control (t = 1)
mean QALY (µe1) 0.873 (0.84;0.906) 0.876 (0.836;0.907) 0.88 (0.839;0.912)
mean cost (µc1) 234 (135;336) 200 (116;336) 198 (116;343)
Intervention (t = 2)
mean QALY (µe2) 0.92 (0.874;0.961) 0.907 (0.859;0.94) 0.895 (0.836;0.938)
mean cost (µc2) 187 (106;267) 189 (89;401) 193 (91;419)
Incremental
QALY differential (∆e) 0.04 (-0.01;0.1) 0.03 (-0.03;0.08) 0.02 (-0.05;0.07)
Cost differential (∆c) 47 (-178;81) -11 (-184;217) -5 (-184;244)
IB (at k = 20000) 927 (-188;2055) 631 (-559;1730) 312 (-1072;1545)
ICER 1067 -355 -339
Table C.13: Means and 95% credible interval estimates of the mean QALYs and cost parameters for the
control (t = 1) and intervention (t = 2) group in the MenSS trial obtained from the Bivariate Normal,
Beta-Gamma and Hurdle model under the “all cases” scenario. Mean QALYs and cost differentials, the
incremental benefits at k = 20000 and the ICERs are also reported. Cost values are expressed in £.
C.3.5 Posterior Predictive Checks
Figure C.8 compares the histograms of the empirical distributions of the QALYs in both treatment
groups of the MenSS study (dark blue bars) with respect to 15 replications of the dataset based
on the samples drawn from the posterior predictive distribution of the Hurdle Model (light blue
bars) in Chapter 5 Most of the replicated QALYs seem to well-capture the empirical distributions
of the observed values, including the spikes at 1 for the data in both the control (panel a) and
intervention (panel b) groups.
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Parameter
Bivariate Normal Beta LogNormal Hurdle Model
Mean 95% interval Mean 95% interval Mean 95% interval
Control (t = 1)
mean QALY (µe1) 0.491 (0.442;0.553) 0.501 (0.452;0.551) 0.491 (0.442;0.544)
mean cost (µc1) 2927 (2165;3692) 2605 (2067;3414) 2639 (2046;3546)
Intervention (t = 2)
mean QALY (µe2) 0.613 (0.56;0.662) 0.571 (0.523;0.623) 0.58 (0.531;0.632)
mean cost (µc2) 5573 (4953;6196) 5111 (4586;5731) 5334 (4665;6090)
Incremental
QALY differential (∆e) 0.12 (0.05;0.19) 0.07 (0.01;0.14) 0.09 (0.02;0.15)
Cost differential (∆c) 2643 (1648;3626) 2484 (1672;3205) 2670 (1688;3543)
IB (at k = 20000) -246 (-2014;1505) -991 (-2575;605) -917 (-2645;835)
ICER 22053 33274 30467
Table C.14: Means and 95% credible interval estimates of the mean QALYs and cost parameters for the
control (t = 1) and intervention (t = 2) group in the PBS trial obtained from the Bivariate Normal, Beta
LogNormal and Hurdle model under the “all cases” scenario. Mean QALYs and cost differentials, the
incremental benefits at k = 20000 and the ICERs are also reported. Cost values are expressed in £.
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Figure C.8: Histograms of the empirical distributions of the observed QALYs (dark blue bars) in the
control (panel a) and intervention (panel b) in the MenSS trial, which are compared with the replications
of the data based on the samples drawn from the posterior predictive distribution of the Hurdle Model. For
visualisation purposes, only 15 replications (out of the 1000 generated) are displayed in the graphs.
Figure C.9 shows the histograms of the proportions of structural ones derived from 1000 repli-
cates of the QALYs in the MenSS study drawn from the posterior predictive distribution of the
Hurdle Model, which are compared with the proportions of ones in the observed QALYs. The
distribution of the replicated proportions of ones is on average close to the corresponding values
observed in the data for both the control (panel a) and intervention (panel b) groups.
Figure C.10 compares the histograms of the empirical distributions of the costs in both treat-
ment groups of the PBS study (dark blue bars) with respect to 15 replications of the dataset
based on the samples drawn from the posterior predictive distribution of the Hurdle Model (light
blue bars)
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Figure C.9: Histograms of the proportions of ones across 1000 replications of the QALYs computed from
the samples of the posterior predictive distribution of the Hurdle Model (light blue bars) compared with
the proportions observed (dark blue lines) in the control (panel a) and intervention (panel b) group in the
MenSS trial.
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Figure C.10: Histograms of the empirical distributions of the observed costs (dark blue bars) in the
control (panel a) and intervention (panel b) in the PBS trial, which are compared with the replications of
the data based on the samples drawn from the posterior predictive distribution of the Hurdle Model. For
visualisation purposes, only 15 replications (out of the 1000 generated) are displayed in the graphs.
The replicated datasets seem to closely approximate the empirical cost distributions in both
the control (panel a) and intervention (panel b) groups.
Figure C.11 shows the histograms of the proportions of sample means derived from 1000
replicates of the costs in the PBS study drawn from the posterior predictive distribution of the
Hurdle Model, which are compared with the sample means in the observed costs.
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Figure C.11: Histograms of sample means across 1000 replications of the costs computed from the
samples of the posterior predictive distribution of the Hurdle Model (light blue bars) compared with the
observed means (dark blue lines) in the control (panel a) and intervention (panel b) group in the PBS trial.
The distribution of the replicated cost means is centered around the sample mean values
computed on the observed data for both the control (panel a) and intervention (panel b) groups.
C.3.6 Gamma vs LogNormal
Figure C.12 compares the density and cumulative density functions (black lines) estimated from
the empirical costs in the two treatment groups of the PBS trial with respect to the theoretical
values obtained from fitting Gamma (red lines) or LogNormal (blue lines) distributions to the data
using maximum likelihood methods.
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Figure C.12: Density and cumulative density plots of the empirical cost data against the theoretical values
obtained from fitting a Gamma or LogNormal distribution via maximum likelihood methods for both the
control (panels a and c) and intervention (panels b and d) group in the PBS trial.
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C.4 Supplementary Analyses: Chapter 6
C.4.1 Prior sensitivity
Figure C.13 and Figure C.14 compare the point and 95% CI estimates for the missingness pat-
terns probabilities ( λrt ) and marginal mean utilities and costs (µujt, µ
c
jt) derived from the models
fitted to the two treatment groups of the PBS trial in Chapter 6 with those obtained under an al-
ternative prior specification for λrt . The original Dirichlet prior (Original), gives more weight to the
completers pattern and the same weights across the non-completers pattern (see Section 6.2.1),
while the alternative Dirichlet(1, . . . , 1) prior (Equal weights) assigns the same weight to all the
patterns.
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Figure C.13: Mean and 95% credible interval estimates of the missingness patterns’ probabilities r in
the control (red dots and lines, panel a) and intervention (blue dots and lines, panel b) group of the PBS
study. The estimates are shown under either the Dirichlet prior for λrt described in Section 6.2.1 (Original)
or the alternative specification Dirichlet(1, . . . , 1), which assigns the same weight to each pattern (Equal
weights).
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Figure C.14: Mean and 95% credible interval estimates of the mean utilities µujt (panels a and b) and
costs µcjt (panels c and d) in the control (red dots and lines) and intervention (blue dots and lines) group
of the PBS study. Estimates are obtained for the model δ = 0 and are shown under either the Dirichlet
prior for λrt described in Section 6.2.1 (Original) or the alternative specification Dirichlet(1, . . . , 1), which
assumes the same weight for each pattern (Equal weights).
C.4.2 Priors and posteriors for the sensitivity parameters
Figure C.15, Figure C.16 and Figure C.17 compare the prior (dashed lines) and posterior (solid
lines) densities of the sensitivity parameters δj used in the model in Chapter 6 for all utility and
cost marginal mean parameters in the control group of the PBS trial, under the nonignorable
scenarios δflat, δskew0 and δskew1, respectively.
Figure C.18, Figure C.19 and Figure C.20 compare the prior (dashed lines) and posterior (solid
lines) densities of the sensitivity parameters δj used in the model in Chapter 6 for all utility and
cost marginal mean parameters in the intervention group of the PBS trial, under the nonignorable
scenarios δflat, δskew0 and δskew1, respectively.
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Figure C.15: Prior densities (dashed lines) and posterior densities (solid lines) of the distributions of the
sensitivity parameters under the scenario δflat for both utilities (panels a,c and e) and costs (panels b,d
and f) at j = 0, 1, 2 in the control group.
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Figure C.16: Prior densities (dashed lines) and posterior densities (solid lines) of the distributions of the
sensitivity parameters under the scenario δskew0 for both utilities (panels a,c and e) and costs (panels b,d
and f) at j = 0, 1, 2 in the control group.
160
utilities
de
ns
ity
−0.3 −0.2 −0.1 0
0.
5
2.
5
4.
5
6.
5
8.
5
10
.5
prior
posterior
(a) δskew1u0
costs
de
ns
ity
0 500 1000 1500 2000
0.
00
01
0.
00
05
0.
00
1
0.
00
15
prior
posterior
(b) δskew1c0
utilities
de
ns
ity
−0.3 −0.2 −0.1 0
0.
5
2.
5
4.
5
6.
5
8.
5
10
.5
prior
posterior
(c) δskew1u1
costs
de
ns
ity
0 500 1000 1500 2000
0.
00
01
0.
00
05
0.
00
1
0.
00
15
prior
posterior
(d) δskew1c1
utilities
de
ns
ity
−0.3 −0.2 −0.1 0
0.
5
2.
5
4.
5
6.
5
8.
5
10
.5
prior
posterior
(e) δskew1u2
costs
de
ns
ity
0 500 1000 1500 2000
0.
00
01
0.
00
05
0.
00
1
0.
00
15
prior
posterior
(f) δskew1c2
Figure C.17: Prior densities (dashed lines) and posterior densities (solid lines) of the distributions of the
sensitivity parameters under the scenario δskew1 for both utilities (panels a,c and e) and costs (panels b,d
and f) at j = 0, 1, 2 in the control group.
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Figure C.18: Prior and posterior densities of the distributions of the sensitivity parameters under the sce-
nario δflat for both utilities (panels a,c and e) and costs (panels b,d and f) at j = 0, 1, 2 in the intervention
group.
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Figure C.19: Prior and posterior densities of the distributions of the sensitivity parameters under the
scenario δskew0 for both utilities (panels a,c and e) and costs (panels b,d and f) at j = 0, 1, 2 in the
intervention group.
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Figure C.20: Prior and posterior densities of the distributions of the sensitivity parameters under the
scenario δskew1 for both utilities (panels a,c and e) and costs (panels b,d and f) at j = 0, 1, 2 in the
intervention group.
C.4.3 Posterior Estimates
Table C.15 compares the point and 95% CI estimates for the mean QALYs and costs and other
incremental parameters (e.g. net benefit), in the two treatment groups of the PBS trial between
eight alternative specifications of the modelling framework described in Section 6.1 and shown in
Table 6.3. These are: CS-CC, CS-ALL, L-CC, L-ALL, δ = 0, δflat, δskew0 and δskew1.
C.4.4 Alternative Missingness Scenarios
The results associated with the Expected Incremental Benefit and the Incremental Benefit distri-
butions (evaluated at k = £20, 000) under the three alternative nonignorable scenarios described
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in Chapter 6 are separately compared with those from the L-CC and L-ALL scenarios, respectively
indicated with red, blue and green lines and shaded areas in the graphs. The three scenarios are
: the benchmark scenario δ = 0 (Figure C.21), δskew0 (Figure C.22) and δskew1 (Figure C.23).
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Figure C.21: Expected Incremental Benefit (panel a) and Incremental Benefit distribution at k = 20000
(panel b) associated with L-CC (blue solid and dashed lines), L-ALL (green solid and dashed lines) and
δ = 0 (red solid and dashed lines) models fitted to the data from the PBS study.
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Figure C.22: Expected Incremental Benefit (panel a) and Incremental Benefit distribution at k = 20000
(panel b) associated with L-CC (blue solid and dashed lines), L-ALL (green solid and dashed lines) and
δskew0 (red solid and dashed lines) models fitted to the data from the PBS study.
The results associated with the Cost-Effectiveness Planes under the three alternative non-
ignorable scenarios described in Chapter 6 are separately compared with those from the L-CC
and L-ALL scenarios, respectively indicated with red, blue and green coloured dots in the graphs.
The three scenarios are : the benchmark scenario δ = 0 (Figure C.24), δskew0 (Figure C.25)
and δskew1 (Figure C.26). In each graph, The ICERs from each model are indicated with corre-
sponding darker coloured dots. Compared with the benchmark δ = 0, the position of the points
in the plane under δskew0 and, especially δskew1, is shifted to the right. At a willingness to pay of
k = £25, 000, the ICERs under these two scenarios fall in the sustainability area and, on average,
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Figure C.23: Expected Incremental Benefit (panel a) and Incremental Benefit distribution at k = 20000
(panel b) associated with L-CC (blue solid and dashed lines), L-ALL (green solid and dashed lines) and
δskew1 (red solid and dashed lines) models fitted to the data from the PBS study.
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Figure C.24: CEPs associated with L-CC, L-ALL and δ = 0 scenarios, respectively represented with
blue, green and red coloured dots.
indicate a higher cost-effectiveness for the new intervention compared with the results under CC,
MAR and δ = 0.
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Figure C.25: CEPs associated with L-CC, L-ALL and δskew0 scenarios, respectively represented with
blue, green and red coloured dots.
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Figure C.26: CEPs associated with L-CC, L-ALL and δskew1 scenarios, respectively represented with
blue, green and red coloured dots.
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Appendix D
missingHE: A R Package to Handle
Missing Data in Economic
Evaluations
D.1 Package Overview
missingHE is a package designed to perform Bayesian health economic analysis in the presence
of missing outcome data. The structure of the package is based on the modelling framework
presented in Chapter 5. In the current version of missingHE there are two main functions to
handle missingness in either or both the effectiveness and cost variables. These are selection
and hurdle, which allow to implement selection and hurdle models, respectively.
Selection models are nonignorable models that factor the full data distribution (y, r | ω) into
the product of the full data response model p(y | ω) and the missing data mechanism p(r |
y,ω). Selection models are attractive as they allow a direct specification of the distribution of the
response and straightforwardly formulate assumptions about the nonresponse mechanism. The
drawback is how we can translate these assumptions into assumptions on the distribution of the
missing data. Indeed, model identification depends on assumptions on the distribution of y (often
difficult to check) and on the form of the missingness model (on which unverifiable assumptions
have to be made). The best way to assess the impact of missingness on the results for selection
models is to vary both the distributional assumptions in the response model and the form of the
missing data mechanism, and assess the robustness of the conclusions to a range of plausible
scenarios.
For the purpose of this thesis, here we only focus on the function hurdle, which allows to imple-
ment hurdle models, and describe its main features and purpose. Figure D.1 shows a schematic
representation of the package.
In the figure, the rectangular box indicates the main function hurdle of the package, which
returns as output an object of class missingHE. Oval boxes indicate generic functions (such as
print or plot) that can be applied to an object of class missingHE to generate the desired output.
The diamond boxes identify the functions that are specific to missingHE. These functions can be
used to compute suitable measures that assess the performance of the model either in terms
of predictive accuracy, using different types of predictive information criteria (pic), or in terms of
MCMC convergence, using different types of diagnostic tools (diagnostic).
The current version of missingHE can be installed in R from the online GitHub repository (https:
//github.com/AnGabrio/missingHE). For example, the function install_github, included in the
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hurdle diagnosticpic
plot
summary print
Figure D.1: A schematic representation of the missingHE package.
package devtools (which should be loaded), can be used to install the package. Once installed,
the package can be loaded into the R workspace using the function require or library.
Suppose that the user has a suitable dataset, perhaps obtained from a RCT, in which data
for each individual are recorded for the effectiveness and cost variables as well as for an arm
indicator specifying whether the individual to whom the data refer belongs in the control or the
intervention group. Other variables may be observed, e.g. relevant covariates such as sex, age or
co-morbidity. Both outcome variables can have missing values while no unobserved values are
allowed for the covariates as missingHE can only deal with missingness in the outcomes.
We now provide a brief summary of the hurdle function along with an explanation of the main
inputs that need to be provided by the user and the outputs generated by the function.
D.2 The hurdle Function
Assume that the data are available in the R workspace as a data frame, say data. Hurdle models
are implemented in missingHE using the hurdle function which calls JAGS, through the R package
R2jags, to fit the model. This function processes the data frame data so that the model output is
in the correct form for other functions in the package missingHE. Therefore, when this function is
called it should be assigned to an object to create an object of class missingHE. For example, we
can generate the object model.hur using the following command.
R> model.hur <- hurdle(data = data, dist_e = "norm", dist_c = "norm",
+ model.eff = e ∼ 1, model.cost = c ∼ e,
+ model.se = se ∼ 1, model.sc = sc ∼ 1, se = 1, sc = 0,
+ type = "SCAR", n.iter = 10000, prior = "default", d_e = my.d_e)
The arguments of the function have the following interpretations:
• data: a data frame that must contain the data to analyse, specified in a data frame format
• dist_e and dist_c: assumed effectiveness and cost distributions, specified as character
names among a set of pre-defined choices. Current available choices are: Normal ("norm")
for both outcomes, Beta ("beta") for the effectiveness and Gamma ("gamma") or LogNormal
("lnorm") for the costs.
• model.eff and model.cost: formulae that specify which variables should be included in
the effectiveness and cost models as covariates (among those available in data). A joint
bivariate distribution can be assumed by placing e on the right-hand side of the formula
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for the costs. By default both formulae do not contain any covariate (indicated with 1) and
assume independence between the outcomes.
• model.se and model.sc: formulae that specify which variables should be included in the ef-
fectiveness and cost structural value models as covariates (among those available in data).
By default no covariate is included (indicated with 1).
• type: type of model for the structural values, either independent of any other variable (called
Structural Completely At Random, "SCAR") or including some covariates in the model (called
Structural At Random, "SAR").
• se and sc: values in the effectiveness and cost data should be treated as structural by the
model (e.g. 1 for e and 0 for c). If structural values are observed only for one outcome it is
possible to set either se = NULL or sc = NULL. In this case, no hurdle model is assumed for
that outcome, which is directly modelled using the distribution specified in dist_e or dist_c.
• prior: prior distributions to be assumed for the parameters of the model (by default vague
priors). The default priors can be overwritten by the user. In this case, the new hyper-
priors for each parameter in the model can be provided by creating a list object that con-
tains the new values. A description of the parameterisation of the model and a list of the
character names to be used to change each parameter’s prior can be accessed by typing
help(hurdle).
• d_e and d_c: (optional) vectors of the structural value indicators to be used in the model for
the effectiveness and costs. If not provided, missingHE internally computes these vectors
based on the observed cases (NA if the cases are missing). When provided, the argument of
d_e and d_c must be vectors of length equal to the number of rows in data, and should take
value 1 or 0 to respectively associate each (missing) case with the (assumed) structural or
non-structural component in the hurdle model.
• Other additional arguments that may be provided are: the burnin period to be discarded
(n.burnin), the number of the chains (n.chains), the thinning interval (n.thin), the ini-
tialised values for the parameters in each chain (inits), the upper and lower bounds of
the credible intervals for describing the uncertainty around the imputed values (prob) and
whether the model text file should be saved in the current working directory (save_model).
The object model.hur contains the following elements which are then used as inputs to the
other functions in the missingHE package.
• model_output: a list storing the output of the JAGS model. Depending on the type of model,
the elements in this list can vary as they contain the posterior samples of the parameters of
interest based on the model specification assumed. In the list, a summary of the posterior
estimates of the JAGS model is also available, taken directly from the output of the function
jags in the package R2jags.
• cea: another list that stores the output of the economic evaluation based on the poste-
rior samples of the marginal mean effectiveness and cost parameters. This object can be
analysed using tailored functions in the package BCEA to visually represent standard CEA
outputs, such as the CEP and the CEAC.
• type: a character name that reports the type of model assumed for the structural values.
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A more detailed explanation of the inputs of each function in the package as well as a running
example on how to perform economic evaluations using missingHE can be found in the pack-
age documentation, which is available at the GitHub repository https://github.com/AnGabrio/
missingHE/blob/master/inst/doc/missingHE.pdf.
An area of possible extension of the current version of missingHE is the incorporation of a
wider range of choice for the distributions of the effectiveness and cost variables. This could
provide the users with more flexibility when fitting the model and compare the performance of
alternative specifications of the model in terms of the fit to the observed data.
In addition, more functions for fitting different types of missing data models will be included in
the package. Specifically, the implementation of alternative approaches to deal with nonignorbale
missingness (e.g. pattern mixture models) will provide greater flexibility for conducting sensitivity
analysis to the missingness assumptions and assess their impact on both the inferences and the
cost-effectiveness conclusions.
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